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1 Foreword 
 
Protein covalent modification and the consequent protein function 
modulation represent a key molecular mechanism for several drugs, 
belonging to different therapeutic classes, such as anti-inflammatory, 
antibiotic and chemiotherapic agents. Indeed, protein covalent adducts 
formation is involved in the toxic mechanisms of electrophilic xenobiotics as 
well as of endogenous cytotoxic mediators. For instance, both the beneficial 
effects and the adverse drug reaction of beta-lactams involve protein covalent 
binding. In particular, the β-lactam nucleus acylates the Ser403 residue of the 
peptidoglycan layer of bacterial cell walls thus blocking the cell wall 
synthesis. Moreover, β-lactam nucleus can covalently react with lysine 
residues of albumin and generate haptens able to induce an immune-mediated 
adverse reaction. Identification and characterization of protein adducts also 
represents a promising approach for the identification of novel drug target. In 
particular, several endogenous harmful agents such as electrophilic 
prostaglandins or lipid-glucose oxidation products, react with some target 
proteins inducing a cascade of toxic effects. Hence the identification of 
protein targets as well as of the electrophilic agents represent a promising 
strategy for the discovery of novel bioactive compounds. Based on these 
premises, it is well clear that the identification and characterization of 
covalent protein adduct, especially when formed in biological matrices, is a 
very stimulating analytical challenge, and of great importance in the different 
branches of the drug discovery program, such as the elucidation of reaction 
mechanisms, prediction of potential iodiosyncratic agents and identification 
of novel drug targets. 
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Among the different analytical techniques so far employed, mass 
spectrometry has attained a central role because of the wealth of structural 
and molecular information that can be obtained. Regarding protein covalent 
binding, the MS approach not only reveals the identity of the adducted 
protein but also clarifies the stoichiometry of reaction, the aminoacidic site 
undergoing biotransformation, the reaction products and hence the 
mechanism of reaction. More recently, the advent of high resolution MS 
analyzer such as the orbitrap, characterized by a significant increase of 
resolution and accuracy in respect to the well established MS analyzers such 
as ion trap, quadruple or time of flight, together with novel stationary phases 
and column dimension which have significantly improved the efficacy and 
resolution of chromatographic separation, has opened novel frontiers in the 
identification and characterization of covalently modified proteins also when 
present in trace amount and in crude biological systems such as cells or 
tissues. 
Considering these issues, aim of my Ph.D work was to set-up MS methods 
for the identification, characterization and quantification of non-enzymatic 
covalently modified proteins and peptides in biological matrices. To reach 
this goal both tandem MS and high resolution approaches were employed due 
to the wealth of structural and molecular information that these techniques 
can provide. As a first step the MS methods were applied for understanding 
in both in vitro and ex vivo conditions the mechanism of protein haptenation 
induced by amoxicillin (AX). The MS approach was then focused to study in 
ex vivo condition the covalent reaction between histidine dipeptides, such as 
carnosine, and toxic endogenous intermediates like reactive carbonyl species 
(RCS)
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2 Introduction on β-lactam antibiotics protein haptenation 
 
2.1 Adverse Drug Reaction 
 
Adverse drug reactions (ADRs) are a major problem in clinical practice. These are 
defined by the World Health Organization (WHO) as any noxious, unintended and 
undesired effect of a drug that occurs at doses used for prevention, diagnosis and 
treatment of a given disease.  
In addition, any drug may be harmful to the organism. It 'has been estimated that 3-
5% of all hospital admissions are caused by adverse drug reactions, and this results 
in 300.000 people hospitalized each year in the USA. The most serious cases in 
which the patient's life is in danger are around 3% concerning in hospital therapy 
and around 0.4% in the classical therapy at home. It should be emphasized that the 
side effects are the primary cause of iatrogenesis. [1]  
Drug reactions are frequently classified as type A and type B reactions, however in 
the last years a more detailed classification system have been drawn. Type A 
reactions stand for “augmented” and are reactions resulting from an exaggeration 
of the drug pharmacological effect and are normally dose-dependent, for example 
respiratory depression with opioids or bleeding with warfarin. These reactions 
account for the 80% of the all ADRs and are usually identified by toxicological 
preclinical test [2]. 
Type B reactions stand form “bizzare” and concern novel adverse drug reactions 
that happen rarely, they are not predictable by preclinical and clinical studies and 
can take place at any therapeutic dose. These are usually defined also as 
idiosyncratic. Examples includes anaphylaxis with penicillin or skin rashes with 
antibiotics, or angioedema caused by ACE inhibitors. 
The new classification includes also type C reaction, or continuing reactions that 
persist for a relatively long time as jaw osteonecrosis caused by bisphosphonates. 
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Then there are type D reactions that are delayed reactions that become apparent 
some time after the use of a medicine, for example leucopoenia which can occur up 
to six weeks after a dose of lomustine. Finally there are type E reactions, or end of 
use reaction that are provoked by the withdrawal of the medicine as in the case of 
the insomnia and anxiety following the withdrawal of benzodiazepines. 
Since the first part of this thesis will concern the interaction between amoxicillin 
and serum proteins, type B idiosyncratic reaction will be deeper examined. 
 
2.2 Idiosyncratic reactions (IDRs) 
 
The idiosyncratic reactions to drugs pose a major problem in clinical practice, the 
main adverse effects are: hepatotoxicity, mild or severe skin reactions, anaphylactic 
reactions, blood dyscrasia. Clinical evidence suggests that the idiosyncratic 
reactions are caused by reactive metabolites and are mostly immune-mediated; 
However the scientific community is still far from understanding the chemical and 
molecular processes involved in the idiosyncratic reactions. Specifically, among all 
adverse drug reactions, those based on immunological or allergic basis account for 
6-10% of all ADRs [3]. 
The IDRs are the hardest obstacles to overcome in order to achieve the full 
development and market success of a drug. The 10.2% of the drugs approved from 
1975 to 2000 have been withdrawn from the market or put in the black box 
warning [1].  
The most significant problem is that many idiosyncratic reactions cannot be 
detected even in meticulous trials with a large number of subjects; and these are 
usually found in the monitoring phase after approval, even at long distance of time 
after the market introduction of the drug. 
Since the IDRs are based on an immunological reaction to drug, these reactions 
require a sensitization period, during which the patient is exposed to the drug that 
stimulates the immune system by producing antibodies, sensitized T cells or both. 
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Allergic drug reactions are reproduced with a new drug exposure and are elicited at 
drug doses far below the therapeutic range, usually subsiding after drug 
discontinuation. As with hypersensitivity reactions in general, drug allergic 
reactions can be classified according to the categories defined by Gell and Coombs 
[4] which have been updated [5] and are as follows: type I or immediate 
hypersensitivity reactions mediated by drug-specific immunoglobulin Ig E 
antibodies; type II or cytolytic or cytotoxic reactions; type III or immune complex-
mediated reactions and type IV or delayed hypersensitivity reactions (mediated by 
drug-specific T lymphocytes). Most of the allergic reactions to drug are IgE (type I) 
or T-cell mediated (type IV). 
Even if any drug can induce an immune response, the drugs most affected by IDRs 
are antibiotics, in particular the IgE mediated immediate hypersensitivity reactions 
to β-lactams. Then there are many cases that involve NSAIDs especially used for 
inflammatory chronic pathologies where in particular it is still too difficult to 
identify the best tolerated therapy. Furthermore, there are allergic drug reactions 
also for anaesthetics and radiological contrast fluids; although less frequent, this 
IDRs constitute an important risk in surgical and diagnostic procedures.  
Mechanistically, three main types of hypothesis attempt to explain immunological 
reactions to drugs. These are a) the hapten hypothesis, b) the danger hypothesis and 
c) the pharmacological interaction hypothesis. 
These three main hypotheses are not to be considered distinct from the other one, 
as in the same context of allergic reaction they may act in a cooperative manner, 
giving as a final result a immunological reaction to that particular drug. 
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2.3 Hapten hypothesis 
 
The formation of a drug-protein adduct plays generally an important role in its 
toxicity, especially concerning the immunological reactions to the drugs. Already 
in 1935 Karl Landsteiner stated that a small molecule is not able to induce an 
immune response unless already is or become chemically reactive and capable of 
binding to protein [6] .The classical theory states that the modified protein by the 
drug is seen as foreign agent (antigen) by the immune system.  
The immune system in the early stages of development is able to differentiate 
"self" from "not-self" [7] and the drug itself is not recognized by the immune 
system due to the low molecular weight. On the contrary, the formation of a 
covalent adduct with the protein is recognized by the immune system as "not-self" 
and triggers the immune response. The drug modified protein is processed 
(hydrolyzed into peptide fragments) by antigen presenting cell (APC) and 
presented by the major histocompatibility complex (MHC) to T helper 
lymphocytes that will and activate CD8
+
 T cells (killer) and B lymphocytes that 
will start the immune response, as shown in figure 1. 
The first mechanism of idiosyncratic reaction studied was the penicillin allergic 
reactions.[8] The β-lactam ring of penicillin irreversibly reacts with the free amino 
groups or sulfhydryl groups present in proteins. In some patients, this leads to an 
immune response against the penicillin-protein adduct. If the response produces a 
sufficient amount of IgE an anaphylactic reaction may be triggered. The 
mechanism of penicillin allergic reaction fits very well with the hapten hypothesis 
since the β-lactam group is an hapten itself, due to its high reactivity towards 
nucleophilic groups. 
One of the major results of this theory is the use of prick test for the detection of 
patients prone to drug allergic reactions. In case of β-lactams, few drops of a 
polymer of lysine covalently linked to penicillin (BPO-Poly-Lys) is introduced in 
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skin by a needle: if the patient is allergic, it will form local redness and 
inflammation and in some worse cases also anaphylaxis. 
In many cases, however, only the active metabolite of the drug can form covalent 
adducts with proteins, so the role of biotransformation is important in protein 
haptenation. As an example we can cite the case of anti-epileptic drug felbamate: 
the reactive metabolite 2-phenylpropenal form covalent adducts with human serum 
albumin (HSA), which is potentially involved in the formation of antigens [9]. 
Ultimately the understanding of the penicillin allergic reactions and the study of the 
hapten hypothesis are cornerstones for the study of other IDRs. 
 
 
 
Fig. 1. On the right panel it is depicted the hapten hypothesis, instead on the left PI 
concept hypothesis is shown The picture is taken from Ariza et al [10].  
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2.4 Danger hypothesis 
 
Although the hapten hypothesis is convincing, it should be noted that drug-protein 
adducts are often detected in tolerant patients, making the mechanism of develop 
drug allergy still a matter of debate. It was thought then that co-stimulatory signals 
are required to activate the immune system. These signals may be infections, 
exposure to endotoxin, stimulation by cytokines, metabolic alterations or drug 
toxicity. All of these have been called "danger signals"[11]. 
Matzinger et al proposed that the primary determiner of an immune response is not 
the "not self" condition of the antigen but rather the "damage" that this antigen can 
induce [12]. Fearon et al described that foreign proteins usually do not cause a 
significant immune response if they are not administered with an adjuvant; the first 
purpose of the adjuvant is the activation of the antigen presenting cell (APC). So 
without APC activation, the immune response can’t be elicited [13].  
The basis of the theory of Matzinger is that an organism cannot trigger an immune 
response against any "not self" protein, unless it’s dangerous. For example human 
organism tolerate different bacteria that live in symbiosis with its body and 
moreover many proteins don’t appear in the human organism until puberty [14]. 
Furthermore the theory states that, in case of a damage, the tissue itself will 
determine the nature of the immune response. The wound tissue will release danger 
signals that will activate the APC and trigger the immune response [15]. Several 
molecules have been proposed as a "danger signal" hydrophobic molecules 
(Hypos) and also proteins such as heat shock proteins (HSP) [16] 
Extending this theory to the idiosyncratic reaction, it could happen that the drug 
itself or its metabolite causes cellular damage and then the release of "danger 
signal" can elicit an immune response [17, 18]. It is possible that other factors may 
contribute to the onset of idiosyncratic reaction such as infection or post-surgical 
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periods, however a linear correlation between a particular health conditions and 
increased incidence of IDRs have not been found.  
The hapten and damage hypotheses can play a synergistic role in the formation of 
IDRs. In case of anaphylactic reactions induced by penicillins the hapten 
hypothesis is convincing, however it seems that the "danger signals" could have a 
primary role in stimulating the formation of a co-signal (B7) exposed by the APC 
on the cell surface: this co-signal eventually bind the T-helper lymphocyte (CD28) 
giving an indispensable contribution to its activation [17, 18]. 
 
2.5 Pharmacological interaction hypothesis 
 
The pharmacological interaction hypothesis states that non-covalent interactions 
may be involved in the pathophysiology of immunological reactions: as shown in 
figure 1, right panel, the activation of the immune system would be mediated by 
the direct binding of drugs to typical receptors of the lymphocytes, such as the 
TCR, main receptor of the T cell and the major histocompatibility complex 
receptors (MHC). The binding is non-covalent therefore it is mediated by Van Der 
Waals forces, electrostatic forces and hydrogen bonds [19].  
It is reported in literature that Pichler generated clones of T lymphocytes from 
patients having a history of IDRs to sulfamethoxazole and noticed that the cells 
proliferated in the presence of the drug. He proposed that some drugs may 
reversibly bind to the MHC complex of T helper cells, and in some cases this can 
lead to IDRs. Furthermore it is known that many metals such as nickel or beryllium 
can cause allergic reactions, by reversibly binding to the MHC [20]. 
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2.6 Review of the methodological approaches used to study the interaction 
between protein and β- lactams antibiotics 
 
2.6.1 From the first studies to immunoenzymatic techniques 
 
The first clinical cases of allergy induced by β- lactam antibiotics, in particular by 
penicillin G, were firstly published around 1945 [21], but in the sixties the 
scientific community began to study the identity of the antigenic determinants 
responsible for hypersensitivity to penicillin G.  
In a paper published in 1961 Levine and Ovary incubated γ-globulin, human serum 
albumin (HSA) and poly-L-Lysine with an excess of penicillin G [22]. The purpose 
was to show that human proteins could be covalently modified by the β- lactam 
antibiotic and elicit hypersensitivity reactions against penicillin G, based on 
Landsteiner hapten hypothesis [23]. 
They showed that these proteins were modified by means of alkaline hydrolysis of 
the pencilloyl group to get the benzyl-penicilloic acid. Afterwards the hydrolyzate 
was analyzed with thin layer chromatography (TLC) together with the benzyl-
penicilloic acid standard. In order to confirm that the hydrolyzate contained benzyl-
penicilloic acid (BPA) the authors relied on BPA retention factor and on the blue 
coloration that is created by adding mercury chloride and arsenic molibdate. 
Furthermore, after a purification step, the penicillin G treated proteins were 
incubated with anti-penicillin G antibodies: the formation of a precipitate 
confirmed the covalent modification of the proteins. 
More modern techniques like electrophoresis and radio immunological assay (RIA) 
began to be used since the end of the sixties. In 1968 Arvan et al [24] reported that 
in patients treated with high concentrations of penicillin was observed a transient 
bisalbuminemia. The bisalbuminemia occurs when there are two types of serum 
albumin that differ in mobility during serum electrophoresis. The techniques used 
2 Introduction on β-lactam antibiotics protein haptenation 
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were the electrophoresis on paper, electrophoresis on cellulose acetate and finally 
electrophoresis on agar gel. Figure 2 shows the paper electrophoresis (panel A), 
cellulose acetate electrophoresis (panel B) and agarose gel electrophoresis (panel 
C): it was clearly shown a definite separation between the faster and slower 
albumin. It was thought, therefore, that this effect was due to a covalent interaction 
between albumin and penicillin. In particular, it was suggested that it was caused 
by the covalent modification of the basic amino acidic residues by the penicilloyl 
group.  
In 1979, Wal and Lapresle repeated [25] the experiment and confirmed that the fast 
albumin is covalently modified by penicillin. Two patients were treated with an 
high dose of penicillin G and then their serum was analyzed by agarose gel 
electrophoresis, resulting in the detection of the bisalbuminemia. Afterwards the 
fast and slow albumins were separated by chromatography with DEAE-Sephadex 
stationary phase. So the two albumins were analyzed using a radioimmunoassay 
(RIA) with antibodies specific for the penicilloyl group. The radioimmunoassay 
(RIA) used in this paper was developed in the article of the same Wal in 
collaboration with other researchers in 1975 [26]. 
In Wal method it was used as a labeled antigen I
125 
bovine albumin modified by 
penicilloyl groups (BPO-BSA- I
125
). This labeled antigen was made to react in 
known quantity with a known and limiting amount of rabbit antibody, that 
recognize the penicilloylated-protein. Consequently there was a specific binding 
between the rabbit antibody and the the penicilloylated-protein. Then in the same 
tube the patient albumins, suspected to contain an unknown quantity of penicilloyl 
groups, were added. Hence the not labelled (cold) antigens of the patient compete 
with labeled (hot) antigens for the binding to the antibodies. The antigens bound to 
antibody are precipitated by means of a secondary sheep antibody that recognized 
the complex between rabbit antibody a the penicilloylated-protein. After 4 hours of 
incubation at 4 degrees, the mixture is centrifuged. Hence a pellet is obtained that is 
constituted by the antigen-antibody complex; instead the supernatant is formed by 
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the unbound antigen. In the method developed by Wal et al the radioactivity of the 
pellet is measured, hence the antigen-antibody complex: more albumin of the 
patient is modified by penicilloyl group, less the complex is radioactive. A 
calibration curve was set up by using known amounts of reagents and therefore  the 
modified albumin present in the serum of patients were quantified. A calibration 
curve used to develop the analytical method is shown in fig 3. By means of this 
RIA, the authors proved that the penicilloyl modifications were on the fast 
albumin. 
Wal examined in depth these studies and in 1980 published an article [27] in which 
the pronase B was used to partially degrade albumin and to expose penicilloyl 
groups making them more accessible to specific antibodies against this antigen. 
Thanks to this work Wal proved the existence of two different types of penicilloyl 
residues, characterized by a different accessibility to antibodies, different quantities 
and elimination kinetics. Wal thus opened new questions about the site and about 
the mechanism in which the albumin was modified by penicillin. Wal also started 
to examine the toxicological and pharmacological significance of penicilloyl 
groups localized within the albumin molecule.  
At the same time Lapresle and Lafaye set up one of the first ELISA [28] test for the 
measurement of the penicilloyl groups. In this technique the alkaline phosphatase 
enzyme, linked to penicilloyl residues, was made to react with anti-penicilloyl 
antibodies fixed on a polystyrene plate. The plate was washed to remove non-
specific binding. Then the alkaline phosphatase substrate was added, that is the p-
nitrophenylphosphate. Hence the enzyme catalyzed a colorimetric reaction whose 
intensity is directly proportional to the amount of labelled penicilloyl groups 
bounded to the antibodies fixed on the plate. If in the serum some penicilloyl 
modified proteins were present, the reaction just described was inhibited and then 
there was a reduction in signal intensity directly proportional to the amount of 
penicilloyl groups present in human serum. By means of a calibration curve the 
penicilloyl groups were quantified up to a picomolar concentration. The authors 
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focused also the penicilloyl residue covalently bound to albumin, and they showed 
once again that after the treatment of albumin with a proteolytic enzyme, the 
amount of detected penicilloyl group increased. 
The studies described up to now allowed to identify the isoform of albumin 
covalently modified by penicillin as well as to prove the presence of different 
modified residues within albumin, while it was not yet been identified nor the 
region of modification, nor the aminoacidic resdiues involved.  
In 1987 Lafaye and Lepresle [29] identified what fragments of human albumin, 
obtained by digestion with CNBr, were modified by penicilloyl groups. In their 
paper the serum from a patient treated with high concentrations of penicillin G for 
40 days were analyzed using a DEAE-Sephadex chromatography to separate the 
two albumin isoform. Then both the albumins were treated with CNBr to obtain the 
fragments that were subsequently reduced with 2-mercaptoethanol. The fragments 
that typically are obtained with the CNBr digestion of albumin are from N-terminal 
to C-terminal: B1-123 , C124-298,  A299-585. In order to identify which one of the three 
fragments was modified by penicilloyl groups an ELISA test was used. It resulted 
that only the fragments C124-298 and A299-585 were identified as modified because 
they showed an inhibition and thus reducing the intensity of the ELISA test: by 
using a calibration curve the authors calculated that each fragment was modified by 
a penicilloyl residue. Moreover it resulted that the 2-mercaptoethanol treatment 
improved the detection of the penicilloyl residue and hence they deduced that 
disulfide bridge have an important role considering the inaccessibility of the 
modified residue. 
This preliminary work was deepened by Yvon and Wal in 1988 [30]. Their paper 
focused on the identifying the penicilloylated residues on the C124-298 fragment. 
Hence the albumin isolated from a patient treated with high concentration of 
penicillin was digested by CNBr and the resulting three fragments were separated 
by preparative chromatography. Hence the C124-298 fragment was isolated and then 
reduced and alkylated on the Cys residues by 2-mercaptoethanol and then digested 
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by tripsin. The resulting peptide mixture was separated by preparative 
chromatography and each fraction was tested with a dedicated ELISA assay. The 
positive fraction was further separated by chromatography and once again each 
fraction was tested by ELISA. The new positive fraction was then sequenced by an 
automatic analyzer Biotronik LC 5000. The modified peptide was identified 
because the modified aminoacid was not recognized by the sequencer and 
moreover the possible modified peptide was tested again by ELISA, confirming the 
penicilloylation. Thanks to this analytical platform the researchers identified one 
modified residue on fragment C124-298, that was Lys 199: this was the first time that 
a penicilloylated residue was identified. 
Furthermore the authors emphasized the importance of the low pKa of the amino 
group of the Lys ε 199 that is approximately 7.9, unlike the other residues Lys in 
which typically the same amino group has a pKa of 11. The lower pKa facilitates 
the nucleophilic attack of the amine on the β-lactam ring: it is necessary that the 
amine is not charged because this reaction is favored. So more the pKa of the 
amine is close to the value of pH of the buffer and more the reaction is favored. 
The same authors in 1989 published an article [31] in which they analyzed again 
fragment C124-298, by applying a similar analytical platform of the previous article, 
but adding a further step of ionic exchange chromatography after the reverse phase 
preparative chromatography, as explained in fig.4. Hence the residues Lys 190, 195 
and 199 were identified as penicilloylated. It is important to notice that each 
modified Lys is near to a Ser residue, spaced by two or three other aminoacids. For 
example Lys 190 is near to Ser 193, Lys 195 has Ser 192 and Lys 199 is near Ser 
202. Moreover all these aminoacids are placed on an α-helix motif in which Lys 
and Ser are very near in the three dimensional space. All these findings supported 
the adduction mechanism proposed by Yamana [32], concerning the formation of 
penicilloylamidic determinants. This mechanism requires that the penicilloylation 
of the hydroxyl group of serine occurs very quickly, assisted by an acid-base 
catalysis towards the penicillin β-lactam to get the corresponding penicilloyl ester, 
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which is rapidly converted to a stable penicilloylamide thanks to the nucleophilic 
attack of a near Lys ε amino group. Furthermore the identified residues were placed 
on a very short fragment of 10 aminoacids localized in a junction between albumin 
domain 1 and domain 2. This flexible junction contains also high affinity binding 
site for salicylates, glucose and warfarine [33]. 
Finally in 1990 the authors completed the identification of the penicilloylated 
residues by analyzing the other fragment A299-585, found positive for penicillin 
modification to the ELISA test. By means of the same analytical platform (fig. 4) 
used for the previous papers Lys, 432, 451 and 545 were found as modified. 
Moreover also the C124-298 was analysed again and Lys 190, 195 and 199 were 
confirmed as penicilloylated. Hence finally the albumin of a patient, treated with 
high concentration of penicillin G, was found to have six lysine as modified [34]. 
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Fig. 2. Penicillin induced bisalbunemia (25.000 units / mL). A) Paper 
electrophoresis  B) Cellulose acetate electrophoresis C) Agar gel electrophoresis. 
The picture is taken from Arvan et al paper [24] 
 
A 
B 
C 
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Fig. 3. Standard curves generated by RIA. The concentration of cold antigens are 
reported on the x axis, instead the radioactivity (cpm) of the antigen-antibody 
complex is reported on the y axis. Penicillin G and derivatives were used as cold 
antigens. It can be noticed that penicilloyl-aminocaproate and penicilloyl-poly-
lysine displaced efficently the labelled antigen BPO-BSA-I
125
. Picture taken form 
Wal et al [26] 
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Fig. 4. Analytical platform used by Yvon et al. [31, 34] 
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2.6.2 The advent of mass spectrometry and chromatography hyphenated 
techniques 
 
Until the late 80s mass spectrometry (MS) was rarely used for the analysis of 
protein and peptide mixtures, although these techniques could easily measure the 
molecular weight of a compound. Since the MS separates and detects ions in the 
gaseous phase it is necessary that the compounds to be analyzed may be ionized 
and converted into the gas phase by various ionization sources. In those days there 
weren’t sources that could ionize and carry large and polar molecules in the gas 
phase without sample degradation.  
Since 1982 the only ionization technique available was the Fast Atom 
Bombardment (FAB) and the analyzer used was a magnetic field. This 
instrumentation was rarely used given the high cost and the low sensitivity which 
required considerably higher amount of protein in respect to the automatic Edman 
degradation, routinely used at that time. 
At the end of the 80s two new techniques of "soft" ionization were developed: the 
Electrospray Ionization (ESI) and Matrix Assisted Laser Desorption Ionization 
(MALDI) which enabled the acquisition of mass spectra of proteins and peptides 
with a quantity used in the order of picomoles. The MALDI sources were usually 
coupled to time of flight analyzers (TOF), while the analyzers coupled to ESI 
source were various: quadrupole, triple quadrupole, ion trap. The two last analyzers 
also permit to acquire the MS/MS spectra of any peptide and based on the 
fragmentation pattern, to identify the sequence. Thanks to these new mass 
spectrometers, the use of this technique grew rapidly in the field of proteomics, 
becoming the technique which is used routinely. In particular, nowadays, it is the 
standard technique in order to identify and sequence proteins, as well as to study 
the physiological post-translational modifications or induced by xenobiotic or 
endogenous electrophilic compounds. Mass spectrometry also allows to thoroughly 
2 Introduction on β-lactam antibiotics protein haptenation 
20 
characterize the type of modification and the site of modification on protein: this 
information is of crucial importance in many fields of proteomics and drug 
development research. 
Regarding the protein haptenation induced by β-lactam, one of the first paper 
employing mass spectrometry is that reporting the metabolism of the benzyl-
penicilloyl residues bound to albumin. The MS spectrometer was equipped with a 
FAB source and it was used to analyze the metabolites of benzyl penicilloyl group 
excreted in the urine, indicating that penicillin G conjugated to albumin was 
excreted as benzyl penicilloic acid more slowly than the free penicillin G.[19]. 
Only in 2000 human albumin treated with penicillin G was analyzed by ESI-MS: 
Bertucci et al in their paper used MS along with circular dicroism in order to asses 
if the penicilloylation of albumin modifies the secondary structure of the protein 
and  the binding properties towards other drugs. The deconvoluted spectra of 
control albumin and treated albumin are reported in fig 5: panel a) shows the 
deconvoluted spectrum of control albumin characterized by a base peak relative to 
the mercapto-albumin chracterized by a mass of 66463 Da. Panel b) shows the 
deconvoluted spectra of albumin incubated with pencillin G for 24 hours with a 
stoichiometric ratio albumin:penicillin G of 1:25. Compared to the control albumin, 
the spectrum is characterized by the presence of an additional peak with a relative 
abundance of about 50 % and characterized by a mass increment of 330 Da in 
respect to the mercaptoalbumin, due to the adduction of one molecule of penicillin 
G. As shown in panel c) and d) the increase of the incubation time is related to an 
increase of the relative content of the protein adducts. Moreover, although circular 
dichroism studies did not find  differences regarding the secondary structure of 
penicilloylated albumin in respect to control albumin, it was observed that the 
binding affinity of the modified albumin towards a series of known ligands such as 
warfarin, diazepam and billirubin, was drastically reduced compared to control 
albumin [35]. 
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Ten years later, mass spectrometry was used to obtain novel  important information 
concerning β-lactams haptenation. In 2011 Meng et al [36] reported the use of MS 
to evaluate the mechanism of reaction between human serum albumin and 
penicillin G and to identify the sites of modification. They isolated the albumin 
from the serum of patients treated with high concentration of penicillin G, then the 
protein was digested with trypsin and the peptides mixture was analyzed by reverse 
phase liquid chromatography coupled to a triple quadrupole in multiple reaction 
monitoring (MRM) analysis. Fourteen lysines were found modified by penicillin G, 
as listed in table 1. Moreover it was shown that penicillin G and benzyl-penicillenic 
acid formed diastereoisomers when bound to the albumin Lys residues. The 
different diastereoisomers were identified on the basis of their different interaction 
with the column stationary phase, leading to well distinguishable chromatographic 
peaks characterized by different retention times. This finding is significant because 
the immune system can discriminate between penicillin stereoisomers [37] and the 
authors suggested that this could be important in the diversity of immunogenic 
responses among different patients. 
In 2009, the same research group [38] characterized the haptenation of human 
albumin by  flucloxacillin both in vitro and in vivo. The flucloxacillin is an 
antibiotic resistant to penicillinases, especially used in infections with 
staphylococci. Similalry to all β-lactam antibiotics, flucloxacillin can cause 
idiosyncratic reactions, and therefore, already in 2005, the consequent protein 
haptenation was studied with immunochemical techniques [39], which did not 
permit a complete structural characterization of the adducted moiety. By means of 
an analytical platform, already reported in the previous article, it was found that 
Lys 190 and 212 were the most reactive Lys residues, and that up to ten Lys 
residues were modified after incubating albumin with an higher concentration of 
flucloxacillin. When the albumin of patients treated with high doses of 
flucloxacillin was analyzed, nine Lys were found modified (table 2). It was 
evidenced that since the ε amino group of Lys 190 is characterized by a pKa of 
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7.42, it is not completely charged at physiological pH thus explaining its 
nucleophilic reactivity to the β-lactam ring. The pKa of the ε amino group of Lys 
212 is 10.5, hence due to the fact that it is charged at physiological pH it should be 
not reactive: however on the basis of molecular modeling studies, the authors 
proposed that Lys 212 is reactive because the surrounding residues form a 
hydrophobic pocket where flucloxacillin non-covalently binds therefore  becoming 
more available for the nucleophilic attack. 
The research group extended the analytical strategy to study the haptenation of 
albumin isolated by patients treated with this flucloxacillin; the following four Lys 
were found to be modified: Lys 190, Lys 195, Lys 432 and Lys 541. 
Figure 6 summarizes the data so far reported, showing a 3D model of human 
albumin where the main aminoacidic residues identified as target of the antibiotic 
covalent modification are highlighted: it can be noticed that among the nucleophilic 
residues, potential target of covalent modification and including His, Ser and Cys, 
only Lys was found to be modified. A possible explanation could be that only Lys 
forms stable reaction products, as suggested by Yvon et al.[34] 
Based on the above reported review on the papers  reporting the β-lactam protein 
haptenation, it can be noticed that penicillin G is the most studied antibiotic and 
albumin the protein target mostly considered and that only recently the interaction 
with other antibiotics was considered and among this amoxicillin whose detailed 
haptenation mechanism represents one of the aim of the PhD thesis.  
. 
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Fig. 5. Deconvoluted ESI mass spectra of defatted samples of HSA. a) After 4 days 
of incubation with an equimolar amount of penicillin G. b) After 1 day of 
incubation with 25:1 molar excess of penicillin G c) After 2 days of incubation with 
25:1 molar excess of penicillin G. d) After 4 days of incubation with 25:1 molar 
excess of penicillin G. The number of adducts is directly proportional to penicillin 
G concentration and the period of incubation. Picture taken by Bertucci et al [35] 
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Tab. 1. The penicilloylated tryptic peptides found by Meng et al are reported [36] 
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Tab. 2. In table A the flucloxacillin modified peptides found with no pre 
fractionation are reported, instead in table B there are the modified peptides found 
after pre fractionation on cationic exchange column. [38] 
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Fig. 6. Main aminoacid residues found modified in the studies regarding penicillin 
G, flucloxacillin and piperacillin haptenation. 
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ABSTRACT 
 
Allergy towards wide spectrum antibiotics such as amoxicillin (AX) is a 
major health problem. Protein haptenation by covalent conjugation of AX is 
considered a key process for the allergic response. However, the nature of the 
proteins involved has not been completely elucidated. Human serum albumin 
(HSA) is the most abundant protein in plasma and is considered a major 
target for protein haptenation by various drugs, including -lactam 
antibiotics. Here we have developed a procedure for immunological detection 
of AX-protein adducts with antibodies recognizing the lateral chain of the 
AX molecule. With this approach we detected human serum proteins 
modified by AX in vitro and identified HSA, transferrin and heavy and light 
chains of immunoglobulins as prominent AX-modified proteins. Since HSA 
was the major AX target, we characterized AX-HSA interaction using high 
resolution LTQ orbitrap mass spectrometry. At 0.5 mg/ml AX, we detected 
one main AX-HSA adduct involving residues Lys 190, 199 or 541, whereas 
higher AX concentrations elicited a more extensive modification. In 
molecular modelling studies Lys190 and Lys 199 were found the most 
reactive residues towards AX, with surrounding residues favouring adduct 
formation. These findings provide novel tools and insight for the study of 
protein haptenation and of the mechanisms involved in AX-elicited allergic 
reactions. 
 
Keywords: drug allergy, -lactam antibiotics, protein haptenation, 
amoxicillin binding, high resolution mass spectrometry, amoxicillin targets 
Abbreviations: AX, amoxicillin; HSA, human serum albumin; ECL, 
enhanced chemiluminiscence 
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3.1 Introduction 
 
The widely prescribed -lactam antibiotics are among the drugs most 
frequently eliciting allergic reactions, thus posing an important clinical 
problem. In the most severe cases allergic reactions may be life-threatening 
and reduce the therapeutic options against infections. Protein haptenation 
plays a key role in immunological reactions to -lactams. This process occurs 
through the nucleophilic opening of the -lactam ring, generally by the attack 
of free amino groups in proteins, and gives rise to a penicilloyl-protein adduct 
which is able to elicit an immune response (reviewed in [1]). See Fig.1 for a 
schematic representation of the formation of an amoxicilloyl-protein adduct. 
Important efforts have been devoted towards the understanding of the 
pathogenic role of protein haptenation by -lactams, the identification of the 
adducts formed and their ability to activate the immune system. Because 
human serum albumin (HSA) is the most abundant protein in serum, most 
works have attempted the characterization of penicilloyl-HSA adducts. The 
first pioneering studies on these aspects, employing HPLC separation of 
tryptic peptides and EDMAN degradation sequencing, were published by 
Yvon et al. [2, 3] and reported the sites of adduct formation in albumin 
obtained from a penicillin-treated patient or prepared by in vitro conjugation. 
More recently, mass spectrometry (MS) has been applied to the study of 
adducts of HSA with various -lactam antibiotics, including benzylpenicillin 
[4], flucloxacillin [5] and piperacillin [6] formed either in vitro or in the 
serum of patients. Noteworthy, there seems to exist a high degree of 
variability among the adducts detected and the factors that influence this 
process are not completely understood. 
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Unlike the other investigated penicillins, amoxicillin (AX) is a zwitterionic 
molecule which possesses a primary amino group and belongs to the class of 
aminopenicillins characterized by a greater activity against gram-negative 
bacteria and a better pharmacokinetic profile [7]. This unique feature of AX 
can heavily influence its reactivity towards nucleophilic centers.  
The detection and characterization of the amoxicilloyl-HSA (AX-HSA) 
adducts formed could be very helpful for the understanding of the pathogenic 
role of protein haptenation in the allergic reaction, as well as for the design of 
more relevant antigens to be used in diagnostic tests. HSA modified in the 
presence of high concentrations of -lactam antibiotics, including 
benzylpenicillin, ampicillin or AX has been widely used in the development 
of diagnostic assays to detect penicillin-reactive IgE antibodies in the serum 
of patients, to evaluate cross-reactivity and as immunogens for the 
development of anti--lactam antisera [8-11]. However there is little 
information on the structural features of HSA modified by AX concentrations 
close to those occurring during treatment with this antibiotic. 
Pharmacokinetic studies of AX in human and animal models reveal that the 
plasma concentrations after oral or intravenous administration may be in the 
order of 20 or 250 g/ml, respectively [12, 13], whereas HSA concentration 
in plasma is approximately 30 mg/ml. Therefore, the molar ratio of antibiotic 
to protein in vivo is not expected to exceed 2:1. 
Here we have undertaken the study of the formation of covalent adducts of 
low AX concentrations with HSA and potentially with other serum proteins, 
as a first step to understand the processes that govern protein haptenation, 
resulting in the identification of a novel set of serum proteins as potential 
targets for modification by AX. Moreover, in the present study we explored 
the potentialities of a novel MS approach based on a high resolution MS 
analyzer (orbitrap) coupled to nanoscale capillary liquid chromatography for 
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the full elucidation of the covalent binding of AX to HSA and in particular to 
obtain the following information: stoichiometry of reaction, chemical nature 
of the covalent adduct and the sites of modification. LTQ Orbitrap mass 
spectrometry is emerging as a powerful tool for protein identification and 
characterization due to its capabilities of high resolution (up to 100,000 for 
small molecules), and excellent mass accuracy (<5 ppm with external 
calibration) in a robust manner even within HPLC time scales [14]. Orbitrap 
has been successfully applied to investigate post-translational modifications 
as well as to fully elucidate protein modifications induced by xenobiotics 
[15]. However, to our knowledge, no applications of orbitrap and in general 
of high resolution MS analyzers have been reported for the study of penicillin 
binding to proteins and for this reason a top-down and an innovative bottom-
up MS approach is here reported to fully elucidate the covalent binding of 
AX towards HSA. 
 
 
 36 
Fig. 1. Interaction of AX with HSA as detected by 
immunological and MALDI-TOF MS approaches. (A) 
Structure of AX and the adduct formed with a protein 
(amoxicilloyl-protein adduct) through a non-specified 
residue. The main nucleophilic sites from the protein 
potentially able to react with the β-lactam ring of AX 
include lysine, histidine, cysteine and the amino terminal 
group. (B) Immunological detection of AX-modified HSA 
by western blot with the AO3.2 monoclonal antibody. 
HSA was incubated in the presence of increasing 
concentrations of AX under the conditions used for 
antibody generation (see methods) and analyzed by SDS-
PAGE followed by western blot and ECL detection. 
Aliquots of the incubations containing decreasing 
amounts of protein (indicated at the bottom) were loaded 
in each lane to avoid saturation of the signal. The 
Coomassie staining of the blot is shown in the lower 
panel. The protein amount of the two lanes on the right 
was close to the detection level. (C) MALDI-TOF MS 
analysis of HSA incubated with the indicated 
concentrations of AX for 16 h at 37ºC. The mass 
increment observed in every condition is indicated on the 
right. Results are representative of at least 4 assays with 
similar results 
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3.2 Materials and Methods 
 
3.2.1 Reagents 
 
Amoxicillin was from GlaxoSmithKline. Human serum was obtained from 
Sigma-Aldrich or prepared from blood samples (male healthy donors) 
collected by venipuncture and allowed to clot at room temperature for no 
longer than 30 min and centrifuged for 10 min at 1500 g. Serum aliquots 
were stored in liquid nitrogen until their use. Iodoacetamide, (D)-threo-1,4-
dimercapto-2,3-butanediol (DTT), tris(hydroxymethyl)aminomethane, 
sodium phosphate dibasic and LC-grade and analytical-grade organic 
solvents were from Sigma-Aldrich. Anti-AX monoclonal antibodies, raised 
against HSA modified in the presence of high concentrations of AX prepared 
in 50 mM Na2CO3/NaHCO3 pH 10.2, have been previously described [10]. 
Anti-penicillin antibody was from AbD Serotec. Reagents for enhanced 
chemiluminiscence (ECL) detection were from GE Healthcare. Human serum 
albumin was obtained from Sigma or purified from serum from young 
healthy donors, as previously described [16]. Custom-synthetized LQQCPF, 
HPYFYAPELLFFAK, LKCASLQK, LVNEVTEF peptides, with 90% purity 
were supplied by Sigma-Aldrich (Milan Italy). Sequence grade modified 
trypsin was obtained from Promega (Milan, Italy) and chymotrypsin from 
Roche Diagnostics S.p.A. (Monza, Italy). 
 
3.2.2 In vitro modification of synthetic HSA peptides by AX 
 
Synthetic HSA peptides containing nucleophilic sites such as LQQCPF 
(Cys34), HPYFYAPELLFFAK (His146), LKCASLQK (Lys199), and 
LVNEVTEF (ctrl) were dissolved in 10 mM PBS (pH 7.4) and diluted to 
3 Protein haptenation by amoxicillin: high resolution mass spectrometry 
analysis and identification of target proteins in serum 
38 
reach a final concentration of 150 µM. Aliquots of an AX solution in PBS pH 
7.4 were then mixed with each peptide to reach a final concentration of 14 
mM. In another set of experiments AX (14 mM final concentration) was 
incubated in the presence of the mixed peptides (150 M each peptide). After 
an overnight incubation at 37°C, an aliquot of each sample was analyzed by 
ESI-MS as described below. Stability analyses were carried out by incubating 
the AX-peptide mixtures in the presence of trypsin and/or by freezing at -20 
°C and thawing. 
 
3.2.3 In vitro modification of HSA or serum proteins by AX 
 
AX was freshly prepared in 50 mM Na2CO3/NaHCO3 pH 10.2 or 10 mM 
PBS pH 7.4, as indicated. For modification by AX, HSA at 10 mg/ml in PBS 
was incubated with AX at the indicated concentrations, for most assays the 
concentration of AX used was 0.5 mg/ml. Mixtures were incubated overnight 
at 37ºC. For modification of serum proteins, human serum was incubated 
with the indicated concentrations of AX for 16 h at 37ºC. 
 
3.2.4 SDS-PAGE electrophoresis and Western blot 
 
Samples from incubations containing 1-4 g of protein were separated in 
12.5% polyacrylamide gels. Proteins were transferred to Immobilon-P 
membranes using a three buffer system according to the manufacturer 
instructions on a semi-dry Western blot system (Bio-Rad). Proteins of 
interest were detected using various primary antibodies typically at 1:500 
dilution followed by incubation with HRP-conjugated secondary antibodies 
(Dako) at 1:2000 dilution and ECL detection. Coomassie staining of blots 
was used as a control for protein loading and transfer. 
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3.2.5 Two-dimensional electrophoresis and protein identification 
 
For two-dimensional electrophoresis, aliquots of control and AX-treated 
human serum containing 100 g of protein were precipitated with 10% TCA, 
and the pellet was washed once with 80% ethanol and twice with acetone. 
The dried pellet was resuspended in 140 l of IEF sample buffer (4% 
CHAPS, 2 M thiourea, 7 M urea, 100 mM DTT, and 0.4% Bio-lyte 
ampholytes) and loaded on ReadyStrip IPG Strips (pH 3-10, Bio-Rad) for 
isoelectric focusing on a Protean IEF cell (Bio-Rad), following the 
instructions of the manufacturer. Before the second dimension strips were 
equilibrated in 6 M urea, 2% SDS, 0.375 M Tris pH 8.8, 20% glycerol, 
containing 130 mM DTT for the first equilibration step and 135 mM 
iodoacetamide for the second step. Strips were then placed on top of 12.5% 
polyacrylamide SDS gels. Gels were run in duplicate. One of the gels was 
subsequently transferred to Immobilon P membrane (Millipore) and used for 
localization of AX-positive spots by Western blot. The duplicate gel was 
stained for total protein with Simplyblue stain (Invitrogen) or SYPRO Ruby 
(Bio Rad) and it was used for spot excising and identification. The EXQuest 
Spot Cutter (BIO-RAD) was used for gel imaging and picking the selected 
spots. Excised spots were deposited in 96-well plates and digested 
automatically using a DigestPro MS (Intavis AG). The digestion protocol 
used was based on Schevchenko et al., [17] with minor variations: gel pieces 
were washed first with 50 mM ammonium bicarbonate (Sigma-Aldrich) and 
secondly with acetonitrile (Scharlau). Trypsin (Promega), at a final 
concentration of 12.5 ng/μl in 50 mM ammonium bicarbonate solution, was 
added to the gel pieces for 8 h at 37 °C. Finally, 70% acetonitrile containing 
0.5% TFA (Sigma-Aldrich) was added for peptide extraction. Tryptic eluted 
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peptides were dried by speed-vacuum centrifugation and resuspended in 4 μl 
of 30% acetonitrile - 0.1% TFA. One μl of each peptide mixture was 
deposited onto an 800 μm AnchorChip (Bruker-Daltonics) and dried at RT. 
One μl of matrix solution (3 mg/ml α-cyano-4-hydroxycinnamic acid) in 33% 
acetonitrile - 0.1% TFA was then deposited onto the digest and allowed to 
dry at RT. Samples were analyzed with an Autoflex III TOF/TOF mass 
spectrometer (Bruker-Daltonics). Typically, 1000 scans for peptide mass 
fingerprinting (PMF) and 2000 scans for MS/MS were collected. Automated 
analysis of mass data was performed using FlexAnalysis software (Bruker-
Daltonics). Internal calibration of MALDI-TOF mass spectra was performed 
using two trypsin autolysis ions with m/z 842.510 and m/z 2211.105; for 
MALDI-MS/MS, calibrations were performed with fragment ion spectra 
obtained for the proton adducts of a peptide mixture covering the m/z 800–
3200 region. The typical error observed in mass accuracy for calibration was 
usually below 20 ppm. MALDI-MS and MS/MS data were combined 
through the BioTools 3.0 program (Bruker-Daltonics) to interrogate the 
NCBI non-redundant protein database (NCBI: 20100306) using MASCOT 
software 2.3 (Matrix Science). Relevant search parameters were set as 
follows: enzyme, trypsin; fixed modifications, carbamidomethyl (C); 
oxidation (M); 1 missed cleavage allowed; peptide tolerance, 50 ppm; 
MS/MS tolerance, 0.5 Da. Protein scores greater than 75 were considered 
significant (p<0.05). 
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3.2.6 Mass spectrometry analysis of AX-modified HSA by MALDI-TOF 
 
For MALDI-TOF MS analysis, HSA incubated in the presence of various AX 
concentrations was purified by ZipTip (C4) from Millipore as indicated by 
the manufacturer. The 2,5-Dihydroxy-acetophenone (2,5-DHAP) matrix 
solution was prepared by dissolving 7.6 mg (50 μmol)  in 375 μl ethanol 
followed by the addition of 125 μl of 80 mM diammonium hydrogen citrate 
aqueous solution. For sample preparation, 2.0 μl the sample (reconstituted in 
water) were diluted with 2.0 μl of 2% trifluoroacetic acid aqueous solution 
and 2.0 μl of matrix solution. A volume of 1.0 μl of this mixture was spotted 
onto the 800 mm AnchorChip MALDI probe (Bruker-Daltonics) and allowed 
to dry at room temperature. The MALDI experiments were performed on an 
Autoflex III MALDI-TOF-TOF instrument (Bruker Daltonics, Bremen, 
Germany) with a smartbeam laser. The spectra were acquired using a laser 
power just above the ionization threshold. Samples were analysed in the 
positive ion detection and delayed extraction linear mode. Typically, 1000 
laser shots were summed into a single mass spectrum. External calibration 
was performed, using bovine albumin from Sigma, covering the range from 
20000 to 70000 Da. 
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3.2.7 Direct infusion electrospray mass spectral analysis (ESI-MS): LTQ 
XL Orbitrap mass spectrometer 
 
Peptide analysis: peptides incubated in the absence and presence of AX as 
described above were analyzed by direct infusion on a LTQ XL Orbitrap 
mass spectrometer (Thermo Scientific, Milan, Italy) equipped with a 
Electrospray Finnigan Ion Max source. An aliquot of each sample was 
diluted 300 fold with CH3CN/H2O/HCOOH (30:70:0.1 v/v/v) for the MS 
analysis and infused into the mass spectrometer at a flow rate of  5 µL/min. 
Analyses were carried out under the following instrumental conditions: full 
scan mode, mass range m/z 200-2000, positive-ion mode, AGC target 
5x10^5, 500 ms maximum inject time, 1 microscan, scan time 1.9 s, 
resolving power 100,000 (FWHM at 400 m/z), capillary temperature 275°C , 
spray voltage applied to the needle 3.5 kV; capillary voltage 40 V ; tube lens 
voltage 100 V ; nebulizer gas (nitrogen) flow rate set 2 a.u. ; acquisition time 
0.5 min. A list of 20 common inquinants of ESI background were used for 
internal mass calibration, i.e. protonated phthlates [dibutylphthlate 
(plasticizer), m/z 279.159086; bis(2-ethylhexyl)phthalate, m/z 391.284286] 
and polydimethylcyclosiloxane ions [(Si(CH3)2O)6 + H]
+
; m/z 445.120025]. 
MS/MS experiments were performed in collision induced dissociation (CID) 
and high energy collision dissociation (HCD) modes (isolation width, 3m/z; 
normalized collision energy, 30 to 50 CID arbitrary units, 25 to 35 HCD 
arbitrary units). 
HSA infusion: Prior to infusion HSA incubated in the presence or absence of 
AX was filtered and desalted by Amicon filter devices, 30 KDa MWCO 
(Millipore S.p.A., Milan, Italy). Three different aliquots were withdrawn 
from each sample and washed using three different procedures: the first 
aliquot was washed four times with 0.3 ml of H2O, the second one twice with 
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0.3 ml H2O and twice with 0.3 ml of a 1:1 (v:v) H2O:EtOH, the third one four 
times with 1:1 (v:v) H2O:EtOH. Then the retained aliquots were dried using 
speedvac and kept frozen at -20°C until analysis.  To detect changes in 
protein mass and to determine the stoichiometry of the reaction, undigested 
native, and AX-treated HSA were analyzed by direct infusion on a linear ion 
trap LTQ Orbitrap™ XL mass spectrometer (Thermo Scientific, Milan, Italy) 
equipped with a an Electrospray Finnigan Ion Max source. An aliquot of the 
dried protein (96 µg) prepared as above described was dissolved with 10 µL 
of H2O, diluted with 200 µL of H2O and 200 µL of CH3CN/H2O/HCOOH 
(60:40:0.4 v/v/v) and infused into the mass spectrometer at a flow rate of 5 
µL/min. The linear ion trap was set under the following instrumental 
conditions: mass range m/z 800-2000, positive-ion mode, capillary 
temperature 300°C , spray voltage applied to the needle 3.5 kV; capillary 
voltage 48 V; tube lens voltage 190 V; nebulizer gas (nitrogen) flow rate set 
8 a.u.; acquisition time 5 minutes. 
 
3.2.8 Liquid chromatography electrospray ionization mass 
spectrometry/mass spectrometry analysis (LC-ESI-MS/MS): LTQ Orbitrap 
XL mass spectrometer 
 
All digested peptide mixtures were separated by online reversed-phase (RP) 
nanoscale capillary liquid chromatography (nanoLC) and analyzed by 
electrospray tandem mass spectrometry (ESI-MS/MS). For sample 
preparation, the lipohylized protein (30 µg) was dissolved in 30 µl 50 mM 
Tris-HCl (pH 7.8) and digested with trypsin and tryspin/chymotryspin 
according to the manufatcurer’s procedure. The tryptic mixtures were 
acidified with formic acid up to a final concentration of 10%. One microliter 
of tryptic digest was injected into a nano chromatographic system, UltiMate 
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3000 RSLCnano System (Dionex). The peptide mixtures were loaded on a 
fused silica reversed-phase column (PicoFritTM Column, HALO, C18, 2.7 
μm, 100 Å, 75 μm i.d. x 10 cm, New Objective). The peptides were eluted 
with a 30 min gradient from 4% buffer A (0.1% formic acid in water) to 60% 
buffer B (0.1% formic acid in acetonitrile) at a constant flow rate of 300 
nL/min. The liquid chromatography system was connected to an LTQ XL-
Orbitrap mass spectrometer (Thermo Scientific, Milan, Italy) equipped with a 
nano spray ion source (dynamic nanospray probe, Thermo Scientific, Milan, 
Italy) set as follows: spray voltage 1.7 Kv; capillary temperature 220 °C, 
capillary voltage 30 V; tube lens offset 100 V, no sheath or auxiliary gas 
flow. During analysis, the mass spectrometer continuously performed scan 
cycles in which first a high-resolution (resolving power 60000, fwhm at m/z 
400) full scan (200-1500 m/z) in profile mode was made by the Orbitrap, 
after which MS2 spectra were recorded in centroid mode for the 3 most 
intense ions, using both CID and HCD modes (isolation width, 3 m/z; 
normalized collision energy, 35 CID arbitrary units, 30 HCD arbitrary units). 
Protonated phthlates [dibutylphthlate (plasticizer), m/z 279.159086; bis(2- 
ethylhexyl)phthalate, m/z 391.284286] and polydimethylcyclosiloxane ions 
[(Si(CH3)2O)6 + H]
+
; m/z 445.120025] were used for real time internal mass 
calibration. Dynamic exclusion was enabled (repeat count, 3; repeat duration, 
10 s; exclusion list size, 50; exclusion duration, 120 s; relative exclusion 
mass width, 5 ppm). Charge state screening and monoisotopic precursor 
selection was enabled, singly and unassigned charged ions were not 
fragmented. 
Identification of the adduct-bearing peptides and the sites of modification 
was carried out by a novel MS strategy based on two different steps: the first 
step consists of the analyses of the MS/MS spectra recorded in HCD mode, in 
order to identify the precursor ions of those found to be diagnostic in this 
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work, namely, ions at m/z 160.04 and 349.08 (see Results). In more detail, a 
list of precursor ions is extracted from the parent ion map displayed by 
setting as product mass the ions at m/z 160.04 (tolerance 0.01). A second ion 
map is then generated by setting as product ion that at m/z 349.08 (tolerance 
0.01). The two lists of parent ions are then exported to Excel and analyzed 
using the following Boolean logic: if value1 > ts, value2 > ts, value$ = value1 
+ value2 or else value$ = 0, where value1, value2 are the relative abundances 
of the precursor ions setting the product ions at m/z 160 (value 1) and 349 
(value 2) and ts is the threshold relative abundance (Fig. 2). Thus, by using 
this approach, each precursor ion is confirmed only when it is present in both 
the ion maps reconstituted by setting the two diagnostic precursor ions, 
otherwise it is discarded. The second step consists in matching the precursor 
ions with a list of theoretical modified ions generated by an in silico digestion 
of albumin carried out by considering the following parameters: 
trypsin/chymotrypsin as enzymes, two missed cleavages and the addition of 
the amoxicilloyl moiety. 
 
3.2.9 Bioinformatics 
 
Direct infusion ESI-MS spectra were deconvoluted using the software 
packages Bioworks 3.1.1 (Thermo-Quest, Milan, Italy) and the software 
MagTran 1.02 [18]. Peptide sequences were identified using the software 
turboSEQUEST (Bioworks 3.1, ThermoQuest, Milan, Italy), and using a 
database containing only the protein of interest and assuming trypsin and 
trypsin/chymotrypsin digestion. The protein sequence of HSA was obtained 
from the Swiss-Prot database (primary accession number P02768). Sequence 
fragments calculator (Bioworks 3.1.1) was used to obtain the theoretical 
digested masses setting trypsin and trypsin/chymotrypsin as enzymes, all the 
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Cys residues as carbamidomethyl-cysteine and considering the oxidation of 
methionine residues and the formation of amoxicilloyl-Lys adducts as 
variable modifications. The predicted y and b series ions were determined 
using the Peptide Sequence Fragmentation Modeling, Molecular Weight 
Calculator software program (ver. 6.37), http://come.to/alchemistmatt.  
 
3.2.10 Molecular modelling 
 
The starting structure of human serum albumin was retrieved by PDB 
Database (PDB Id: 1AO6) [19]. The experimental structure was completed 
by adding the hydrogen atoms using VEGA software [20] and underwent 
preliminary minimizations keeping fixed the backbone atoms to preserve the 
experimental folding. The optimized structure was then used to predict the 
ionization constants for lysine residues using PropPka [21] and in the 
following docking simulations. AX was considered in its zwitterionic form 
and its conformational profile was explored by a clustered MonteCarlo 
simulation to generate 1000 minimized conformers. The so obtained lowest 
energy structure was used in the docking analyses.  For each identified site of 
addition, a docking search was performed using the AutoDock 4.0 software 
and considering a 12 Å sphere around the adducted lysine, which was 
considered in its neutral form. AX was docked into this grid with the 
Lamarckian algorithm and the ligand flexible bonds were left free to rotate. 
The genetic-based algorithm generated 100 poses with 2,000,000 energy 
evaluations and a maximum number of generations of 27,000. The crossover 
rate was increased to 0.8, and the number of individuals in each population to 
150. All other parameters were left at the AutoDock default settings [22]. The 
obtained complexes were ranked considering both the docking scores and the 
distance between the lysine’s amino group and the AX β-lactam carbonyl 
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group. The chosen complexes were finally minimized keeping fixed the 
atoms outside a 15 Å radius sphere around the bound substrate and then used 
to recalculate docking scores. 
 
 
 
Fig. 2. Mass spectrometric strategies employed to identify AX modified 
residues. 
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3.3 Results 
 
3.3.1 Detection of AX-HSA adducts by western blot 
 
Anti-AX antibodies have been previously used for a variety of applications. 
However, the detection of AX-protein adducts by Western blot has not been 
previously documented. To explore this possibility, we incubated HSA with 
AX concentrations close to those used to generate AX-HSA for 
immunological studies or for the generation of antibodies (1 to 100 mg/ml) 
[8-11]. Interestingly, analysis of HSA incubated with high concentrations of 
AX by western blot with an anti-AX antibody, previously used for ELISA 
(AO3.2), showed a clear immunoreactive signal. Moreover, an increase in the 
apparent molecular weight of the HSA band was observed, as expected from 
the increment of mass produced by the incorporation of several AX 
molecules. In addition, higher molecular weight species appeared suggestive 
of the formation of HSA aggregates during incubation with the antibiotic. As 
a control for this assay, AX-modified HSA samples were analysed by 
MALDI-TOF MS. Incubation of HSA in the presence of increasing 
concentrations of AX induced a concentration-dependent increase in the mass 
of the protein as detected by MALDI-TOF MS (Fig. 1). A displacement of 
the centroid of the HSA peak was evident even with the lowest concentration 
of AX tested (0.5 mg/ml). In the spectrum of HSA treated with 5 mg/ml of 
AX, two poorly defined peaks could be observed showing m/z increments of 
830 and 1476 with respect to the native protein, compatible with the 
incorporation of 2 and 4 molecules of AX, respectively. Finally, the spectrum 
of HSA treated with 10 mg/ml AX, conditions which are close to those 
routinely used for obtaining the AX-HSA complex for immunological 
applications, showed a major peak with at 68220.4, representing a m/z 
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increment of approximately 1813.6 with respect to control HSA. This 
increment could be due to the incorporation of up to five AX molecules 
and/or to the occurrence of other modifications in the HSA molecule during 
incubation in the presence of the -lactam, as suggested by the western blot 
assay (Fig. 1).  
 
3.3.2 Immunological detection of AX-modified HSA with various anti--
lactam antibodies 
 
In previous works several monoclonal antibodies were obtained using HSA 
treated with high concentrations of AX as immunogen [10]. Competition 
studies with various moieties of the AX molecule in ELISA indicated that the 
antibodies obtained were directed towards different parts of the molecule. 
Therefore, we assessed the ability of several of these monoclonal antibodies 
to detect AX-modified HSA by western blot. As it can be observed in Fig. 3, 
two monoclonal antibodies, AO3.2 and AO19.1, effectively detected the AX-
HSA adduct. The AO3.2 antibody, which recognizes the lateral chain plus a 
part of the nuclear region of AX, allowed the detection of an immunoreactive 
signal above the background even after incubation of HSA in the presence of 
0.025 mg/ml AX, which is in the range of the concentrations expected to 
occur in vivo [12, 13] and indicates that this procedure shows high 
sensitivity. The AO19.1 antibody, which recognizes the lateral chain plus the 
open -lactam ring, also gave a positive signal although it showed less 
sensitivity. In contrast, several monoclonal antibodies reportedly recognizing 
the lateral chain of AX (with a -lactam ring absent or open), including 
AO24.1 (Fig. 3), AO14.1 and AO18.2 (results not shown), gave no signal in 
this assay, although they previously showed immunoreactivity in direct and 
inhibition ELISA [10] using exhaustively modified protein as antigen. 
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Finally, we used a commercial anti-penicillin antibody for comparison. This 
antibody showed much lower sensitivity towards AX-modified HSA than the 
AO3.2 antibody and, used at the same concentration, only detected HSA 
modified by high concentrations of AX after long exposures. 
 
3.3.3 Detection of AX candidate target proteins in human serum 
 
HSA is the most abundant protein in human plasma and therefore it is 
considered the main target for protein haptenation. However, as binding of 
haptens to proteins depends on their structure, other plasma proteins may 
result covalently modified by AX to a significant proportion and therefore, 
may also be good candidates for mediating the immunological reactions 
towards this antibiotic. To assess this possibility we incubated human serum 
with AX and applied immunological detection. This allowed the observation 
of multiple positive bands, even with the lowest concentration of amoxicillin 
used (Fig. 4). In order to get insight into the nature of these proteins we 
carried out two-dimensional electrophoresis followed by peptide fingerprint 
analysis by tryptic digestion and MALDI-TOF MS (Fig. 4, Table 1). Protein 
identification was confirmed by MALDI-TOF-TOF MS/MS analysis of 
selected peptides from every protein. Identified proteins included HSA, 
several forms of transferrin, and heavy and light immunoglobulin chains. In 
contrast, other abundant proteins, like apolipoprotein or haptoglobin were 
negative in this assay. It should be noted that according to the signal given by 
the antibody, the relative modification of transferrin under these conditions 
was more extensive than that of HSA, thus suggesting that this and other 
serum protein(s) may play an important role in AX-induced reactions. Of 
particular interest is the modification of immunoglobulins, which could have 
functional consequences related to the immune response. 
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Tab. 1: Protein identification by MALDI TOF/TOF and LTQ mass spectrometers 
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Fig. 3. Immunological detection of AX-modified HSA by western blot with 
various antibodies. HSA was incubated in the presence of increasing 
concentrations of AX. Aliquots of the incubations containing 2 µg of protein 
were analyzed by SDS-PAGE followed by western blot with the indicated 
antibodies and ECL detection. In panel B, the times of exposure of films for 
signal detection is indicated on the right. Results are representative of four 
assays. Panels underneath each blot show the corresponding Commassie 
staining. 
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Fig. 4. Immunological detection of adducts of AX and serum proteins and 
identification of targets. (A) Human serum or HSA was incubated with the 
indicated concentrations of AX for 16 h at 37ºC and analyzed by western 
blot. AX-modified proteins were detected with the AO3.2 antibody. Lower 
panel shows the Coomassie staining of the blot. (B) Samples of serum 
incubated in the absence or presence of 0.5 mg/ml AX were subjected to 2D-
electrophoresis on duplicate gels, after which, one of the gels was used for 
detection of modified proteins by western blot and the other one was used for 
protein staining with Coomassie staining. Matched spots were excised from 
the gel and used for tryptic digestion and peptide fingerprint analysis. Results 
are representative of multiple assays. 
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3.3.4 AX reaction with His, Lys and Cys containing peptides from HSA 
 
As reported above, HSA is the main plasma protein target of AX, and for this 
reason, we undertook a detailed characterization of the AX-HSA interaction, 
including the elucidation of the reactivity and the reaction mechanism, and 
identifying and characterizing the reaction products of AX towards the main 
nucleophilic sites of HSA potentially able to covalently react with the -
lactam ring, namely Lys, Cys, and His residues and the amino terminal 
group. As a first approach to achieve a detailed characterization of AX-HSA 
adducts, peptides containing the most reactive HSA nucleophilic residues, as 
determined by previous studies [16], were used for the in vitro reactions and 
in particular: Lys199 (
198
LKCASLQK
205
), His146 
(
146
HPYFYAPELLFFAK
159
), Cys34 (
31
LQQCPF
36
).  
The reactivity of the amino terminal group was tested by considering 
42
LVNEVTEF
49
 as model peptide, since it does not contain any nucleophilic 
amino acid residue. The MS spectra of each peptide incubated in the absence 
of AX showed the corresponding [M+H]
+
 and [M+2H]
2+
 ions (data not 
shown). When AX was added at a 1:90 molar ratio and incubated for 18 
hours, all the adduct-bearing peptides were characterized by an increase of 
365.10454 Da, compatible with the addition of the amoxicilloyl moiety 
(empirical formula C16H19N3O5S), with respect to the native forms and they 
were easily determined in the case of peptides containing Lys199, His146 
and to a lesser extent (<0.5% relative abundance), but still detectable, for the 
peptide LVNEVTEF and that containing Cys34 (Fig. 5). If we consider that 
the amoxicilloyl modification impacts the response factors of the adducts to a 
similar extent, the relative abundance of the adducts can be considered as a 
good index of the chemical reactivity of the peptide towards AX. The relative 
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abundances of the adduct-bearing with respect to the native peptides were 
found to be different: the Lys199-containing peptide was the most reactive 
(12%) followed by the His146-containing peptide (3%), while LVNEVTEF 
and the Cys34-containing peptide were modified to a negligible extent 
(<0.5%). The modification site of each peptide was then identified by 
MS/MS experiments. The peptide 
198
LKCASLQK
205
 contains three potential 
nucleophilic sites: Lys199, the C-terminal Lys205 and the amino terminal 
group. MS/MS fragmentation pathway of the native peptide was carried out 
by selecting the [M+2H]
2+
 as precursor ion at m/z 445.76 Da. The peptide 
sequence agrees well with the y and b ions series as determined by MS/MS 
experiments carried out in CID and HCD modes (data not shown). The 
fragmentation of the amoxicilloyl-peptide adduct was then analyzed by 
selecting the [M+2H]
2+
 ion at m/z 628.31 (365.1 Da increase) as precursor 
ion (Fig. 6). The MS/MS fragment ions as detected in CID mode show an 
unmodified y ion series from y2 to y6, excluding the formation of an 
amoxicilloyl-Lys205 adduct and this is well explained by considering that the 
amino group forms a salt bridge with the carboxyl group; by contrast the b-
ion series (from b2 to b7) increased by 365.1 Da although their relative 
abundance is very low, excluding the amino terminal involvement and 
confirming Lys199 as main site for adduct formation. As a further 
confirmation, the y ion series was found to be modified from y7 to y8 (see the 
abundant ion at m/z 619.8 relative to y8
*++
-NH3). By comparing the MS/MS 
spectrum of the adducted with respect to the native peptide, several other 
abundant fragment ions were observed and in particular the ion at m/z 553.78 
(base peak) which can be attributed to the y8
*2+
 ion adducted by the 
amoxicilloyl moiety with the loss of the 4-hydroxybenzylamine group (M1 
ion series). Two other diagnostic abundant ions were then observed at m/z 
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548.79 and 540.28 which were assigned to the y8
*2+
 and y8
*2+
-NH3 of the 
amoxicilloyl group with the loss of the thiazolidinic group (M2 ion series).  
As shown in Fig. 6, the main differences between the MS/MS spectra of the 
adducted peptide recorded in CID and HCD is that the spectrum recorded in 
the latter mode is characterized by the presence of the ions at m/z 160.04222 
(AX1) and 349.08467 (AX2), corresponding to the thiazolidinic moiety of AX 
and to AX minus the aminic residue, respectively. 
The 
146
HPYFYAPELLFFAK
159
 peptide contains three potential nucleophilic 
residues, the amino terminal group, His146 and the C-terminal Lys159, 
although the latter should be excluded since it forms a salt bridge with the 
terminal carboxyl group as reported above. The MS/MS spectrum recorded in 
CID mode shows the unmodified y ion series from y4 to y13 as well as the b 
ion series from b5 to b13 to indicate that the modification is unstable and is 
lost during the collision. No diagnostic y and b fragment ions of the AX-
adducted peptide were found (M0 series). The comparison of the MS spectra 
of the native and adducted peptides indicates that the latter is characterized 
by intense ions at m/z 980.47 and 975.48 relative to the y14
2+
 of the M1 and 
M2 series, accompanied by the corresponding –NH3 ions. HCD spectrum 
shows a similar fragmentation pattern and in contrast to that observed for 
Lys199 no ions relative to the thiazolidinic ring of AX or to AX minus the 
aminic residue of the R group were detected (data not shown). 
Taken together, these data indicate that among the nucleophilic sites present 
in HSA and potentially able to covalently react with the -lactam ring, lysine 
residues are the most reactive sites towards AX and that the amoxicilloyl 
adduct represents the main reaction product. It should be noted that the order 
of reactivity as determined using HSA peptides takes into account only the 
intrinsic reactivity of the nucleophilic amino acid as well as the effect of the 
vicinal amino acids, while it does not consider other parameters related to the 
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arrangement of the amino acid in the three-dimensional protein structure 
which can increase or reduce the reactivity, for example surface exposure or 
the presence of surrounding residues that can affect the nucleophilicity of the 
residues. The determined reactivity appears to be roughly proportional to the 
basicity of the nucleophilic site. This result is in line with other reported 
studies and confirms the key role of general acid catalysis exerted by the 
protonated amine to promote the breakdown of the tetrahedral intermediate 
by donating a proton to the -lactam nitrogen atom [23]. The unexpected lack 
of reactivity of the cysteine residue, which is in contrast with several studies 
reporting the thiolysis of penicillins [24], could be justified by considering 
the effect of the protonated amine which attracts the reactive thiolate function 
hampering its proper attach to the β-lactam carbonyl group.  
From an analytical point of view we found that the fragmentation patterns of 
the adduct-bearing peptides differ on the basis of the modified amino acid. In 
the case of Lys, both CD and HCD are characterized by diagnostic y and b 
fragment ions bearing fragmented AX and in particular the AX moiety 
arising by the loss of the 4-hydroxybenzylamine group (M1 ion series) and 
the thiazolidine ring (M2 ion series). Moreover, HCD but not CID spectra are 
characterized by the cleaved thiazolidine ring at m/z 160 and by the fragment 
at m/z 349.08 arising from the cleavage of the AX moiety and concomitant 
loss of the amino group.  
We then evaluated the effect of trypsin incubation as well as sample freezing-
thawing (both procedures used for the bottom-up analysis of the HSA sites 
modified by AX, vide infra) on the stability of the AX-peptide adducts. 
Trypsin digestion, freezing-thawing, as well as both the procedures did not 
affect the stability of adducts since the relative abundances were unchanged 
with respect to control samples before and after sample treatment. 
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Fig. 5. In vitro modification of HSA peptides by AX. Deconvoluted MS 
spectra obtained by ESI-MS direct infusion experiments of HSA peptides 
incubated overnight at 37°C with AX. See material and methods for 
experimental details. Native and AX-modified peptides are labeled in each 
spectrum. 
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Fig. 6. ESI-MS/MS spectra and fragmentation pathway of the AX-modified 
peptide LK#CASLQK. Panels (a) and (b) show the ESI-MS/MS spectrum 
recorded in CID mode and with a mass range 250-1100 m/z and 530-640, 
respectively. Panel (c) shows the ESI-MS/MS spectrum recorded in HCD 
mode. In the upper part is shown the fragmentation pathway of the adducted 
peptide LKCASLQK leading to the M0, M1 and M2 ion series as well as the 
two diagnostic fragment ions at m/z 160 and 349 generated in HCD mode. 
 
3.3.5 AX reaction with HSA: top-down experiments 
 
A summary of the MS strategy used to characterize the AX-HSA adduct, 
including top-down and bottom-up approaches is shown in Fig. 2. The ability 
of AX to covalently react with HSA and the stoichiometry of the reaction 
were firstly evaluated by top-down experiments, consisting of directly 
infusing the AX-HSA reaction mixture. Fig. 7, panel (a) shows the 
deconvoluted MS spectrum of HSA incubated in absence of AX, which is 
characterized by the main peak at 66439 Da relative to the mercaptoalbumin 
and by two minor peaks at 66559 Da (+120 Da) and 66603 Da (+164 Da) 
which are attributed to the cysteinylated and glycated forms, respectively, as 
previously reported [16]. Fig. 7 panels (b) and (c) show the deconvoluted MS 
spectra of HSA incubated at pH 7.4 for 18 hours in the presence of AX at a 
molar ratio HSA:AX 1:9 (AX 0.5 mg/ml) and 1:90 (AX 5 mg/ml), 
respectively. When HSA was incubated with the lowest concentration of AX, 
an easily detectable single adduct at 66804 Da was observed, shifted by 365 
Da with respect to mercaptoalbumin and referred to as the amoxicilloyl 
derivative. This adduct represented 20% of the native protein. By increasing 
AX concentration to 5 mg/ml, the relative abundance of the three native 
isoforms of albumin was drastically reduced and three main HSA adducts 
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appeared at 66804, 67169 and 67534 Da, shifted by 365, 730 and 1095 Da, 
respectively, with regard to the native forms, which can be attributed to AX-
HSA adducts with the following stoichiometric ratios: 1:1, 1:2; 1:3 (Fig. 7 
panel c). The cysteinylated and glycated HSA forms were also found to be 
modified to a similar extent than mercaptoalbumin, thus indicating that 
Cys34 (the site of cysteinylation) as well as Lys525 (the main glycation site) 
are not involved in the reaction with AX. It should be underlined that all 
samples were washed several times with an EtOH:H2O mixture before MS 
analysis, until the relative abundances of the adducts were constant. This 
procedure was adopted in order to remove non-covalent protein-AX adducts 
that could be maintained in the gas-phase, although the sample is sprayed 
under denaturing conditions. In fact, when HSA was incubated with AX at a 
molar ratio of 1:9 and injected after a washing step carried out only with 
water, apart from mono-adduct, adducts with stoichiometric ratios 1:2 and 
1:3 were observed due to the presence of non-covalent interactions which 
disappeared upon extensive washing with the EtOH:H2O mixture (data not 
shown).  
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Fig. 7. Top-down approach for characterization of HSA modification by AX. 
Deconvoluted MS spectra of HSA incubated in the presence of AX. 
Deconvoluted MS spectra recorded by direct infusion experiments of HSA 
incubated in absence (a) and presence of 0.5 mg/ml (b) and 5 mg/ml (c) of 
AX. Mercaptoalbumin isoform is at 66439 (peak A). The peaks A1B, A2B, 
A3B and A4B are referred to the HSA:AX adducts at the following 
stoichiometric ratio: 1:1, 1:2, 1:3, 1:4. 
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3.3.6 Identification of the HSA sites modified by amoxicillin: bottom-up 
experiment 
 
Identification of the HSA sites modified by the amoxicilloyl residue was 
carried out by a bottom-up approach using trypsin and trypsin plus 
chymotrypsin for protein digestion (Fig. 2). Double digestion with trypsin 
plus chymotryspin was used since the modified Lys residues are not 
recognized by trypsin and this would increase the MW and the length of the 
adduct-bearing peptides to values not suitable for the LC-ESI-MS analysis. 
The protein coverages of both native and AX-modified HSA were always 
higher than 90% and 85% for trypsin and trypsin/chymotrypsin digestions, 
respectively (see Fig. 8). It should be noted that the most reactive Lys 
residues as reported in the literature and predicted by molecular modelling 
studies were covered. 
The first attempt to identify the AX-modified peptides and the corresponding 
sites of modification was based on the Sequest algorithm search by setting 
the amoxicilloyl modification (+365 Da) as a variable modification on Lys, 
His, Cys and Ser. Such an automatic approach is of great value for the 
identification of the amino acids covalently modified by different xenobiotics 
as well as by post-translational modifications. However, this approach was 
not suitable to identify the AX-modified peptides and this can be clearly 
explained by considering the typical MS/MS pathways of the AX-peptide 
adducts, which are characterized, as reported above, by the cleavage of the 
amoxicilloyl moieties, leading to the formation of unpredictable y and b ion 
series. 
The MS approach was then optimized on the basis of the fragmentation 
pathway of the peptides adducted on the Lys residue as described above and 
summarized in Fig. 2. As shown above, using model peptides we found that 
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the MS/MS spectra of the AX-Lys adducts recorded in HCD mode are 
characterized, besides by the y and b fragment ions, by the cleaved 
thiazolidine ring at m/z 160 and by the fragment at m/z 349.08, which arises 
from the cleavage of the amoxicilloyl moiety and the concomitant loss of the 
amino group. Therefore, such specific and diagnostic fragments were then set 
as product ions to generate the maps of precursor ions. The ion map relative 
to the sample of HSA incubated in presence of AX at the higher molar ratio 
(1:90) reported 11 precursor ions and 8 of them were attributed to 6 adducted 
peptides which were reduced to 3 peptides (five precursor ions) at the lowest 
molar ratio, as reported in Table 2. The method was found highly specific 
since no precursor-ions were detected in the control sample. To further 
confirm that the precursor ions are referred to the adducted peptides, SIC 
traces were then reconstituted for each of them by setting a 5 ppm tolerance. 
A well detectable peak was identified for each of the precursor ions selected 
and whose area dose dependently increased by increasing AX concentration 
in the reaction mixture, while it was absent in the control.  
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Sequence coverage obtained by using chymotrypsin/trypsin digestion= 86% 
 
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEV
TEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCA
KQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKY
LYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDEL
RDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEV
SKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKEC
CEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDV
FLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYA
KVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQV
STPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLH
EKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHAD
ICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCC
KADDKETCFAEEGKKLVAASQAALGL  
 
Sequence coverage obtained by using trypsin digestion= 91% 
 
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEV
TEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCA
KQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKY
LYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDEL
RDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEV
SKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKEC
CEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDV
FLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYA
KVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQV
STPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLH
EKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHAD
ICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCC
KADDKETCFAEEGKKLVAASQAALGL 
 
Fig. 8. Sequence coverage of native HSA after chymotrypsin/trypsin (upper 
sequence) and trypsin (bottom sequence) digestion and LC-MS/MS analyses. 
The covered sequence is highlighted in yellow and the amoxicillin adducted 
peptides are underlined. 
  
3 Protein haptenation by amoxicillin: high resolution mass spectrometry 
analysis and identification of target proteins in serum 
66 
 
3.3.6.1 Identification of the sites modified by AX in purified HSA 
 
By matching the precursor ions with a list of theoretical adducted ions, 8 
precursor ions, relative to 6 adducted peptides, were identified and the 
sequence as well as the sites of adduct formation were then determined by 
analysing the MS/MS spectrum and attributing the y and b ions. In particular, 
Lys190, 199, 351, 432, 541 and 545 were found adducted when purified HSA 
was incubated with AX at 5 mg/ml and Lys 190, 199 and 541 when 
incubated in the presence of AX at 0.5 mg/ml (Table 2).  
As an example of peptide matching and identification of the modified site, 
here below is described the approach we used to identify Lys 541 as 
adduction site. The ion map and Boolean logic identified two multi-charged 
precursor ions at m/z 591.79474 and m/z 394.86562 referred to the z=2 and 
z=3 of the adducted peptide. The SIC ion trace relative to the sample 
incubated with 0.5 mg of AX was characterized by a well detectable peak at 
RT of 8 min and whose area increased by almost ten-fold in the presence of 5 
mg of AX and was absent in the control sample (Fig. 9). Matching such 
precursor ions with a list of theoretical AX-modified precursor ions, 
permitted to identify the peptide with the sequence 
539
ATK#EQLK
545
 and 
whose identity and the site of modification were determined by analyzing the 
MS/MS spectrum as reported in Fig. 9. 
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Fig. 9. Bottom-up approach for the study of HSA modification by AX showing the identification of the adduct at Lys541. 
Panel A: SIC ion traces reconstituted by setting the ion at m/z 591.79474 relative to the z=2 of the adducted peptide 
539
ATK#EQLK
545
 as filter ion. SICs are referred to HSA incubated in absence, and presence of AX 0.5 mg/ml and 5 
mg/ml. Panels B and C show the MS/MS spectra of the adducted peptide 
539
ATK#EQLK
545 
in CID and HCD mode, 
respectively. 
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3.3.6.2 Identification of the sites modified by AX in HSA in complete human 
serum 
 
We then analysed the AX-HSA adducts formed when complete human serum 
was incubated in the presence of the antibiotic. For this, after incubation, 
HSA was purified as described in Methods and subjected both to 
immunological detection of the modification and to proteomic analysis 
following the same approach described above. In general, adducts identified 
when using isolated HSA were confirmed in these experiments. In particular, 
when serum was incubated with AX at 5 mg/ml, the following HSA Lys 
residues were found to be modified by AX: Lys 190, 199, 351, 432, 541 and 
545. At 0.5 mg/ml AX, a slight difference in the modification sites was 
observed with respect to the experiments carried out with purified HSA, since 
Lys 190 and Lys 432 but not Lys199 or Lys541 were found to be modified.   
 
3.3.7 Peptide consumption 
 
The relative consumption of the peptides undergoing AX modifications were 
determined as here below reported and compared to that calculated for 
peptides not covalently modified. The ion responses of the selected peptides 
were determined by measuring the peak areas in the selected ion 
chromatograms (SICs) reconstituted by using the [M+nH]
n
+ as filter ions. 
The peptide responses were normalized with respect to peptide 
LVAASQAALGL, chosen as reference peptide because it does not contain 
nucleophilic residues and hence represents an off-target of AX. Relative 
consumption of the adducted peptides in AX-treated HSA with respect to 
native HSA was determined by using the following equation: peptide 
consumption (%)=100-[(A-AX)/(A-native)*100] where A-AX and A-native 
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are the normalized peptide ion response of the target peptide from HSA 
incubated in the presence and absence of AX, respectively.  
As shown in Table 3 the peptides containing the Lys residues modified by 
AX and in particular P18-19 (Lys190), P21-22 (Lys 199), P39 (Lys 351), P60 
(Lys 541) and P61 (Lys 545) were found to be concentration-dependently 
consumed. In particular, when AX was added at 0.5 mg/ml the peptide P18-
19 underwent the highest consumption (85%), followed by P21-22 (54%). By 
considering the peptide consumption as an index of reactivity the following 
rank can be drawn: Lys 190 > Lys 199 > Lys 541  Lys 351 > Lys 545. The 
consumption of the native peptide containing Lys 432 (
429
NLGK
432
) was not 
determined because it was not covered due to its small length. The method 
was then validated by calculating the peptide consumption of four peptides 
containing Lys residues but not undergoing AX adduction as determined by 
MS studies (negative controls). As summarized in Table 3, the consumption 
of the peptides considered as negative controls at either of the two AX 
concentrations was well below 20%, a value selected as the threshold level. 
At the highest AX concentration (5 mg/ml), the consumption of other 
peptides, namely, those containing Lys12, Lys73, Lys402 and Lys525, was 
higher than the threshold level. However, as the corresponding AX adducts 
were not found by either the precursor ion scanning approach or the manual 
search, their modification cannot be confirmed 
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Tab. 2: Matched precursor ions by means of bottom up experiments 
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Tab. 3: Peptides consumption for the peptides undergoing modification by 
AX and for four selected peptides not modified by AX and considered as 
negative control. Lys 190 containing peptide (P18-P19) is the most reactive, 
followed by Lys 190 containing peptide (P21-P22). 
 
3.3.8 Molecular modelling 
 
With a view to rationalizing in-depth the reactivity of the adducted lysine 
residues, molecular modelling studies were performed investigating the 
intrinsic reactivity of albumin Lys residues as well as the specific recognition 
between AX and the regions surrounding the modified residues. Analysis of 
some relevant physicochemical properties of all HSA Lys residues indicated 
that the reactivity of the modified Lys residues can be rationalized in terms of 
exposure and abundance of neutral form (Table 4). In particular, the 
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comparison of all the 58 Lys residues of HSA emphasizes that the adducted 
Lys residues are characterized either by a very low basicity which render 
them extremely reactive regardless of their accessibility (as in the case of 
Lys190 and Lys 199), or by a significant accessibility which markedly 
facilitates their approach by AX (as seen for Lys351, Lys541 and Lys545). 
Yet again, Table 4 evidences that the adducted residues are surrounded by 
other positively charged residues whose abundance appears in line with the 
reported reactivity. This finding has two explanations. First, positively 
charged residues contribute to low basicity of the adducted lysine; second, 
they can act as general acid catalysts breaking down the tetrahedral 
intermediates. 
Furthermore, docking simulations were utilized to investigate whether the 
region surrounding the adducted Lys residues can stabilize convenient 
complexes with AX so further promoting adduct formation. Firstly, it should 
be noted that the docking scores for the minimized complexes are in 
agreement with the reported reactivity thus suggesting that the capacity to 
suitably harbour AX is another key factor which influences the reactivity of 
Lys towards AX for adduct formation. As an example, Fig. 10 illustrates the 
minimized complexes showing the interactions stabilizing AX in the 
proximity of Lys190 (Fig. 10A) and Lys199 (Fig. 10B), two residues that are 
modified under all experimental conditions used in this study. It is worth 
noting that in both complexes the adducted lysine is clearly close to the β-
lactam carbonyl carbon atom with an arrangement favourable for adduct 
formation. In both cases, the β-lactam carbonyl oxygen atom elicits a H-bond 
(with Arg186 for Lys190 and with His242 for Lys199) which polarizes the 
carbonyl group favouring the aminolysis and mimicking the effect of the 
oxyanion hole of hydrolases. Moreover, Fig. 10A and 10B show that the AX 
ionizable groups are always involved in salt bridges (with Arg186 and 
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Glu425 for Lys190 and with with Arg257 and Glu292 for Lys199) which 
play a pivotal stabilizing role and should minimize electrostatic interferences 
with adduct formation. Additional polar interactions involving the AX phenol 
ring characterize both complexes, which are also stabilized by apolar contacts 
between the dimethyl thiazolidinic ring and surrounding aliphatic residues. 
Beside the conducive distance between the adducted lysine and the β-lactam 
ring, all AX complexes obtained for the other reactive sites  share similar salt 
bridges involving at least the AX carboxylate group, thus suggesting a third 
role for the basic residues surrounding the adducted lysine, namely attracting 
the AX negative center to reduce its interference with adduct formation 
 
 
 
Fig. 10. Main interactions stabilizing the AX molecule in the proximity of the 
target residues. The residues potentially establishing interactions with AX in 
the region surrounding Lys190 (A) and Lys199 (B) are shown. 
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Table 4: Physicochemical descriptors for the 58 
lysine residues of serum albumin 
Lysine pK 
SAS 
(Å
3
) Lys/Arg Score 
12 10.58 138.8 1 ---- 
20 10.5 138.8 2 ---- 
41 11.15 110.1 1 ---- 
51 10.74 102.9 1 ---- 
64 10.45 72.2 0 ---- 
73 10.82 53 1 ---- 
93 10.36 96.1 1 ---- 
106 7.36 17.6 0 ---- 
136 9.68 45.6 2 ---- 
137 10.51 103.5 1 ---- 
159 10.87 87.6 2 ---- 
162 10.62 81.1 2 ---- 
174 11.24 67.9 0 ---- 
181 10.62 69.7 1 ---- 
190 8.71 63.3 3 -9.92 
195 9.99 88.4 3 ---- 
199 6.78 27 3 -10.42 
205 10.5 148.9 2 ---- 
212 10.67 78.3 1 ---- 
225 10.94 99.1 2 ---- 
233 11.17 87.5 0 ---- 
240 10.93 123.8 0 ---- 
262 10.83 127.9 2 ---- 
274 11.12 48 2 ---- 
276 10.73 132.4 1 ---- 
281 10.4 107.4 1 ---- 
286 10.09 43.8 2 ---- 
313 10.51 171.9 1 ---- 
317 11.45 163.1 1 ---- 
323 10.62 103.3 1 ---- 
351 9.86 116.3 2 -7.20 
359 10.41 169.4 0 ---- 
372 10.62 136.8 2 ---- 
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Lysine 
 
pK 
 
SAS 
(Å
3
) 
 
Lys/Arg 
 
Score 
378 10.7 138.2 2 ---- 
389 10.46 130.5 1 ---- 
402 10.44 117.3 1 ---- 
413 9.5 45.3 4 ---- 
414 8.47 10.6 4 ---- 
432 9.24 53 3 ---- 
436 9.5 99.2 4 ---- 
439 10.5 201.7 2 ---- 
444 10.34 116.8 1 ---- 
466 10.88 102.9 1 ---- 
475 10.39 129.7 0 ---- 
500 10.43 159.9 1 ---- 
519 10.5 122.9 1 ---- 
524 10.27 99.7 5 ---- 
525 9.96 11.2 3 ---- 
534 9.16 21.5 2 ---- 
536 9.51 36.4 2 ---- 
538 11.51 214.3 2 ---- 
541 10.03 181.9 3 -8.26 
545 10.12 110.1 2 -7.53 
557 10.47 131.3 2 ---- 
560 10.54 172.4 1 ---- 
564 10.47 194.2 1 ---- 
573 10.42 141.7 0 ---- 
574 10.48 173.9 1 ---- 
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3.4 Discussion 
 
Drug allergy constitutes an important clinical problem the molecular basis of 
which is not fully understood. AX is among the drugs most frequently 
eliciting allergic reactions. Untangling the mechanisms underlying allergy to 
-lactam antibiotics will require multidisciplinary approaches. Here we have 
set up an in vitro model that may shed light into the process of protein 
haptenation. Our results show that HSA can be modified in vitro by 
concentrations of AX in the range of those expected to occur in vivo. 
Moreover, we have detected this modification by high resolution MS, 
proteomic and immunological methods with high sensitivity. Using these 
approaches we have identified other potential candidates for protein 
haptenation in human serum. Moreover, we have highlighted the structural 
features of the protein and of the antibiotic that would be important for the 
interaction. These findings may help to design and interpret in vivo studies 
addressing the mechanisms of drug allergy. 
Immunological methods have been previously used to detect adducts of 
proteins and -lactam antibiotics [25], and HSA and transferrin were 
identified as target proteins for binding of ampicillin [26]. Our results show 
that, in addition to these major targets, other serum proteins are modified by 
AX. Therefore, the potential involvement of these newly identified adducts in 
the immune response to AX deserves further study. In particular, 
modification of immunoglobulins by AX will surely need to be taken into 
account in the context of the immune response. In addition, covalent AX 
binding to serum proteins including immunoglobulins will need to be 
considered for the interpretation of the results of immunoassays aimed at 
detecting anti-AX antibodies in patients. 
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Importantly, it is clear that the extent of AX addition is protein-specific. 
Transferrin appears to be modified by AX in a high proportion, which, taking 
into account the plasma concentration of this protein, could represent a 
modification 10-fold higher than that of HSA. Therefore, although HSA is 
the most abundant protein in serum, contribution of adducts of AX with other 
proteins may play an important role as providers of haptens. Interestingly, 
other relatively abundant serum proteins do not form detectable adducts 
under our experimental conditions. Therefore, factors other from protein 
abundance may influence AX binding. 
In the early works by Yvon and co-workers, six major penicilloyl binding 
sites were identified in HSA, namely Lys 190, 195, 199, 432, 541 and 545 [2, 
3]. Recently, using proteomic approaches, the formation of adducts between 
HSA and flucloxacillin, piperacillin and benzypenicillin has been 
characterized [4-6]. In this case, the MS approach applied consisted of 
generating multiple reaction monitoring (MRM) transitions, specific for drug-
modified peptides by selecting the m/z values calculated for all the possible 
peptides with a missed cleavage at a Lys residue plus specific fragments such 
as that at m/z 160 attributed to the cleaved thiazolidine ring, combined with 
MS/MS sequencing of the identified peptides. Interestingly, the nature of the 
residues modified appears to vary widely between subjects, and adducts with 
residues Lys190, 195, 432 and 541 have been detected in the plasma of 
patients treated with piperacillin, whereas multiple adduct-bearing peptides 
have been detected in patients treated with benzylpenicillin or flucloxacillin. 
Under our experimental conditions, both covalent and non-covalent modes of 
interaction of AX with HSA were detected, the latter being evidenced by 
their reversal by extensive washing of AX-incubated HSA. Our data indicate 
that the covalent coupling takes place by amide bond formation between 
primary amines from Lys residues and the carboxylic group from the -
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lactam ring, to afford the amoxicilloyl moiety. This is in agreement with what 
has been described for other -lactams and it is also supported by data from 
the NMR characterization of an AX-butylamine complex (Montañez, M.I., 
personal communication). The major sites for addition of AX at low 
concentrations in isolated HSA were Lys 190, 199 and 541. Modelling 
studies were able to rationalize the marked reactivity of the targeted Lys 
residues confirming that their reactivity can be vastly influenced by the 
surrounding microenvironment and that residue accessibility, albeit relevant, 
cannot be seen as the sole factor governing the reactivity. The 
microenvironment can enhance the intrinsic reactivity of the Lys residues and 
it can contribute to the binding of AX through a sort of recognition process 
which can stably constrain AX in a pose conducive to adduct formation thus 
explaining the fine selectivity of the modification sites. Nevertheless, at high 
AX concentrations other sites of modification were found. Moreover, the 
modification of other residues in vivo cannot be excluded. Indeed, we noted 
that the main HSA sites modified by low AX concentrations when incubation 
was carried out in complete serum were Lys190 and Lys 432. The differences 
found in the residues modified by AX depending on the incubation 
conditions, either purified HSA or complete serum, suggest that the protein 
context may influence the nature of the adducts formed. This raises the 
possibility that changes in serum composition occurring in 
pathophysiological situations may influence protein haptenation. It should be 
noted that -lactam-peptide adducts will be formed both in non-allergic 
subjects and in subjects developing allergic reactions, the factors determining 
the development of allergy not being currently understood.  
The so-called danger signals are thought to play an important role in allergic 
reactions. It has been shown that sulfamethoxazole forms adducts with 
proteins in antigen presenting cells and that the amount of adducts formed 
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increases when cells are exposed to bacterial endotoxin, cytokines or a 
variety of inflammatory or stress-inducing stimuli [27]. This underlines the 
importance of concomitant factors for protein haptenation. It is known that 
HSA is the target of various modifications by reactive lipids generated under 
situations of inflammation or oxidative stress, including 4-hydroxy-2-nonenal 
and cyclopentenone prostaglandins [16, 28, 29]. Moreover, HSA is sensitive 
to various oxidative modifications [30]. It has been reported that HSA 
modification may drastically alter its binding properties and even its 
immunogenic and proinflammatory potential [31]. In preliminary 
experiments we have observed that pretreatment of HSA in vitro in the 
presence of certain oxidative agents alters its modification by amoxicillin, as 
evidenced by immunological detection (Ruiz-Abánades et al., unpublished 
observations). Further studies are needed to assess the biochemical basis of 
these effects.  
In summary, this study sets the basis for the highly sensitive detection and 
identification of AX-protein adducts. Future studies will allow the 
identification of AX binding sites in other proteins as well as in vivo thus 
broadening the information on protein haptenation by AX and hopefully 
contributing to the development of diagnostic tools and to the 
characterization of the pathogenic mechanisms of allergic reactions towards 
AX. 
 
  
3 Protein haptenation by amoxicillin: high resolution mass spectrometry 
analysis and identification of target proteins in serum 
80 
 
3.5 References 
 
1. Ariza A, Montañez MI, Pérez-Sala D. Proteomics in immunological 
reactions to drugs. Curr Opin Allergy Clin Immunol. 2011;11:305-12. 
2. Yvon M, Anglade P, Wal JM. Identification of the binding sites of 
benzyl penicilloyl, the allergenic metabolite of penicillin, on the serum 
albumin molecule. FEBS Lett. 1990 Apr 24;263(2):237-40. 
3. Yvon M, Wal JM. Identification of lysine residue 199 of human 
serum albumin as a binding site for benzylpenicilloyl groups. FEBS Lett. 
1988 Nov 7;239(2):237-40. 
4. Meng X, Jenkins RE, Berry NG, Maggs JL, Farrell J, Lane CS, et al. 
Direct evidence for the formation of diastereoisomeric benzylpenicilloyl 
haptens from benzylpenicillin and benzylpenicillenic acid in patients. J 
Pharmacol Exp Ther. 2011 Sep;338(3):841-9. 
5. Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, 
Park BK. Characterisation of flucloxacillin and 5-hydroxymethyl 
flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl. 
2009 Jun;3(6):720-9. 
6. Whitaker P, Meng X, Lavergne SN, El-Ghaiesh S, Monshi M, 
Earnshaw C, et al. Mass spectrometric characterization of circulating and 
functional antigens derived from piperacillin in patients with cystic fibrosis. J 
Immunol. 2011 Jul 1;187(1):200-11. 
7. Acton G. Aminopenicillins: Advances in research and application. 
Atlanta, USA: Scholarly Editions; 2012. 
8. Zhao Z, Batley M, D'Ambrosio C, Baldo BA. In vitro reactivity of 
penicilloyl and penicillanyl albumin and polylysine conjugates with IgE-
antibody. Journal of immunological methods. 2000 Aug 28;242(1-2):43-51. 
9. Audicana M, Bernaola G, Urrutia I, Echechipia S, Gastaminza G, 
Munoz D, et al. Allergic reactions to betalactams: studies in a group of 
patients allergic to penicillin and evaluation of cross-reactivity with 
cephalosporin. Allergy. 1994 Feb;49(2):108-13. 
10. Mayorga C, Obispo T, Jimeno L, Blanca M, Moscoso del Prado J, 
Carreira J, et al. Epitope mapping of beta-lactam antibiotics with the use of 
monoclonal antibodies. Toxicology. 1995 Mar 31;97(1-3):225-34. 
3 Protein haptenation by amoxicillin: high resolution mass spectrometry 
analysis and identification of target proteins in serum 
81 
11. Fujiwara K, Shin M, Miyazaki T, Maruta Y. Immunocytochemistry 
for amoxicillin and its use for studying uptake of the drug in the intestine, 
liver, and kidney of rats. Antimicrob Agents Chemother. 2011 Jan;55(1):62-
71. 
12. Hoizey G, Lamiable D, Frances C, Trenque T, Kaltenbach M, Denis 
J, et al. Simultaneous determination of amoxicillin and clavulanic acid in 
human plasma by HPLC with UV detection. Journal of pharmaceutical and 
biomedical analysis. 2002 Oct 15;30(3):661-6. 
13. Serrano JM, Hita J, Ponferrada CJ, López MC, Cárceles CM. 
Intravenous Pharmacokinetics and binding to plasmatic proteins of 
Amoxycillin and Clavulanic acid in sheeps. AN VET. 1989;5:75-87. 
14. Makarov A, Denisov E, Kholomeev A, Balschun W, Lange O, Strupat 
K, et al. Performance evaluation of a hybrid linear ion trap/orbitrap mass 
spectrometer. Analytical chemistry. 2006 Apr 1;78(7):2113-20. 
15. Perry RH, Cooks RG, Noll RJ. Orbitrap mass spectrometry: 
instrumentation, ion motion and applications. Mass spectrometry reviews. 
2008 Nov-Dec;27(6):661-99. 
16. Aldini G, Gamberoni L, Orioli M, Beretta G, Regazzoni L, Maffei 
Facino R, et al. Mass spectrometric characterization of covalent modification 
of human serum albumin by 4-hydroxy-trans-2-nonenal. J Mass Spectrom. 
2006 Sep;41(9):1149-61. 
17. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel 
digestion for mass spectrometric characterization of proteins and proteomes. 
Nat Protoc. 2006;1(6):2856-60. 
18. Zhang Z, Marshall AG. A universal algorithm for fast and automated 
charge state deconvolution of electrospray mass-to-charge ratio spectra. 
Journal of the American Society for Mass Spectrometry. 1998 Mar;9(3):225-
33. 
19. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal 
structure of human serum albumin at 2.5 A resolution. Protein engineering. 
1999 Jun;12(6):439-46. 
20. Pedretti A, Villa L, Vistoli G. VEGA: a versatile program to convert, 
handle and visualize molecular structure on Windows-based PCs. Journal of 
molecular graphics & modelling. 2002 Aug;21(1):47-9. 
3 Protein haptenation by amoxicillin: high resolution mass spectrometry 
analysis and identification of target proteins in serum 
82 
21. Olsson MHM, Sondergard CR, Rostkowski M, Jensen JH. 
PROPKA3: Consistent treatment of internal and surface residues inempirical 
pKa predictions. J Chem Theory Comput. 2011;7:525-37. 
22. Morris G, Goodsell D, Halliday R, Huey R, Hart W, Belew R, et al. 
Automated docking using a Lamarckian genetic algorithm and an empirical 
binding free energy function. J Comput Chem. 1998;19:1639-62. 
23. Llinas A, Page M. Intramolecular general acid catalysis in the 
aminolysis of beta-lactam antibiotics. Org Biomol Chem. 2004;2:651-4. 
24. Llinas A, Vilanova B, Page M. Thiol-catalysed hydrolysis of 
cephalosporins and possible rate-limiting amine anion expulsion. J Phys Org 
Chem. 2004;17:521-8. 
25. Carey MA, van Pelt FNAM. Immunochemical detection of 
flucloxacillin adduct formation in livers of treated rats. Toxicology. 
2005;216(1):41-8. 
26. Magi B, Marzocchi B, Bini L, Cellesi C, Rossolini A, Pallini V. Two-
dimensional electrophoresis of human serum proteins modified by ampicillin 
during therapeutic treatment. Electrophoresis. 1995 Jul;16(7):1190-2. 
27. Lavergne SN, Wang H, Callan HE, Park BK, Naisbitt DJ. "Danger" 
conditions increase sulfamethoxazole-protein adduct formation in human 
antigen-presenting cells. J Pharmacol Exp Ther. 2009 Nov;331(2):372-81. 
28. Aldini G, Vistoli G, Regazzoni L, Gamberoni L, Facino RM, 
Yamaguchi S, et al. Albumin is the main nucleophilic target of human 
plasma: a protective role against pro-atherogenic electrophilic reactive 
carbonyl species? Chem Res Toxicol. 2008 Apr;21(4):824-35. 
29. Yamaguchi S, Aldini G, Ito S, Morishita N, Shibata T, Vistoli G, et al. 
Delta(12)-Prostaglandin J(2) as a Product and Ligand of Human Serum 
Albumin: Formation of an Unusual Covalent Adduct at His146. J Am Chem 
Soc. 2010;132:824-32. 
30. Oettl K, Stauber RE. Physiological and pathological changes in the 
redox state of human serum albumin critically influence its binding 
properties. Br J Pharmacol. 2007 Jul;151(5):580-90. 
31. Kormoczi GF, Wolfel UM, Rosenkranz AR, Horl WH, Oberbauer R, 
Zlabinger GJ. Serum proteins modified by neutrophil-derived oxidants as 
mediators of neutrophil stimulation. J Immunol. 2001 Jul 1;167(1):451-60. 
4 Mass spectrometric strategies for the identification and characterization of 
Human Serum Albumin covalently adducted by Amoxicillin: ex vivo studies 
83 
 
4 Mass spectrometric strategies for the identification and 
characterization of Human Serum Albumin covalently adducted by 
Amoxicillin: ex vivo studies 
 
Davide Garzon
a
, Adriana Ariza
b,c,
,Luca Regazzoni
a
, Riccardo Clerici
a
, Alessandra 
Altomare
a
, Federico Riccardi Sirtori
a^
, Marina Carini
a
, María José Torres
d
,  Dolores 
Pérez-Sala
b
 and Giancarlo Aldini
a*
   
 
a
Department of Pharmaceutical Sciences, Università degli Studi di Milano, via 
Mangiagalli 25, 20133, Milan, Italy 
b
Department of Chemical and Physical Biology, Centro de Investigaciones 
Biológicas, C.S.I.C., Ramiro de Maeztu, 9, 28040 Madrid, Spain. 
c
Research Laboratory, IBIMA – Hospital Regional Universitario de Málaga - 
UMA, Málaga, Spain 
d
Allergy Unit, IBIMA – Hospital Regional Universitario de Málaga – UMA, 
Málaga, Spain 
 
 
^ present address: Oncology Business Unit, Nerviano Medical Sciences, Viale 
Pasteur 10, 20014 Nerviano (MI), Italy 
  
4 Mass spectrometric strategies for the identification and characterization of 
Human Serum Albumin covalently adducted by Amoxicillin: ex vivo studies 
84 
 
ABSTRACT 
 
This study addresses the detection and characterization of the modification of 
human serum albumin (HSA) by amoxicillin (AX) in ex vivo samples from healthy 
subjects under oral amoxicillin administration (acute intake of 1 g every 8 h for 48 
h). To reach this goal we have used an analytical strategy based on targeted and 
untargeted mass spectrometric approaches. Plasma samples withdrawn before AX 
oral intake represented the negative control samples to test the method selectivity, 
while HSA incubated in vitro with AX was the positive control. Different MS 
strategies were developed and in particular: 1) Multiple Reaction Monitoring 
(MRM) and Precursor Ion Scan (PIS) using a HPLC system coupled to a triple 
quadrupole MS analyser; 2) a dedicated data-dependent scan and a customized 
targeted MS/MS analysis carried out using a nano-LC system coupled to a high 
resolution MS system (LTQ Orbitrap XL).  
Lys 190 was identified as the only modification site of HSA in the ex vivo samples. 
The AX adduct was identified and fully characterized by complementary targeted 
approaches based on triple quadrupole (MRM mode) and orbitrap (SIC mode) as 
mass analyzers. The SIC mode also permitted to measure the relative amount of 
AX adducted HSA, ranging from 1 to 2% (6-12 µM) after 24 and 48 hours from the 
oral intake. No adduct in any ex vivo sample was identified by the untargeted 
methods (PIS and data dependent scan mode analysis).  
The results on one hand indicate that MS and in particular high resolution MS 
analyser represents a suitable analytical tool for the identification/characterization 
of covalently modified proteins/peptides; on the other hand they give a deeper 
insight into the AX-induced protein haptenation, which is required for a better 
understanding of the mechanisms involved in AX-elicited allergic reactions. 
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Keywords:  Amoxicillin, human serum albumin (HSA), haptenation, Lys 190, 
protein covalent binding, Multiple Reaction Monitoring, Orbitrap. 
Abbreviations: AX, amoxicillin; CID collision induced dissociation; HCD high 
energy collision induced dissociation HSA, human serum albumin; MRM, Multiple 
Reaction Monitoring; MS, mass spectrometry; PIS,  Precursor Ion Scan; SIC, 
single ion chromatogram; TQ, triple quadrupole, TSQ, triple stage quadrupole. 
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4.1 Introduction 
 
Allergy to β-lactam antibiotics poses important clinical problems per se and 
reduces the therapeutic possibilities in a time when bacterial infections are again 
rising as important causes of morbidity and mortality.[1, 2] Covalent binding of 
drugs to protein structures, in a process known as haptenation, is believed to be 
essential to give rise to a stable structure capable of eliciting an immune 
response.
3,[3]
 Identification and characterization of the protein targets for 
modification by drugs may help delineate the mechanisms involved in drug 
sensitization.[4] Amoxicillin (AX) is a wide spectrum β-lactam antibiotic, the use 
of which has been increasing steadily during the past decades becoming the most 
commonly consumed betalactam in many countries.[5, 6] Incidence of allergy to 
AX has increased in parallel with its consumption in such a way that nowadays it is 
the antibiotic eliciting a higher frequency of allergic reactions.[7, 8] A recent data 
analysis on 333 cases of allergy reaction shows that the 50% of hypersensitivity 
reactions are due to β-lactam antibiotics and among them AX was incriminated in 
65 % of the patients.[9]  
Patients who have developed an allergic reaction to AX are evaluated and 
diagnosed on the basis of either: i) the presence of AX-reactive IgE in serum 
detected by in vitro immunoassays, ii) the responsiveness of their basophil cells or 
the specific lymphocyte proliferation in presence of the antibiotic by in vitro 
basophil activation test or lymphocyte transformation test, respectively iii) the 
responsiveness of their mast cells and T cells by skin test and, iv) provocation tests 
by oral administration of AX.[10] Nevertheless, skin and oral provocation tests 
imply higher risks than ex vivo testing and have to be carried out in a hospital 
setting.[11] Therefore, diagnosis through ex vivo tests is preferable. Strategies for 
these tests include, besides the use of AX, AX-derivatized dendrimeric structure or 
extensively modified homopolymers and proteins such as poly-L-lysine and serum 
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albumin, respectively.
15-
[12] However, the sensitivity of the present diagnostic 
tools is still limited and oral drug administration is required in a considerable 
percentage of patients  in order to confirm the diagnostic.[10, 13-15] A current 
interpretation of this phenomenon postulates the contribution of endogenous 
protein structures to the formation of the antigenic determinant(s) important for 
antibody recognition. Identification of endogenous targets for haptenation could 
therefore render a battery of new tools that could be explored to increase diagnostic 
efficiency. 
With a view to fully elucidating the target protein of AX haptenation, we recently 
described the in vitro modification of various serum proteins by AX and 
characterized the modification of HSA both by immunological and mass 
spectrometric (MS) approaches. Under the conditions of the previous study, several 
lysine residues in HSA, in particular Lys 190 and 199, were found to be the most 
reactive to AX. In addition, we observed that Lys 190 was modified by AX either 
using the isolated protein or whole serum.[16] Figure 1 reports the reaction 
mechanism between AX and Lys 190 together with the diagnostic fragment ions 
that were used for the adduct characterization by MS studies.[16] In the current 
study we have addressed the detection and characterization of the modification of 
HSA by AX in ex vivo samples from subjects under oral administration of AX. To 
reach this goal we used both immunological and MS methods. The MS approach 
we used is based on the most suitable techniques and MS analyzers (triple 
quadrupole and orbitrap) applied to identify and characterize peptide/protein 
covalent adducts. Using this approach we have been able to detect the addition of 
AX to Lys 190 of HSA and to determine the relative content in respect to the native 
peptide. These findings set the basis for the study of this structure as antigenic 
determinant and the development of novel diagnostic tools. 
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Fig.1. Reaction mechanism between Lys 190 and AX and chemical structure of AX 
diagnostic fragment ions. The amoxicilloyl modification induces a mass increase of 
+365.1 Da. HCD or CID fragmentation of the Lys 190 AX modified peptide 
generates two diagnostic fragment ions : AX1 referred to the thiazolidinic ring and 
AX2, attributed to the cleavage of AX from Lys 190 and by the concomitant loss of 
the amine group. The two fragment ions structure were predicted by Mass Frontier 
software. 
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4.2 Material and methods 
 
4.2.1 Reagents 
 
AX was from Glaxo SmithKline (Madrid, Spain). Iodoacetamide (IAA), (D)-threo-
1,4-dimercapto-2,3-butanediol (DTT), tris (hydroxymethyl) aminomethane, sodium 
phosphate dibasic and LC-grade and analytical-grade organic solvents were from 
Sigma-Aldrich. Sequence grade modified trypsin was obtained from Promega 
(Milan, Italy). 
The monoclonal antibody anti-amoxicillin (AO3.2) was the generous gift of Dr. 
Cristobalina Mayorga (Research Laboratory, IBIMA – Hospital Regional 
Universitario de Málaga - UMA, Málaga, Spain).[16] 
 
4.2.2 AX administration, serum collection and HSA isolation 
 
AX (Glaxo Smithkline, Madrid, Spain) was orally administered (1 g every 8 h for 
48 h) to two healthy volunteers, not allergic to this antibiotic and identified as 
subject A and B within the manuscript. The extraction of peripheral blood using 
tubes with gel (Vacuette Greiner Bio-One, Kremsmünster, Austria) immediately 
before (T0) the intake of the first pill and 24 (T24) and 48 h (T48) after the intake 
of the first pill (with an accumulated dose of 3 and 6 g) was done at the Regional 
University Hospital of Malaga (Spain). Serum was obtained by centrifugation of 
the samples at 4000 rpm for 5 min and it was frozen in aliquots at -80ºC until their 
analysis. The study was conducted according to the Declaration of Helsinki 
principles and was approved by the Malaga Research Ethics Committee (Spain). 
All subjects included in the study were informed orally about the study and signed 
the corresponding informed consent form.  
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4.2.3 HSA isolation 
 
HSA was isolated from the serum by affinity chromatography using Affi-Gel
®
 blue 
gel (Bio-Rad, Segrate, Italy). An aliquot of 50µL of serum was diluted with 150 µL 
of sodium phosphate dibasic 20 mM, pH 7.1 (buffer A) and kept at room 
temperature for 15 minutes. In the meanwhile a Sigma Prep Spin column was filled 
with 500 µL of BlueGel Affigel and the gel was activated as indicated by the 
protocol. Aliquots of 200 µL of the diluted serum were pipetted in the column and 
washed three times with buffer A. Albumin was eluted by pipetting two aliquots of 
250 µL of NaCl 1.4 M (buffer B) in the column. For each step the columns were 
centrifuged by means of a mikro 120 Hettich centrifuge for one minute at 20 g. The 
recovery of HSA and of AX modified HSA ranged from 85 to 92% and did not 
changes significantly. HSA concentration was determined spectrophotometrically 
at 280 nm. 
 
4.2.4 In vitro modification of serum proteins by AX 
 
AX was freshly prepared in 50 mM Na2CO3/NaHCO3 pH 10.2. For western blot 
analysis, HSA was incubated in the presence of 0.5 mg/ml AX for 16 h at 37ºC. 
AX incorporation into serum proteins was assessed by SDS-PAGE followed by 
western blot and detection with anti-AX monoclonal antibody AO3.2, as 
previously described.[16] AX-modified HSA as positive control for MS study was 
prepared by incubating 150 µM HSA (10 mg/mL) with 13.5 mM AX (5 mg/mL) in 
PBS overnight at 37ºC (stoichiometric ratio HSA:AX of 1:90) 
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4.2.5 HSA protein digestion for LC-ESI-MS analysis 
 
Aliquot of 30 µg of HSA was dissolved in 30 µL 50 mM Tris-HCl (pH 7.8) and 
digested with trypsin according to the manufatcurer’s procedure. Firstly DTT was 
added at a final concentration of 2 mM and the sample was incubated for 60 min at 
37 °C; then IAA was added to the solution at a final concentration of 4 mM and the 
sample was incubated for 45 min at 37 °C in the dark. In order to quench the excess 
of IAA, DTT was added again at a final concentration of 4 mM and the sample was 
incubated for 60 min at 37 °C degrees. CaCl2 was spiked at a final concentration of 
1 mM and then trypsin was added to the sample at a trypsin to protein ratio of 1:30. 
After an overnight period at 37 °C the tryptic mixtures were acidified with formic 
acid up to a final concentration of 10%. The digested HSA was then analyzed by 
triple quadrupole and orbitrap mass spectrometer, using both targeted and 
untargeted approaches, as summarized in Figure 2. 
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4.2.6 Multiple Reaction Monitoring and Precursor Ion Scan analyses 
 
Aliquots of 5µg of digested HSA were dissolved in 20 µL of buffer A (0.1% formic 
acid in water) and injected onto a reversed-phase Agilent Zorbax SB-C18 column 
(4 mm i.d., particle size 3.5 μm, CPS Analitica, Milan, Italy) protected by an 
Agilent Zorbax RP guard column. The peptides were eluted with a 55 min gradient 
from 98% buffer A (0.1% formic acid in water) to 60% buffer B (0.1% formic acid 
in acetonitrile) at a constant flow rate of 200 µL/min. The triple quadrupole TSQ 
Quantum Ultra (ThermoQuest, Milan, Italy) was set in positive ion mode and with 
the following ion source parameters: capillary temperature 275° C; spray voltage 
4.5 kV; capillary voltage 35 V; tube lens voltage 120 V. The flow rate of the 
nebulizer gas (nitrogen) was 50 a.u. 
MRM of each of the AX adducted peptides previously identified under in vitro 
conditions[16] was carried out by setting as diagnostic fragments the ions at m/z 
160.0 and 349.1, corresponding to the thiazolidinic moiety of AX and to AX minus 
the aminic residue, respectively. The AX modified peptides and the corresponding 
transitions are summarized in Table1. 
The parameters influencing these transitions were optimized as follows: argon gas 
pressure in the collision Q2, 1.5 mbar; peak full width at half-maximum (FWHM), 
0.70 m/z at Q1 and Q3; scan width for all MRM channels, 1 m/z; scan rate (dwell 
time), 0.05 s/scan. Data processing was performed by the Xcalibur 2.0 software. 
Fragmentation was done using CID mode (isolation width, 1 m/z; normalized 
collision energy, 28 CID arbitrary units).  
Precursor Ion Scan analysis was carried out by setting as diagnostic ions the ions at 
m/z 160.0 and 349.1 which are characteristic of the AX moiety.[16] MS parameters 
were set as follows: collisional voltage at 30 V, mass unit resolution, scan time of 1 
s for both Q1 and Q3, m/z 300–1500 as Q1 scan range. 
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Multiple reaction monitoring: transition list 
Modified 
residue 
Sequence 
Precursor ion 
(m/z) 
Product ions 
(m/z) 
K 190 
182
LDELRDEGK#ASSAK
195
 628.6 160.0 +349.1 
K 199 
198
LK#C$ASLQK
205
 656.8 160.0 +349.1 
K 351 
349
LAK#TYETTLEK
359
 554.6 160.0 +349.1 
K 432 
429
NLGK#VGSK 
436
 584.3 160.0 +349.1 
K 541 
539
ATK#EQLK 
545
 591.8 160.0 +349.1 
K 545 
542
EQLK#AVMDDFAAFVEK
557
 736.0 160.0 +349.1 
 
Table 1. AX modified peptides searched by MRM analysis. For each peptide the 
sequence and the m/z of the corresponding precursor ion and product ions used for 
the transition are reported. The symbol # indicates the modification site and $ the 
carbamidomethylated Cys. 
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4.2.7 Liquid chromatography electrospray ionization mass spectrometry/mass 
spectrometry analysis (LC-ESI-MS/MS): LTQ Orbitrap XL mass spectrometer 
 
Peptides from HSA digestion were then separated by reversed-phase (RP) 
nanoscale capillary liquid chromatography (nanoLC) and analyzed by electrospray 
tandem mass spectrometry (ESI-MS/MS). Digested peptides arising from 1.5 µg of 
HSA were dissolved in 10 µL of buffer A (0.1% formic acid in water) and injected 
into a trapping column in order to purify and concentrate the sample. The trapping 
column was a Acclaim PepMap 100, nanoviper C18, 100 Å, 100 µm i.d. x 2 cm, 
Thermo Scientific.  The flow rate was of 10 µL/min for 4 minutes. After 4 minutes 
the valve switched and the peptide mixture was loaded onto a fused silica reversed-
phase column (PicoFritTM Column, HALO, C18, 2.7 μm, 100 Å, 75 μm i.d. x 10 
cm, New Objective). The peptides were eluted with a 55 min gradient from 99% 
buffer A (0.1% formic acid in water) to 35% buffer B (0.1% formic acid in 
acetonitrile) at a constant flow rate of 300 nL/min. The nano chromatographic 
system, an UltiMate 3000 RSLCnano System (Dionex), was connected to an LTQ-
Orbitrap XL mass spectrometer (Thermo Scientific, Milan, Italy) equipped with a 
nanospray ion source (dynamic nanospray probe, Thermo Scientific, Milan, Italy) 
set as follows: spray voltage 1.8 Kv; capillary temperature 220 °C, capillary 
voltage 30 V; tube lens offset 100 V, no sheath or auxiliary gas flow.  
The LTQ-Orbitrap XL mass spectrometer was set to perform scan cycles 
consisting, firstly, of recording a high-resolution (resolving power 60000, FWHM 
at m/z 400) full scan (200-1500 m/z) in profile mode, then by the acquisition of the 
MS/MS spectra of the three most intense ions in centroid mode, using both CID 
and HCD fragmentation (isolation width, 3 m/z; normalized collision energy, 35 
CID arbitrary units, 30 HCD arbitrary units). Protonated phthalates 
[dibutylphthalate (plasticizer), m/z 279.159086; bis(2-ethylhexyl)phthalate, m/z 
391.284286] and polydimethylcyclosiloxane ions [(Si(CH3)2O)6 + H]
+
; m/z 
4 Mass spectrometric strategies for the identification and characterization of 
Human Serum Albumin covalently adducted by Amoxicillin: ex vivo studies 
95 
445.120025] were used for real time internal mass calibration. Dynamic exclusion 
was enabled (repeat count, 2; repeat duration, 45 s; exclusion list size, 50; 
exclusion duration, 80 s; relative exclusion mass width, 10 ppm). Charge state 
screening and monoisotopic precursor selection was enabled, singly and 
unassigned charged ions were not fragmented. 
Identification of the peptides covalently modified by AX as well as the 
modification sites, was carried out by the MS strategy previously described and 
based on two different steps.[16] The first step consisted of identifying the 
precursor ions of diagnostic fragment ions at m/z 160.04 and 349.08. In more 
detail, the precursor ions were extracted from the two parent ion maps displayed by 
setting as product mass the ions at m/z 160.04 (tolerance 0.01) and the ion at m/z 
349.08 (tolerance 0.01). The two lists of parent ions were then exported to Excel 
Microsoft and analyzed using the following Boolean logic: if value1 > ts, value2 > 
ts, value$ = value1 + value2 or else value$ = 0, where value1 and value2 are the 
relative abundances of the precursor ions setting the product ions at m/z 160.04 
(value 1) and 349.08 (value 2) and ts is the threshold relative abundance. By using 
this approach, each precursor ion was confirmed only when it was present in both 
the ion maps which were reconstituted by setting the two diagnostic precursor ions, 
otherwise it was discarded. The second step consisted of matching the precursor 
ions with a list of theoretical modified ions generated by an in silico digestion of 
albumin carried out by considering the following parameters: trypsin as enzyme, 
two missed cleavages and the addition of the amoxicilloyl moiety at the Lys 
residues.  
Targeted MS/MS scan analyses were carried out by setting the LTQ-Orbitrap XL 
mass spectrometer to perform two scan cycles, one in full scan (200-1500 m/z), the 
other based on the inclusion list reported in Table 2:  
MS/MS experiments were carried out in CID mode (isolation width, 3 m/z; 
normalized collision energy, 33 CID arbitrary units). Protonated phthalates 
[dibutylphthalate (plasticizer), m/z 279.159086; bis(2- ethylhexyl)phthalate, m/z 
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391.284286] and polydimethylcyclosiloxane ions [(Si(CH3)2O)6 + H]
+
; m/z 
445.120025] were used for real time internal mass calibration. 
 
Targeted Orbitrap MS/MS analysis: inclusion list 
Modified 
residue 
Sequence 
Exact mass 
(m/z) 
Charge (z) 
K 190 
182
LDELRDEGK#ASSAK
195
 628.63163 +3 
K 199 
198
LK#C$ASLQK
205
 656.82303 +2 
K 351 
349
LAK#TYETTLEK
359
 554.60787 +3 
K 432 
429
NLGK#VGSK 
436
 584.29496 +2 
K 541 
539
ATK#EQLK 
545
 591.79479 +2 
K 545 
542
EQLK#AVMDDFAAFVEK
557
 736.01134 +3 
 
Table 2. Inclusion list used for targeted orbitrap MS/MS analysis. For each 
targeted peptide the sequence, the exact mass and the charge are reported. Mass 
tolerance was set at 10 ppm. 
The symbol # indicates the modification site and $ the carbamidomethylated Cys. 
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4.2.8 Bioinformatics 
 
Peptide sequences were identified using the software turboSEQUEST (Bioworks 
3.1, ThermoQuest, Milan, Italy), and using a database containing only HSA and 
assuming trypsin digestion. The protein sequence of HSA was obtained from the 
SwissProt database (primary accession number P02768). Sequence fragments 
calculator (Bioworks 3.1.1) was used to obtain the theoretical digested masses 
setting trypsin as enzyme, all the Cys residues as carbamidomethyl-cysteine and 
considering the oxidation of methionine residues and the formation of 
amoxicilloyl-Lys adducts as variable modifications. The predicted y and b series 
ions were determined using the Peptide Sequence Fragmentation Modeling, 
Molecular Weight Calculator software program (ver. 6.37), 
http://come.to/alchemistmatt.The chemical structure of amoxicillin diagnostic 
fragments were predicted by the software Mass Frontier 5.0 (HighChem ltd, 
Slovakia).
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Fig. 2. Overview of the MS targeted and untargeted methods used to identify AX covalent adducts to HSA. 
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4.3 Results 
 
4.3.1 Detection of AX-HSA adducts in human serum by Multiple Reaction 
Monitoring and Precursor Ion Scan: LC-ESI-MS/MS studies 
 
Multiple Reaction Monitoring: development of allergy towards AX occurs most 
frequently after oral intake of the antibiotic. We were therefore interested in 
detecting AX-protein adducts under these conditions. Multiple Reaction 
Monitoring (MRM) is commonly used for targeted quantitative analyses.[17] 
Concerning -lactams-induced protein haptenation, it was applied by Jenkins et 
al.[18] in order to identify the HSA residues modified by flucloxacillin in both in 
vitro and in vivo conditions. 
Firstly, based on its well-established selectivity and sensitivity, the Multiple 
Reaction Monitoring scan mode was employed in order to identify the adducted 
peptides arising from the digested HSA isolated from subjects treated with AX. 
Transitions (fragment ions associated to the precursor ions) were set on the bases of 
the in vitro studies previously reported[17]
1  
and are summarized in Table 1.  
The method was firstly validated by identifying all the previously identified 
adducted peptides in the positive control sample (HSA incubated with AX)(Figure 
3). Each adducted peptide was also identified on the basis of the retention time and 
the three most intense ions were K199-AX, K541-AX and K190-AX.  Adducted 
peptides are named on the basis of the modified Lys: K190-AX, K199-AX, K351-
AX, K541-AX, K545-AX and K432-AX. All the peptides monitored were not 
detected in the negative control samples T0A and T0B. The method was then 
applied to the ex vivo samples T1A, T1B, T2A and T2B. Only the peak 
corresponding to the Lys 190 adducted peptide ion (m/z 628.6  160.0 + 349.1), 
and characterized by a retention time of 28 minutes, was detected in all ex vivo 
samples with comparable intensity. Figure 4 (left panel) shows the MRM traces of 
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Lys 190 adducted peptide relative to the negative and positive control and to the set 
of the ex vivo samples. The method was found to be selective since no peak of the 
adducted peptide ion was present in the negative control samples obtained by HSA 
isolated from samples collected before AX intake (T0A and T0B).  
Although the MRM mode was found to be sensitive enough to identify the Lys 190 
adducted peptide, it was unable to characterize the peptide or to identify the site of 
modification because of the lack of additional information such as accurate mass, 
isotopic pattern and MS/MS fragmentation pattern. To overcome this limitation, a 
mixed MRM-data-dependent scan was applied. The approach was effective for the 
positive control sample while in ex vivo samples the fragment ions did not reach 
suitable intensity values, even when concentrating the sample, so that no MS/MS 
spectra were recorded for the peptide characterization.  
Another limitation of the MRM approach resides in the fact that it cannot perform a 
semi-quantitative analysis (the relative content of the adducted in respect to the 
native peptide) due to the fact that the product ions are characteristic only of the 
adducted peptides since they referred only to the AX moiety. 
The PIS method was then used as an untargeted method in order to identify the 
unknown AX-modified peptides in addition to those already detected by using the 
MRM mode. However, as reported in Figure 5, this approach was not able to 
identify any AX modified peptides in the ex vivo samples. 
By considering that the same set of samples were analysed in both MRM and PIS 
mode, we can confirm that the PIS mode is less sensitive in respect to the MRM 
mode and that in this study it was not useful for the untargeted identification due to 
the low abundance of the analytes. 
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Fig. 3. Multiple Reaction Monitoring traces of the modified peptides were reconstituted by setting the transitions reported in 
table 1. Each column refers to a different adducted peptide ion and each row refers to a different sample, The method was 
found to be selective (no peak before AX administration; T0A and T0B) and able to identify the known adducted peptides 
formed under in vitro conditions (HSA-AX). In samples collected after AX administration  (24 h for T1A, T1B and 48 h for T2A, 
T2B) only one peak at retention time 28 min was identified and attributed to K190-AX (m/z 628.6  160.0+349.1).  
*
*
*
*
*
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Fig. 4. Left panel: Multiple Reaction Monitoring. The Multiple 
Reaction Monitoring trace of the Lys 190 AX-modified peptide 
was reconstituted by setting the corresponding transition reported 
in table 1. The method was found to be selective (no peak before 
AX administration; T0A and T0B) and able to identify the Lys 190 
AX modified peptide formed under in vitro conditions (HSA-AX). 
In samples collected after AX administration  (24 h for T1A, T1B 
and 48 h for T2A, T2B) the peak at retention time 28 min was 
attributed to K190-AX (m/z 628.6  160.0+349.1).  
Right panel: Single Ion Chromatogram (SIC). Single Ion 
Chromatogram (SIC) of Lys 190 AX modified peptide was 
reconstituted by setting the [M+3H]
3+
 of the modified peptide as 
filter ion. Orbitrap was used as MS analyser. The peak eluting at 
11.2 min was attributed to  K190-AX and it was identified in all 
the samples collected after AX administration (T1A, T1B, T2A, 
T2B) but not in samples T0A and T0B. 
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Fig. 5. Precursor Ion Scan analyses. No peak referred to the precursor ions of the diagnostic fragment ions at m/z 160.0+349.1 
was identified either before (T0 A and B) or after AX administration (T1 A and B, T2 A and B). The approach only permitted 
identification of a peak with RT of 28 min in the positive control (HSA incubated with AX at a molar ratio of 1:90) which was 
attributed to K190-AX. 
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4.3.2 Detection of AX-HSA adducts by LC-MS/MS Orbitrap  
 
The second step of the work was to apply a high resolution MS analyser coupled to 
a nano LC system in order to detect and identify the AX-adducted peptides. MS 
analyses were performed in two different scan modes, a data-dependent scan and a 
customized targeted MS/MS mode.  
Data-dependent scan: The identification of AX-modified peptides was then carried 
out using a standard data-dependent scan as explained in the methods and in Figure 
2. It should be noted that such an approach is per se not selective since it does not 
distinguish native and adducted peptides; hence when it was applied to the HSA 
digested samples, a large number of MS/MS spectra arising from the fragmentation 
of both native and adducted peptides was generated. Hence, the identification of 
AX-modified peptides was by necessity based on a post-run analysis. In particular 
for this analysis the same MS strategy described in our previous study[16] was 
employed in order to identify amoxicilloyl-modified peptides (+365.10454 Da). 
Although this approach confirmed all the 6 different adducted peptides in the 
positive control sample (see supporting information Figure S3), it was not able to 
identify any modified peptide in the ex vivo samples. It should be noted that the 
lack of adduct identification is not due to a poor sequence coverage, since the 
protein coverage of both control and AX-treated HSA samples was always higher 
than 80% (see supplementary Figure 8) and the most reactive Lys residues, as 
reported in the literature and predicted by molecular modelling studies, were 
covered. 
 
4.3.2.1 Customized targeted MS/MS mode 
 
The next step was to search for the adducted peptides using a targeted method, 
based on reconstituting the single ion chromatograms (SIC) by extracting the 
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current ion relative to the m/z ion of each of the adducted peptides as previously 
identified, and setting a 5 ppm tolerance.  
Figure 4 (right panel) shows the SICs relative to the positive control where only a 
single and well defined peak is observed for Lys 190 AX modified peptide. The 
retention time of the adducted peptide ion is clearly quite different from that 
observed in the MRM analysis, due to the different chromatographic configuration. 
By contrast, in the blank samples T0A and T0B, several peaks were detected but 
none at the RT of the analyte. SIC traces show the presence of the adducted peptide 
ion K190-AX, for all the ex vivo samples analysed (T1A, T1B, T2A, T2B). 
Regarding the peptide K190-AX, the method was found not to be highly selective 
since several peaks were present in the SIC trace, with a higher intensity compared 
to the adducted peptide although with a different RT. The adduct was assigned on 
the basis of the accurate mass and retention time and by considering the isotopic 
pattern of the multiply charged ion at m/z of 628.63184, overlapping the simulated 
data (Figure 6). These results also indicate that the failure to identify the K190-AX 
peptide by using the untargeted methods above reported (Sequest search algorithm 
and reconstituted precursor ion maps), is not due to the absence of the precursor 
ion, but to the fact that the target peptide was not fragmented. We then sought the 
reason for the lack of fragmentation. The first hypothesis was the poor intensity of 
the target ion. However a manual inspection of the SIC trace revealed that the 
intensity of the multiply charged ion relative to the target peptide was higher with 
respect to the ion threshold set in the data-dependent scan. We then found that 
several peptide ions eluted at the same retention time as the target peptide and that 
the dynamic exclusion did not succeed in excluding all the redundant ions. 
In order to record the MS/MS spectrum of the target peptide, the threshold intensity 
was decreased and the dynamic exclusion modified. Although different attempts 
were made and the ion at m/z 628.63163 ion was always detectable in the full mass 
spectrum, the adducted peptide was never automatically fragmented (data not 
shown) and this prompted us to set-up a targeted MS/MS method. In this last 
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approach, the LTQ-Orbitrap XL mass spectrometer continuously performed scan 
cycles consisting of a high-resolution full scan (200-1500 m/z) followed by the 
MS/MS analysis of only those ions included in the list of AX adducted peptides as 
previously detected.[16] 
This targeted-target approach was found to be highly informative since each adduct 
was identified not only by the accurate mass and isotopic pattern but also by the 
MS/MS fragmentation pattern. 
This method identified the K190-AX adduct in all the ex vivo samples which was 
finally confirmed and fully characterized by the MS/MS spectrum (Figure 7), a 
result which was not achieved in the other MS approaches as above reported. 
The peptide containing Lys190 (
182
LDELRDEGK#ASSAK
195
) contains three 
potential nucleophilic sites: Arg186, Lys190 and C-terminal Lys 195. The MS/MS 
fragment ions as detected in CID mode show an unmodified b series from b2 to b8 
thus excluding the binding to Arg186. Moreover, in the spectrum there was an 
unmodified y series from y3 to y5 excluding the adduction on the C-terminal Lys 
195. By contrast, the y series from y7 to y13 and the b series from b9 to b10 
showed a mass increase of 365.1 Da due to the AX adduction, thus confirming that 
Lys190 is the modification site. As further confirmation of AX adduction, the 
spectrum showed the ion at m/z 349 which is a diagnostic fragment of modification 
by AX. The areas of the peaks relative to K190-AX and to the corresponding native 
peptide were determined by reconstituting the selected ion chromatograms (SICs), 
setting the filter ions at m/z 628.63163 z=3 and m/z 537.77492 z=2, respectively, 
and assuming that the ionic responses of the filter ions were similar. The relative 
content of the modified peptide with respect to the native one was then calculated 
and the results summarized in Table 3. The relative content of the modified 
peptides in the ex vivo samples obtained after either 24 or 48 h AX intake ranged 
from 1 to 2 % corresponding to a concentration range from 6 to 12 µM given that 
HSA is 600 µM 
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Fig. 6. Experimental and calculated isotopic pattern of K190-AX. The upper panel shows the experimental isotopic pattern of 
the ion at m/z 628.63184 (z=3) extracted from the peak eluting at 11.2 min for T1A and referred to as K190-AX. The lower 
panel shows the theoretical isotopic pattern of K190-AX calculated by considering the chemical formula C78H126N22O30S and 
z=3.  
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Fig. 7. MS/MS analysis of K190-AX. Tandem MS spectrum of the adducted peptide 
182
LDELRDEGK#ASSAK
195 
(K190-AX) was 
recorded in CID mode and set a mass range 180-1020 m/z. The spectrum is characterized by the diagnostic y and b fragment 
ion series confirming the modification of Lys 190. AX adduction is further confirmed by the diagnostic ion fragment at m/z 349. 
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Fig. 8. Sequence coverage of HSA after trypsin digestion and LC-MS/MS analyses. The covered sequence for the analyzed 
samples was >85%. As an example, the figure reports the covered sequence highlighted in yellow for the sample T1A which 
accounted for 86%. The peptides bearing the amoxicilloyl adduct and identified in vitro by incubating HSA with AX are 
underlined. The AX modified lysine residues are highlighted in bold type. 
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCV
ADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKD
DNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYK
AAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWA
VARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQD
SISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAK
DVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEF
KPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLG
KVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNR
RPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKA
TKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 
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Sample K190-AX 
Area (10^6) 
K190-native 
Area (10^6) 
Modification 
(%) 
HSA-AX 146.0 ± 5.7 4.5 ± 0.6 97.0 ± 0.5 
T0 A 0.0 11.1 ± 0.6 0.0 
T0 B 0.0 11.0 ± 1.4 0.0 
T1 A 0.5 ± 0.1 47.3 ± 1.8 1.1 ± 0.1 
T1 B 0.13 ± 0.0 11.7 ± 0.6 1.5 ± 0.1 
T2 A 0.3 ± 0.0 16.5 ± 0.6 1.8 ± 0.3 
T2 B 0.9 ± 0.1 44.1 ± 2.2 1.9 ± 0.0 
 
Tab. 3. Relative content of K190-AX in the in vitro and ex vivo samples. The 
relative content of K190-AX with respect to the native peptide (K190-native) was 
calculated by integrating the area of the peaks identified in the SICs traces as 
shown in Figure 4. The standard deviation of each value is calculated on three 
replicates for each sample. The following equation was used to calculate the % of 
adduction: [K190-AX / (K190-AX + K190-native)] * 100 where K190-AX and 
K190-native refer to the peak areas.  
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4.3.3 Comparing MS approaches with immunological methods 
 
We have previously used immunological methods to detect AX-protein adducts 
formed in vitro.[16] For this reason we also explored the possibility of using 
immunological approaches for the detection of AX-protein adducts in ex vivo 
samples obtained after AX oral administration. Commercial human serum 
incubated with AX in vitro was used as a positive control. As described earlier, 
several adducts were detected under these conditions (Figure 9A). The major 
adducted proteins have been previously identified and can be assigned to 
transferrin (Trf), HSA, and heavy and light chains of immunoglobulins (Ig HC and 
Ig LC, respectively). Incubation of serum samples from healthy subjects with AX 
in vitro led to the detection of similar adducts (Figure 9B).  However, analysis of 
serum from the same subjects after oral intake of AX for 24 or 48 h by this method 
did not allow the detection of signals above background levels (Figure 9C). Nor did 
the analysis of the same samples by 2D-electrophoresis using 100 g of total 
protein allow the detection of specific signals (results not shown). Therefore, 
detection of AX-adducts formed in vivo by use of the available antibody may 
require enrichment steps. Alternatively, more sensitive methods, like the ones 
developed herein, need to be employed. 
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Fig. 9. Immunological detection of adducts of AX with serum proteins. Samples 
analyzed were: (A) commercial human serum or (B) serum from two different 
healthy subjects incubated in vitro with the indicated concentrations of AX for 16 h 
at 37ºC, and (C) serum samples from healthy subjects before and after the intake of 
AX. Aliquots from all samples containing 2 µg of total protein were analyzed by 
SDS-PAGE and western blot with anti-AX AO3.2 monoclonal antibody. Exposure 
times were 10 s for (A) and (B) and 1 min for (C). Trf, transferrin; HSA, human 
serum albumin; Ig HC, immunoglobulin heavy chain; Ig LC, immunoglobulin light 
chain.  
  
Time     0    24   48  
  (h) 
200 - 
150 - 
100 - 
75 - 
50 - 
37 - 
25 - 
200 - 
150 - 
100 - 
75 - 
50 - 
37 - 
25 - 
C 
    AX         0     0.5 
(mg/ml) 
200 
150 - 
100 - 
75 - 
50 - 
37 - 
25 - 
A 
200 - 
150 - 
100 - 
75 - 
50 - 
37 - 
25 - 
200 - 
150 - 
100 - 
75 - 
50 - 
37 - 
25 - 
B 
    AX         0     0.5 
(mg/ml) 
-Trf 
-HSA 
-Ig HC 
-Ig LC 
4 Mass spectrometric strategies for the identification and characterization of 
Human Serum Albumin covalently adducted by Amoxicillin: ex vivo studies 
113 
 
4.4 Discussion 
 
As reported elsewhere, when AX is orally administered at a dose of 1 g, the plasma 
concentration of the antibiotic increases rapidly reaching at 2-3 hours a 
concentration peak of approximately 10-20 g/ml. After this period, the AX plasma 
concentration decreases rapidly, reaching after 8 hours an almost negligible 
concentration. The kinetics of plasma AX levels upon repeated doses has been 
modeled and is thought to give rise to a series of peaks, not exceeding 20 
g/mL.[19] We have previously shown that immunological methods can detect 
HSA-AX adducts formed in vitro after incubation of HSA in the continuous 
presence of AX at 25 g/mL for 16 h at alkaline pH.[16] However, under these 
conditions, the extent of modification of HSA is higher than that occurring at 
neutral pH (not shown). As stated above, oral administration of AX results in the 
modification of only 1-2% of serum HSA, as detected in ex vivo samples by MS. 
Therefore, immunological methods using the AO3.2 antibody may not be suitable 
to detect AX-protein adducts in ex vivo serum samples withdrawn after AX oral 
administration, due to either the lower extent of HSA modification or the higher 
background given by serum samples.   
We have previously reported MS strategies for the identification and 
characterization of the AX modifications.[16] Therefore, in this paper we turned to 
MS approaches in order to achieve high sensitivity. Figure 2 overviews the 
different targeted and untargeted approaches we used. None of the untargeted 
approaches considered (Precursor Ions Scan and data-dependent scan mode) were 
able to identify any AX-adducted peptides generated by the enzymatic digestion of 
isolated HSA and this is probably due to the lack of sensitivity of the PIS approach 
and to the limited scan rate of the orbitrap MS analyzer used in the present work. 
Moreover the limited amounts of the AX adducts present in the ex vivo samples 
with respect to the native peptides should also be considered. To overcome these 
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limitations a sample preparation method should be set-up in order to isolate HSA-
AX adducts from unmodified-modified HSA. Moreover the use of a more sensitive 
MS analyzer for PIC analysis and of a HRMS characterized by a faster scan rate 
would facilitate the untargeted search.  
The targeted approaches set-up on the basis of the known AX adducts previously 
identified in in vitro conditions, confirmed that AX only modifies Lys190 in vivo. 
The MRM approach was found to be highly selective and sensitive but limited with 
regard to the analyte structure confirmation. The SIC approach carried out in the 
HRMS orbitrap, although less selective, gave additional information concerning the 
accurate mass, the isotopic pattern and the MS/MS fragmentation pathway, leading 
to the structure confirmation of the AX adduct. The SIC approach also permitted 
the establishment of the relative content of the adduct with respect to the native 
peptide. Although the approach is limited since it assumes that the ionization 
efficiency of the native and adducted peptides overlaps, it represents the first 
attempt of measuring the formation of the adducted peptide in a semi-quantitative 
way. A MRM method based either on isotope labelled or unlabelled standards is 
needed to measure the absolute amount of native and modified peptides. 
In conclusion, Lys 190 was identified as the modification site of AX orally given to 
human volunteers. The AX adduct was identified and fully characterized by 
complementary targeted approaches based on triple quadrupole (MRM mode) and 
orbitrap (SIC mode) as mass analyzers. The SIC mode also permitted the semi-
quantitative measurement of AX-HSA amount, ranging from 1 to 2% (6-12 µM) of 
the total amount of HSA, 24 and 48 hours after the beginning of the oral intake. 
It should be noted that several analytical methods have been developed towards the 
identification of the adducts formed between proteins and -lactams. Because HSA 
is the most abundant protein in serum, most works have attempted the 
characterization of HSA adducts. The first pioneering studies employed the HPLC 
separation of tryptic peptides and Edman degradation sequencing coupled to the 
Enzyme Immuno Assay analysis (EIA).[20] Such strategies were able to identify 6 
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different Lys sites modified by penicillin. More recent works have studied the 
interaction between HSA and flucloxacillin, piperacillin and benzylpenicillin 
[21]
,
[22] by using different mass spectrometric strategies which permitted the 
characterization of the adducted peptides and the identification of the modification 
sites. As an example of MS strategy, the Accurate Inclusion Mass Screening[23]  
was developed to identify and characterize the penicilloyl-HSA adducts. It is 
interesting to note that, in contrast to our results, several adducted sites were 
detected in the previous works. Several possibilities could account for these 
differences. In some of the studies the routes of administration were different (i.e. 
intravenous or intramuscular). In addition, it is possible that if the modified 
proteins are stable, adduct accumulation at other sites of the protein or on other 
proteins could occur after prolonged administration of the antibiotic. Moreover, the 
presence of concomitant treatments or the pathophysiological conditions could 
affect plasma protein concentrations. 
Accumulating evidence indicates that HSA adduction by AX occurs upon 
administration of the antibiotic in healthy subjects, not developing AX allergy. 
Therefore, other factors should intervene for the allergic reaction to occur. Apart 
from genetic predisposition, repeated administration, concurrent infections, 
inflammatory settings or other circumstances associated, known generically as 
“danger signals”, could potentiate the sensitization towards the antibiotic.[4] In 
addition, whether the nature or the amount of adducts formed are important factors 
for allergy development requires further study. 
The methods so far reported together with the approaches herein described 
represent a starting point to stimulate further studies aimed at setting-up advanced 
MS strategies for untargeted identification and for the accurate quantitative analysis 
of penicillin protein adducts. The application of such methods would permit a 
better understanding of the haptenation pathways and the development of more 
specific allergy diagnostic tools.  
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5.1 Reactive carbonyl species and protein covalent modification 
 
Reactive carbonyl species (RCS) are a class of exogenous and endogenous 
reactive compounds that can covalently react with nucleophilic targets such as 
proteins, phospholipids and nucleic acids, forming damaging adducts [1]. Proteins 
represent the most studied target of RCS and the corresponding reaction products 
are named advanced lipoxidation end products (ALEs) when the modifying 
moiety derives from lipids, and advanced glycation end products (AGEs) when it 
comes from sugar. 
From a chemical point of view, the RCS so far reported to react in vivo with 
proteins are quite heterogeneous and can be divided into the following groups: 1) 
α,β-unsaturated aldehydes; 2) di-aldehydes; 3) keto-aldehydes. The following 
paragraphs briefly describe the sources of RCS and their mechanism of reactions 
with proteins (please refer to the review by Vistoli et al.  [2] for a more detailed 
description of RCS). 
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 Reactive carbonyl species are cytotoxic compounds generated by 
oxidative damage; 
 Reactive carbonyl species can be formed either by lipid or sugar 
oxidation; 
 Reactive carbonyl species react with proteins forming protein adducts that 
can induce cell damage;  
 Reactive carbonyl species are involved in the pathogenesis of some 
oxidative based diseases; 
 a strict correlation between the amount of RCS, of the corresponding 
protein adducts in tissues and fluids and disease states has been found in 
both animal and human subjects;  
 a substantial amount of literature is now available reporting the molecular 
and cellular pathogenic mechanisms for the involvement of reactive 
carbonyl species in the onset and progression of various diseases, 
including atherosclerosis, diabetes and some neurological disorders; 
 Reactive carbonyl species are detoxified by phase I and II metabolism 
forming unreactive metabolites; 
 Carnosine reacts with reactive carbonyl species and is believed to take part 
to their detoxification; 
 compounds effective as inhibitors of reactive carbonyl species or able to 
block their biological effects have been found to significantly ameliorate 
different oxidative based diseases.  
 Reactive carbonyl species are now considered as promising drug targets 
 
Tab. 1. This table lists the key facts or reactive carbonyl species (RCS) which are 
reactive by-products of lipids and sugars oxidation 
  
5 Carnosine and derivatives as inhibitors of protein covalent modifications 
induced by reactive carbonyl species 
122 
 
 
 
Fig. 1. Major classes and chemical structures of the most studied reactive 
carbonyl species (RCS). RCS are break-down products formed by the oxidative 
damage of lipids and sugars, belonging to different chemical classes including 
α,β-unsaturated aldehydes, di-aldehydes anc keto-aldehydes. RCS are 
electrophilic compounds able to form covalent adducts with nucleophilic 
substrates such as proteins, forming adducts (AGEs and ALEs) that can elicit a 
damaging response. 
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5.1.1 α,β-unsaturated aldehydes 
 
α,β-unsaturated aldehydes include hydroxylated (i.e. 4-hydroxynonenal [HNE], 4-
hydroxyhexenal [HHE]) and non-hydroxylated (acrolein [ACR], crotonaldehdye, 
nonenal, hexenal) derivatives. They can have either endogenous or exogenous 
sources and different mechanisms of formation, although the lipid-peroxidation 
cascade involving free PUFAs or phospholipids represents the main pathway [2]. 
Acrolein is also generated in inflammatory condition by the degradation of 
threonine and of spermine and spermidine by myeloperoxidase and amine 
oxidase, respectively [3, 4]. 
The reactivity of the α,β-unsaturated aldehydes towards the nucleophilic sites of 
proteins (Lys, His, Cys, Arg and the terminal amino group) is regulated by their 
electrophilic nature, due to the carbonyl function which acts as an electron-
withdrawing group, decreasing the electron-richness of the conjugated alkene 
group and making the alkene β-carbon atom electron deficient [5]. The Michael 
adduct represents the main reaction product and it is formed by the covalent 
reaction between the electrophilic β-carbon atom of the unsaturated aldehydes and 
the nucleophilic (electron-rich species) sites of the protein such as the thiolate 
anion of cysteines, the -amino group of lysines and the imidazolic ring of 
histidines (Figure 2). The α,β-unsaturated aldehydes can also generate a reversible 
Schiff base through the dehydration reaction between the aldehydic carbonyl 
group and the primary amino group of the protein (the -terminal group of Lys or 
the amino-terminus of the protein) (Figure 2).  
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Fig. 2. Covalent adduction of α,β-unsaturated aldehydes with nucleophilic sites of 
proteins. C3 of α,β-unsaturated aldehydes react with the nucleophilic sites of 
proteins (His, Cys and Lys) forming Michael adducts and with the -amino group 
of Lys forming the corresponding Schiff base. 
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5.1.2 Di-aldehdyes 
 
Malondialdehyde (MDA) and glyoxal (GO) are the two most studied di-aldehydes 
involved in the formation of protein adducts. The former is generated by the lipid 
peroxidation cascade involving PUFA and it reacts with both Lys and Arg, 
forming several protein adducts and cross-links. The protein covalent adduction 
of MDA is due to the non-dissociated enolate form (the β-hydroxyacrolein) 
which, by reacting with the -amino group of Lys, forms the N-(2-
propenal)lysine (N-propenal-Lys), a reactive intermediate that can further react 
forming additional products (Figure 3). 
Glyoxal has both exogenous and endogenous sources. Exogenous sources include 
cooked foods [6] and environment (combustion) [7]. Exogenous glyoxal is easily 
absorbed. At endogenous level, glyoxal can be generated by the oxidation of both 
lipids and sugars [8] as well as by the degradation of the Amadori products [9]. 
N

-(carboxymethyl)lysine (CML) and S-(carboxymethyl)cysteine (CMC) 
represent the two main reaction products of GO with proteins. Glyoxal can also 
react with Arg forming imidazolinone derivatives and N-(carboxymethyl) 
arginine. Due to the presence of the two carbonyl groups, GO can also react with 
two nucleophilic sites forming cross-links named GOLD and GODIC, formed by 
the reaction of one molecule of glyoxal with two Lys or with one Lys and one 
Arg, respectively (Figure 3). 
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Fig. 3. Reaction mechanisms of formation for the malondialdehyde- (upper panel) 
and glyoxal-based adducts with nucleophilic sites. Upper panel – MDA, througth 
the non-dissociated enolate form (the β-hydroxyacrolein) is able to react with the 
-amino group of Lys, forming the N-propenal-Lys, a reactive intermediate that 
can further react forming additional products. 
Lower panel - Glyoxal can react with Lys and Cys forming N-
(carboxymethyl)lysine (CML) and S-(carboxymethyl)cysteine (CMC) which 
represent the two main reaction products of GO with proteins. Glyoxal can also 
react with Arg forming imidazolinone derivatives and N-(carboxymethyl) 
arginine. Due to the presence of the two carbonyl groups, GO can also react with 
two nucleophilic sites forming cross-links named GOLD and GODIC, formed by 
the reaction of one molecule of glyoxal with two Lys or with one Lys and one Arg, 
respectively. 
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5.1.3 Keto-aldehydes 
 
Methylglyoxal (MGO), 4-oxo-nonenal (ONE) and isoketals (also called 
levuglandins) are the most studied keto-aldehydes responsible of protein covalent 
modifications. 
MGO has different exogenous and endogenous sources and several mechanisms 
of formation. At endogenous level, the main source is represented by the 
involvement of the enzymatic or non-enzymatic degradation of the triose 
phosphate intermediates originating from the glycolytic processes [10]. MGO 
reacts primarily with Arg and Lys forming imidazolinone derivatives and 
carboxyethyl-lysine (CEL) adduct, respectively. Similarly to GO, it can also form 
crosslinks involving Lys and Arg residues (Figure 4). 
4-oxo-nonenal (ONE) is generated by the lipid-oxidation and it is more reactive 
than HNE towards nucleophilic sites. It forms Michael adducts by the reaction of 
C2 and C3 with His, Lys and Cys; moreover, it can form cross-links and Schiff 
base by reacting with Lys. 
Isoketals are highly reactive γ-ketoaldehydes generated by the free radical 
mediated lipid peroxidation of H2-isoprostanes. Isoketals react with the -amino 
group of Lys forming a reversible imine derivative or an irreversible pyrrol 
adduct through a pyrrolidine intermediate [11] (Figure 4).  
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Fig. 4. Reaction mechanisms of formation for the methylglyoxal- (upper panel) 
and isoketals-based adducts with nucleophilic sites. Upper panel: reaction 
pathway of MGO. MGO reacts primarily with Arg and Lys forming imidazolinone 
derivatives and carboxyethyl-lysine (CEL) adduct, respectively. Similarly to GO, 
it can also form crosslinks involving Lys and Arg residues. 
Lower panel: reaction patway of isoketals. Isoketals are highly reactive γ-
ketoaldehydes able to react react with the -amino group of Lys forming a 
reversible imine derivative or an irreversible pyrrol adduct through a pyrrolidine 
intermediate. 
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5.2 Biological implications of RCS induced protein covalent modifications 
 
In the past, RCS such as HNE and MDA and the corresponding protein adducts 
were mainly considered as biomarkers of oxidative damage [12-14]. Several 
assays for their measurement have been set-up and used extensively; among the 
most widespread, there is the TBARS assay, based on thiobarbituric acid, for 
measuring MDA and the assay based on the derivatizing agent 2,4-
dinitrophenylhydrazine, to quantify protein carbonyl [15]. Later, several studies 
demonstrated that RCS and the corresponding protein adducts are also involved in 
the onset and progression of several oxidative-based diseases such as diabetes, 
atherosclerosis and some neurological disorders, therefore nowadays, RCS are 
widely studied as pathogenetic factors as well as drug targets [1, 16]. Several 
mechanisms have been considered to explain the biological effects induced by 
RCS and protein adducts, as summarized below. 
 
5.2.1 Protein function derangement 
 
When RCS react with a target protein, the function of the protein itself can be 
deranged due to several mechanisms, such as a conformational change or the 
impairment of the interaction with the natural substrate when the RCS bind the 
active site of the protein. Proteomic studies have identified several proteins highly 
susceptible to RCS modification and undergoing function derangement [17, 18]. 
In general, most of the target proteins are characterized by nucleophilic sites that 
are not only solvent accessible, but also characterized by a peculiar amino acid 
surrounding environment that stabilizes the most nucleophilic forms (the thiolate 
anion in the case of Cys or the uncharged -amino group in the case of Lys). 
Accordingly, as an example, we found that actin is a very susceptible cellular 
target of electrophilic agents due to the presence of several accessible 
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nucleophilic targets; among these Cys374 was found to be the most reactive [19]. 
The peculiar reactivity of Cys374 can be explained not only by considering its 
accessibility, but also by the presence of surrounding amino acids that stabilize 
the thiolate anion [19]. By using MS strategies we found that actin is the protein 
target of several electrophilic agents including HNE, ACR, [20] and 15-deoxy-
delta 12,14-prostaglandin J2 (15d-PGJ2) [21]. In the case of quite bulky 
electrophiles, such as 15d-PGJ2, the function of actin was found compromised 
also at cellular level, due to a conformational change which induces a 
depolymerization process of fibrillar actin as well as the inhibition of actin 
polymerization, leading to cytoskeletal damage and cell death [21].  
The liver fatty acid-binding protein (L-FABP) is another interesting example 
regarding the derangement of protein function induced by the covalent 
modification generated by RCS. L-FABP adduction by HNE, that has been found 
in several pathological conditions such as alcoholic liver disease, impairs its 
stability and ligand binding ability [22]. 
Other proteins whose functions are altered by RCS covalent adducts have recently 
been reviewed [23, 24]. 
 
5.2.2 The antigenic properties of RCS protein adducts 
 
The antigenic properties of RCS protein adducts and the consequent inflammatory 
response represents an additional mechanism of oxidative damage. Circulating 
antibodies against epitopes formed by the reaction of RCS with proteins were 
found in the sera of patients affected by chronic obstructive pulmonary disease 
(COPD), as well as in a murine model of chronic ozone exposure [25]. HNE 
protein adduction was also proposed as a possible antigenic stimulus for systemic 
lupus erythematosus (SLE) autoantibodies. Alzolibani et al. recently 
demonstrated that the structural perturbation of histone-H2A by HNE makes the 
protein immunogenic and that the neo-epitope might play a role in the induction 
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of circulating autoantibodies in SLE [26]. Human serum albumin is another 
protein that, once modified by RCS such as HNE, increases the production of 
autoantibodies [27]. 
 
5.2.3 The damaging AGEs-RAGE axis 
 
More recently, the role of the receptor RAGE has been widely considered as 
additional mechanism of oxidative damage. RAGE is a multiligand 
transmembrane receptor consisting of an extracellular region, which is composed 
of one ligand-binding V-type Ig domain and two Ig-like C-domains (C1 and C2), 
a short hydrophobic transmembrane-spanning region, and a signal-transducing 
cytoplasmic domain [28]. The RAGE receptor is activated by AGEs, in particular 
those generated by GO and MGO [29]. RAGE activation induces the transcription 
factor NFk-B, leading to a pro-inflammatory and pro-fibrotic response [30]. The 
involvement of RAGE activation for some AGEs has been well documented in 
some animal models, although a clear structure affinity relationship between 
AGEs and RAGE is still missing. 
 
5.2.4 The amyloidogenic properties of RCS protein adducts 
 
RCS can induce oligomerization and aggregation of some target proteins. As an 
example, HNE covalently reacts with amyloid-beta peptides forming cross-links 
and promoting Alzheimer protofibril formation [31]. α-synuclein was reported as 
another RCS target; its covalent modification has been found to induce protein 
oligomerization [32] and an increase of dopaminergic toxicity [33].  
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5.3 Endogenous detoxification of RCS  
 
RCS are efficiently detoxified to unreactive derivatives by both phase I and II 
metabolic pathways. Phase I metabolism is mainly mediated by aldehyde-
oxidizing enzymes and by aldehyde-reducing enzymes, while phase II by 
glutathione-dependent enzymes, as reviewed by O’Brien et al. [8].  
 
5.3.1 phase I metabolism 
 
The oxidation of the carbonyl group to the corresponding carboxylic function is 
usually catalyzed by aldehyde dehydrogenase enzymes (ALDH) and NAD
+
 as 
cofactor. Different aldehyde-oxidizing enzymes, characterized by different levels 
of affinity towards RCS, have so far been reported. For example, ALDH2 
efficiently oxidizes HNE [34], but not MGO, while -oxoaldehdye 
dehydrogenase oxidizes MGO to pyruvate, but not glyoxal nor 3-deoxyglucosone 
[35]. 
The reduction of RCS to the corresponding aldehydes is catalyzed by enzymes 
belonging to three groups of enzymes: the alcohol dehydrogenase family, the 
aldo-keto reductase superfamily and the short-chain dehydrogenase/reductase 
family [8]. 
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Fig. 5. GSH dependent metabolic pathways for the detoxification of α,β-
unsaturated aldehydes (left) and oxoaldehydes (right).  
GSH dependent detoxification of α,β-unsaturated aldehydes- The glutahione 
(GSH) transferases catalyze the conjugation of GSH with the C3 of α,β-
unsaturated alkenals and hydroxyalkenals forming the corresponding Michael 
adducts that are further metabolized by ALDH or ADH to form the corresponding 
acid or alcohol derivatives. In the kidney, the GSH adducts are then hydrolyzed 
and acetylated forming the mercapturic acid derivatives, which are then excreted 
in the urine.  
MG detoxification - The metabolic detoxification of MG starts with the GSH-
methylglyoxal hemithioacetal that is formed by the non-enzymatic reaction 
between glutathione and MG; the metabolite is then isomerized to S-D-
lactoylglutathione by glyoxalase 1 and is then converted to D-lactate and GSH by 
the enzyme glyoxalase 2. 
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5.3.2 phase II metabolism 
 
Two main GSH-dependent enzymes are involved in the phase II metabolism of 
RCS: the glutathione transferases and the glyoxylase system.  
The glutahione transferases (GSTs) catalyze the conjugation of GSH with the C3 
of alkenals and hydroxyalkenals forming the corresponding Michael adducts. The 
adducts still maintain the aldehydic function and can be further metabolized by 
ALDH or ADH to form the corresponding acid or alcohol derivatives. In the 
kidney, the GSH adducts are then hydrolyzed and acetylated forming the 
mercapturic acid derivatives, which are then excreted in the urine [36] (Figure 5).   
The glyoxylase system detoxifies oxoaldehydes, such as glyoxal and 
methylglyoxal, into the corresponding α-hydroxyacid; it consists of two enzymes, 
glyoxalase 1 and glyoxalase 2 and of GSH as a cofactor. As an example, the 
metabolic detoxification of MG starts with the GSH-methylglyoxal 
hemithioacetal that is formed by the non-enzymatic reaction between glutathione 
and MG; the metabolite is then isomerized to S-D-lactoylglutathione by 
glyoxalase 1 and is then converted to D-lactate and GSH by the enzyme 
glyoxalase 2 [37] (Figure 5). 
 
5.3.3 Carnosine and histidine dipeptides as RCS sequestering agents 
 
Carnosine (β-alanyl-L-histidine) is a physiological dipeptide present in large 
amounts in muscular and nervous tissues of vertebrate animals. Interest in this 
endogenous compound is due not only to its high concentrations in some tissues 
(spanning the millimolar range in the skeletal muscle), but also to the fact that its 
synthesis, modulation, transport, and degradation is regulated by a quite complex 
and energy-consuming molecular system [38]. After its discovery at the 
beginning of the XX century, its biological role remained obscure for many 
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decades, although several hypotheses have been proposed: among others, 
carnosine and derivatives such as anserine, balenine and homocarnosine (Figure 
6) have been proposed as possible buffering agents, metal ion chelators, 
antioxidants and neuromodulators, as recently reviewed by Boldyrev et al. [38].  
 
 
 
Fig. 6. Chemical structures of carnosine and its naturally occurring derivatives. 
Carnosine is a dipeptide, composed of beta-alanine and L-histidine. Carnosine is 
the archetype of a family of naturally-occurring derivatives including anserine, 
ophidine (balenine), the L-histidine methylated, and homocarnosine, in which 
beta-alanine is replaced by gamma-aminobutyric acid (GABA). 
 
Moreover, carnosine was found to inhibit protein oxidation, glycation and 
covalent adduction induced by RCS. In this regard, the quenching activity (ability 
of a compound to react with RCS forming unreactive adducted metabolites) of 
carnosine and related histidine dipeptides towards the different classes of RCS 
has been studied in vitro and in vivo since the late 90’s. Overall, these studies 
proposed carnosine, together with GSH, as the most important RCS sequestering 
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agents in vertebrate organisms, and suggested its role in preventing the formation 
of AGEs and ALEs [39]. Such mechanism has been tested in several in vitro and 
in vivo studies conducted by different research groups and besides contributing 
towards a better understanding of the biological role of the endogenous dipeptide, 
it also opened a growing interest towards carnosine derivatives as a novel class of 
bioactive compounds [40]. The in vitro and in vivo studies demonstrating the 
quenching activity of carnosine towards different RCS are summarized below. 
 
5.4 In vitro studies 
 
The first experiments demonstrating the in vitro ability of carnosine to react with 
RCS were performed by incubating the molecule in the presence of different RCS 
at physiological pH (generally pH 7.4) and temperature (37-40C); the reactivity 
was then estimated by measuring the RCS disappearance by HPLC [41]. More 
complex experiments were then carried out, consisting of incubating pure proteins 
with RCS, and then estimating the effect of carnosine on the formation of protein 
carbonyls by observing the modulation of protein crosslinks and oligomers by 
electrophoresis [42, 43]. Later, molecular studies on the reaction between 
carnosine and α-β-unsaturated aldehydes were performed not only to characterize 
their reaction products, but also to elucidate their reaction mechanism [44, 45]. It 
should be noted that analyses aiming at the study of the reaction mechanisms of 
carnosine towards other classes of RCS, such as di-aldehydes and keto-aldehydes, 
are still missing; also the comparison of the quenching efficiency of carnosine in 
respect to the well-known RCS quenchers, such as aminoguanidine, hydralazine 
and pyridoxamine has not yet been reported.  
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5.4.1 α-β-unsaturated aldehydes 
 
Carnosine was reported to quench trans-2-hexenal and 4-hydroxy-2-trans-
nonenal (HNE) by measuring by HPLC their disappearance upon incubation with 
carnosine [41]. The quenching activity of carnosine was higher in respect to its 
constituent amino acids, β-alanine and histidine, as well as of other histidine-
containing dipeptides such as leucyl-histidine, isoleucyl-histidine and valyl-
histidine. Polyunsaturated aldehydes (trans,trans-2,4-decadienal and trans,trans-
2,4-hexadienal) and the non-conjugated monounsaturated aldehyde trans-4-
decenal reacted weakly with carnosine.  
  
5 Carnosine and derivatives as inhibitors of protein covalent modifications 
induced by reactive carbonyl species 
138 
 
 
Fig. 7. Reaction mechanism of carnosine with HNE. With permission from Aldini, 
G., M. Carini, et al. (2002). CAR reacts with HNE trougth a two-steps 
mechanism. The reaction starts with the formation of a reversible Schiff base (an 
,-unsaturated imine, 2a) to yield the macrocyclic adduct 3a through an 
intramolecular Michael addition, which hydrolyzes to form the stable hemiacetal 
derivative 5a 
 
Further studies confirmed carnosine as effective quencher of HNE and identified 
and characterized the reaction products by MS [44]. In particular, two reaction 
products were identified by incubating HNE with carnosine: an imine 
macrocyclic derivative (2a in Figure 7) and a Michael adduct, stabilized as a 5-
member cyclic hemi-acetal (5a). The suggested adduction chemistry presents 
multiple steps: it begins with the formation of a reversible Schiff base (an ,-
unsaturated imine, 2a) to yield the macrocyclic adduct 3a through an 
intramolecular Michael addition, which hydrolyzes to form the stable hemiacetal 
derivative 5a [44, 45]. Structural analyses were based on NMR and mass 
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spectrometry and were performed on carnosine and its analogues N-acetyl-
carnosine and anserine (a N

-methyl derivative of carnosine). N-acetylation of the 
-alanine amine group significantly reduced the quenching activity; this, together 
with the observation on the limited quenching capability of the two constitutive 
amino acids, suggested that both the amino group of the -alanyl residue and the 
imidazole ring of L-histidine synergistically trap HNE. The two step reaction of 
carnosine with HNE also explains the selectivity of the dipeptide towards α,β-
unsaturated aldehydes and that carnosine does not cross-react with physiological 
aldehydes, such as pyridoxal phosphate, a damaging mechanism quite common to 
well-known RCS scavenging agents such as hydralazine, aminoguanidine and 
edaravone [46].  
The fact that HNE reacts with proteins mainly on Lys and His residues [47] 
suggests that carnosine may act as a detoxifying agent by mimicking the target 
amino acids of proteins. 
  
5 Carnosine and derivatives as inhibitors of protein covalent modifications 
induced by reactive carbonyl species 
140 
 
 
 
Fig. 8. LC/MS analysis (positive-ion mode) of skeletal muscle homogenate 
incubated with HNE (5 nmoles/mg protein).  
The upper panel shows the total ion current (TIC); the lower panel shows the MS 
spectrum of the peak eluted at of 9.4 min. The ions at m/z 383, m/z 397 and m/z 
464 correspond to Michael adducts of HNE with carnosine, anserine and GSH, 
respectively. Figure is adapted from Aldini, G., P. Granata, et al. (2002). 
 
Such quenching activity was then demonstrated in tissue by detecting the 
carnosine-HNE Michael adduct 5a in rat skeletal muscle homogenate (Figure 8) 
upon in vitro spontaneous oxidation in aerobic conditions [44] [48, 49], thereby 
confirming the RCS scavenging of carnosine in biological media and that 
carnosine-HNE can be considered as a biomarker of lipid peroxidation. In these 
studies, the anserine-HNE Michael adduct was observed for the first time in 
oxidized rat muscle, too (Figure 8). This finding is consistent with the fact that 
anserine is also present at high concentration in rat muscle and exerts quenching 
activity similar to carnosine in vitro. 
Recently, the ability of carnosine and other carbonyl quenchers (hydralazine, 
aminoguanidine and pyridoxamine) to quench HNE was compared, using 
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ubiquitin as a model of protein undergoing RCS-induced carbonylation [50]. 
HNE covalently modified ubiquitin on lysine and histidine residues, to form 
Schiff base and Michael adducts: all tested compounds were found to dose-
dependently inhibit ubiquitin carbonylation, but carnosine and hydralazine were 
the most effective quenchers. 
 
 
 
Fig. 9. Predominant reaction pathways of CAR with ACR. With permission from 
Carini, M., G. Aldini, et al. (2003).Carnosine reacts with ACR forming several 
molecular species, among which the predominant are: (a) the 14-membered 
macrocyclic derivatives, deriving from the formation of the iminic bond between 
the terminal amino group followed by intramolecular Michael addition of the 
C(3) of the ACRmoiety to histidine; (b) the N
β
-(3-formyl-3,4-dehydropiperidino) 
derivatives arising from the Michael addition of two acrolein molecules to the 
amino group of b-alanine, followed by an aldol condensation and dehydration. 
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In addition to HNE, the reaction between carnosine and acrolein was also 
described in detail[51]. The reaction products obtained in vitro were analyzed by 
mass spectrometry; several molecular species were detected, including 
macrocyclics deriving from the formation of the iminic bond between the 
terminal amino group followed by intramolecular Michael addition of the C3 of 
acrolein to histidine (Figure 9, 1c). Additional reaction products were the N(β)-3-
formyl-3,4-dehydropiperidinos (Figure 9, 2c) deriving from the Michael addition 
of two acrolein molecules to the amino group of β-alanine, followed by aldol 
condensation and dehydration. 
 
5.4.2 Di-aldehydes and ketoaldehydes 
 
Besides α,β-unsaturated aldehydes, carnosine was reported to directly react with 
other reactive RCS [52], such as the di-aldehydes MDA and GO, the keto-
aldehyde MGO as well as with reducing sugars [53]. Several analytical and 
biochemical methods were used to demonstrate the RCS quenching effect, 
although the reaction mechanisms as well as the reaction products have not yet 
been elucidated. For example, the reaction obtained in vitro between carnosine 
and methylglyoxal was observed by spectrophotometry: carnosine was found to 
inhibit methylglyoxal-mediated modification of ovalbumin, chosen as model 
protein [42]. Carnosine also reacts with MDA [43], as demonstrated by its effect 
in preventing MDA-induced protein cross-link and oligomerization. Carnosine 
was also found to protect cultured human and rat cells against the effects of toxic 
RCS such as formaldehyde, acetaldehyde, sugar-deriving AGEs and MDA itself. 
The in vitro studies carried out by Hipkiss [54] et al. mainly focused on the RCS 
quenching ability of carnosine and had a pioneering role in highlighting the 
protective role of carnosine against protein carbonylation in cells, promoting 
carnosine and related analogues as therapeutic targets for the treatment of 
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pathologies involving noxious RCS, such as secondary diabetic complications, 
inflammation and possibly Alzheimer's disease.  
 
5.5 In vivo studies 
 
GSH dependent conjugation represents the most efficient phase II detoxification 
reaction towards electrophilic compounds, including RCS, leading to urinary 
mercapturic acid metabolites. As above reported, in vitro studies carried out either 
in solution or in skeletal muscle homogenates indicate that carnosine and 
analogues can also act as nucleophilic agents able to detoxify RCS (in particular 
,-unsaturated aldehydes), forming unreactive conjugated metabolites. Such 
studies suggest that besides GSH, carnosine could also represent an important 
detoxification pathway of RCS, acting in particular areas, such as skeletal muscle, 
or when GSH is depleted. This important issue has been investigated, although 
not conclusively, in several in vivo studies, as reported in the present chapter. 
One of the first pieces of evidence on the in vivo formation of covalent adducts 
between toxic endogenous aldehydes and histidine dipeptides was reported by 
Orioli et al in 2007 [55]. An analytical LC-MS method was developed and 
validated for the determination of RCS adducts with mercapturic acid and 
carnosine in the urine of obese Zucker rats. The Zucker rat was selected because 
it represents a well-established animal model of metabolic syndrome, since it is 
characterized by obesity, hyperlipidaemia, insulin resistance and renal injury; in 
this animal, the oxidative stress and lipid hydroperoxides lead to RCS and 
ultimately to protein carbonylation processes that are involved in the onset and 
progression of tissue damage [56]. The mass spectrometry method applied in this 
study was set to scan the molecules able to generate the immonium ion of 
histidine (m/z 110), which was used as a diagnostic marker of carnosine products; 
this method, based on the precursor ion scan (PIS) mode, allowed identifying the 
urinary metabolites of carnosine. 
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His containing 
metabolites 
 Urine  
Lean Rats  
4 week old 
Lean Rats 
6 months old 
Zucker 
Rats 
His-DHN 
(m/z 314) 
 
O
NH2
N
N
OH
OH
OH
 
Not found Found Found 
His-HNA 
(m/z 328) 
 
O
NH2
N
N
OH
OH
O
OH
 
Not found Not found Found 
CAR-HNE 
(m/z 383) 
 
OH
O
O
OH
NH
O
NH2
N
N
 
Not found Found Found 
 
Tab. 2. RCS adducts metabolites containing histidine found in the rats’ urine by 
precursor and product ion scan analyses. Two adducts were found in the old lean 
rats, three in the Zucker rats and none of the adducts were found in the young 
lean rats. Data are adapted from Orioli et al [55] 
 
The method was applied to compare the urine of young lean rats (4 weeks old), 
old lean rats (6 months old) and Zucker rats. As reported in Table 2, three distinct 
precursor ions at m/z 314, 328 and 383 were identified in Zucker rats; none of 
them was identified in young lean rats, while two of them (m/z 314 and 383) were 
detected in old lean rats. The characterization of the three carnosine products by 
MS/MS led to the identification of His-1,4-dihydroxynonane (His-DHN, at m/z 
314), His-1,4-hydroxynonanoic acid (His-HNA, at m/z 328) and the Michael 
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adduct carnosine-HNE (CAR-HNE, at m/z 383). These results confirm that RCS - 
and in particular HNE - is generated in physiological conditions, and that its 
formation is associated with aging and with the metabolic syndrome. Once 
identified and characterized, a validated Multiple Reaction Monitoring (MRM) 
method was set-up for their quantitation and to measure HNE-mercapturic acid 
metabolites, such as the 1,4 dihydroxynonane mercapturic acid (DHN-MA), with 
a good sensitivity. 
 
His 
containing 
metabolites 
 
Urine  
Lean Rats 
(nmoles/24h) 
Zucker Rats 
(nmoles/24h) 
His-DHN 
(m/z 314) 
0.9 3.8 
DHN-MA 
(m/z 322) 
16 60 
CAR-HNE 
(m/z 383) 
0.8 2 
 
Tab. 3. Quantitative analysis of RCS metabolites containing His in lean and 
Zucker rat urine. Data are from Orioli et al. [55] 
 
The results, summarized in table 3, well indicate that GSH and carnosine act as 
nucleophilic substrates in the detoxification of HNE, and that GSH is more 
reactive, highlighting the role of GSH as first-line defense against cytotoxic HNE. 
Upon a significant oxidative stress, GSH is likely to be consumed, therefore 
carnosine, due to the fact that it is quite stable towards oxidation (it has a poor 
antioxidant activity in respect to GSH), might acquire a crucial role in detoxifying 
cytotoxic RCS: this mechanism would suggest an interesting cooperation between 
the histidine dipeptides and GSH in RCS metabolism. It is still not clear whether 
the His-HNE metabolites detected in  Zucker rats derive from carnosine-HNE 
adducts or from other sources, such as HNE-protein digestion. 
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The ability of carnosine to form covalent adducts with HNE has been confirmed 
by different studies, which show that the formation of carnosine-HNE metabolites 
correlate with the inhibition of protein carbonyls formation and with a protective 
effect as well, suggesting that the pharmacological activity of carnosine can be 
mediated by the RCS detoxifying activity and by the prevention of ALEs 
formation. In particular, the chronic administration of L-carnosine and of its 
enantiomer, D-carnosine (β-alanyl-D-histidine), to Zucker obese rat significantly 
reduced the development of dyslipidemia, hypertension and renal injury, as 
demonstrated by urinary parameters and by microscope analysis of renal tissue 
biopsies [57]. Such a pharmacological effect was associated with an improved 
excretion of HNE, as carnosine-HNE and histidine-HNE, thereby reducing the 
accumulation of AGEs and protein carbonyls. These data suggest that the 
biological effect of endogenous L-carnosine is not based on a pro-histaminic 
effect, since D-carnosine does not undergo peptidic hydrolysis and therefore it is 
not a histidine precursor; conversely, a direct carbonyl quenching mechanism can 
explain, at least partially, the pharmacological effects of carnosine[57].  
The protective and HNE quenching effect of carnosine was then confirmed in 
apoE null mice feeding a western and pro-atherogenic diet [58]. Treatment with 
D-carnosine octylester (a D-carnosine pro-drug, see chapter 5) attenuated 
atherosclerosis and renal diseases, an effect which was associated with increased 
urinary levels of HNE-carnosine adducts and reduced protein carbonylation, 
circulating and tissue ALEs, expression of receptors for these products, and 
systemic and tissue oxidative stress [58]. 
The RCS quenching ability and the anti-atherogenic effect of D-carnosine (given 
as octyl-ester) was confirmed and further characterized by an independent 
research group [59]. Oral treatment with the drug decreased atherosclerotic lesion 
formation in the aortic valves of apolipoprotein E-null mice. Such 
pharmacological activity was associated with a RCS scavenging effect of D-
carnosine, determined by a decrease in the accumulation of the adducts protein-
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acrolein, protein-4-hydroxyhexenal and protein-4-hydroxynonenal in 
atherosclerotic lesions and by a concomitant increase of urinary excretion of 
aldehydes as carnosine conjugates [59]. 
 
Adduct Urine 
Concentration 
(pmoles/mg 
creatine) 
 Urine  
Healthy Humans  
 
Carnosine-
propanal 
(m/z 283) 
O
OH
NH
O
NH2
N
N
O  
66 ± 17 
 
Carnosine-
propanol 
(m/z 285) 
O
OH
NH
O
NH2
N
N
OH 
200 ± 75 
 
Histidine-
propanal 
(m/z 212) 
O
NH2
N
N
OH
O
 
227 ± 150 
 
Histidine-
propanol 
(m/z 214) 
O
NH2
N
N
OH
OH
 
127 ± 84 
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Adduct Urine 
Concentration 
(pmoles/mg 
creatine) 
 Urine  
Healthy Humans  
 
3-HPMA 
(m/z 220) 
OHNH
S
O
O
OH
 
695 ± 213 
Carnosine-DHN 
(m/z 385) 
OH
OH
O
OH
NH
O
NH2
N
N
 
Found at trace 
levels 
His-HNE 
(m/z 312) 
O
NH2
N
N
OH
OH
O
 
2.7 ± 1 
 
His-DHN 
(m/z 314) O
NH2
N
N
OH
OH
OH
 
2.9 ± 1 
 
Tab. 4. Quantitative analysis of RCS adducted metabolites containing histidine in 
healthy humans.  Acrolein adducts are the most abundant ones, in particular 3-
HPMA, carnosine-propanol, histidine propanol. The concentration is reported as 
pmoles/mg creatine. The data are from [60]. 
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The first paper reporting the identification of carnosine-RCS metabolites in 
humans was published by Baba et al [60]. Urine samples from healthy, non-
smoker adults were analyzed by LC/MS with the aim of identifying carnosine-
aldehyde metabolites. The most abundant metabolites identified by this study 
were carnosine-propanol (m/z 285), carnosine-propanal (m/z 283), histidine-
propanol (m/z 214) and histidine-propanal (m/z 212), resulting from the acrolein 
adduction by carnosine followed by reduction and hydrolysis. The majority of the 
metabolites (75%) were in their reduced form, suggesting that the reduction of 
carnosine/histidine conjugates is an important step of their metabolism. The 
origin of the histidine conjugates is not clear, since they can arise either from the 
hydrolysis of the adducted carnosine, from the direct reaction between histidine 
and acrolein or from the hydrolysis of adducted histidines in proteins. HNE 
adducts were found as well, but in lower amounts than ACR metabolites; for 
example, the urinary concentration of His-HNE (m/z 310) was 75-fold lower than 
His-propanal concentration. Moreover, only trace levels of carnosine-HNE (m/z 
383) and its reduced form carnosine-DHN (m/z 385) were detected. It is important 
to notice that these observations were made on samples obtained from healthy 
volunteers, while no data have been reported for pathological conditions, where a 
significant increase of HNE is expected 
61
.   
Taken together, the above mentioned studies indicate as follows: 1) carnosine and 
its analogues, together with GSH, represent an efficient endogenous detoxifying 
system for RCS and in particular for α,β-unsaturated aldehydes; 2) the 
metabolites arising from the adduction of carnosine/histidine and RCS are 
excreted in the urine mainly in their reduced form, both in healthy humans and 
rodents; 3) the carnosine adduction pathway seems a relevant metabolic fate of 
acrolein’s overall metabolism; and finally that 4) in healthy rat and human urine 
only a low amount of HNE adducts were found: this can be explained by 
considering that in physiological conditions HNE is mainly detoxified by GSH 
and/or that HNE is degraded to generate other metabolites 
60
. 
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Concerning the reduction of RCS-carnosine adducts, Baba et al. [60] found that 
aldose reductase is the enzyme involved in the reducing reaction and that it is able 
to catalyse the reduction not only of carnosine-propanals but also of other 
histidine peptides conjugates such as homo-carnosine and anserine. Studies 
performed on mice lacking aldose reductase (KO mice) confirmed this 
observation, since no reduced metabolites were detected in the urine of these 
animals. The enzyme showed a limited catalytic activity on HNE conjugates; this 
can explain the low levels of the CAR-DHN adduct, in respect to its non-reduced 
form, in both rodent and human urines. Such limited activity was explained by 
considering that in HNE conjugates, HNE is in an hemiacetal form so that the 
aldehyde group is not available for the reducing reaction.   
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5.6 Carnosine derivatives as a novel class of bioactive compounds 
 
Carnosine and the methyl derivatives anserine and ophidine (balenine) are dietary 
dipeptides found in significant amounts in red and white meat and in some fish 
such as tuna, salmon and trout.  
 
 
 
Fig. 10. Metabolic fate of carnosine orally ingested in humans. 
Carnosine is absorbed in intact form, primarily in the jejunum, through an active 
transport, which is accomplished by the oligopeptide transporter 1 (PEPT1). 
Once absorbed, carnosine is hydrolyzed by serum carnosinase. The constitutive 
amino acids histidine and β-alanine are then absorbed from the serum to the 
tissues, where they are the substrates of the carnosine synthase that produces 
carnosine. 
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The dipeptides are absorbed in intact form, primarily in the jejunum, through an 
active transport, which is accomplished by the oligopeptide transporter 1 
(PEPT1). In humans, once absorbed, carnosine and derivatives are efficiently 
hydrolyzed by specific hydrolytic enzymes, named carnosinase (Figure 10). Two 
forms of carnosinase have been identified so far: CN1, or serum carnosinase, and 
CN2, also named tissue carnosinase or cytosolic nonspecific dipeptidase [61]. 
CN1 is highly expressed in the serum of humans and causes the limited 
bioavailability of carnosine, as observed in intervention studies [62]. The 
constitutive amino acids histidine and β-alanine are then absorbed from the serum 
to the tissues, where they are the substrates of the carnosine synthase that 
produces carnosine [63]. By contrast CN1 is absent is non-primate mammals; this 
explains the bioavailability of such dipeptides in the rodents blood.  
Considering the involvement of RCS in the pathogenetic mechanisms of several 
human diseases based on oxidative stress, serum RCS represents an important 
drug target for the discovery of bioactive compounds able to detoxify RCS [1, 
16]. Such an innovative drug target has been validated by testing the efficacy of 
carnosine in several animal models of oxidative-stress based diseases, such as 
metabolic syndrome [57] and atherosclerosis [58, 59] - where RCS act as 
pathogenetic factors. The observed pharmacological activity of carnosine in 
animal models can be explained by considering that the absence of serum 
carnosinase in rodents allows carnosine to reach a plasma concentration able to 
trap circulating RCS, as evidenced by the detection of its adducts in plasma and 
urine. In humans, carnosine probably acts as endogenous detoxifying agent of 
RCS in those tissues where it is present in a high concentration such as skeletal 
muscle, brain and heart, but not in the blood stream due to the presence of 
carnosinase, even following treatment with oral doses of 60 mg/kg body [62, 64].  
Evidence, although indirect, of the potential activity of carnosine, when 
bioavailable in serum, is given by genetic studies. Jansenn et al. first reported that 
diabetic patients with a decreased risk of developing diabetic nephropathy are 
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characterized by a polymorphism of the CNDP1 gene, leading to a reduced 
secretion of serum carnosinase [65]. The disease-protecting effect of lower serum 
carnosinase activity probably relies on the higher stability of carnosine in the 
blood stream or to a local effect of enhanced carnosine availability in the kidney, 
as commented by Boldyrev et al. [38]. 
All the evidence reported above prompted the design of carnosine derivatives 
that, on one hand, maintain or improve the RCS quenching efficacy and 
selectivity of carnosine, and on the other hand are characterized by improved 
bioavailability, as a result of being recognized by PEPT1, but not by carnosinase 
[40]. The first strategy used to obtain stable derivatives involved the inversion of 
the chiral center of histidine leading the enantiomer D-carnosine [57]. D-CAR 
was found to be stable in the plasma, since it is not recognized by carnosinase; its 
HNE quenching efficacy and selectivity were superimposable on those of L-
carnosine. However, D-CAR is less recognized by PEPT-1 in respect to L-CAR, 
resulting in a lower absorption, thus reducing bioavailability despite its 
carnosinase stability. With the aim of improving the bioavailability of D-
carnosine, a set of lipophilic pro-drugs have been designed and synthetized to be 
absorbed through a passive absorption [66]. Among these, the octyl ester of D-
CAR was selected for in vivo studies; its pharmacokinetic profile confirmed the 
improved bioavailability and its efficacy was tested in several animal models, 
including obese Zucker rats and ApoE null mice fed with a Western diet (see 
above) [58, 59]. 
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5.7  Conclusions 
 
Several pieces of evidence indicate that carnosine, together with GSH, is an 
endogenous nucleophilic peptide able to detoxify cytotoxic RCS and in particular 
α,β-unsaturated aldehydes, such as HNE and ACR. 
Michael adducts between carnosine and α,β-unsaturated aldehydes, in both 
reduced and non reduced form, represent the main metabolites so far identified in 
both human and rodent urine and plasma. However several questions remain 
open; in particular it is still not clear whether the carnosine detoxification 
pathway is catalysed by enzymes. Recent evidence indicates that aldose reductase 
is involved in reducing the carbonyl group of the Michael adducts, thus forming 
more stable and unreactive adducts [60]. However, the existence of an enzyme 
catalysing the formation of the Michael adduct and the biological function of 
these metabolites are still unexplored. 
It is now well established that carnosine-mediated detoxification of RCS is 
associated with a protective effect in some animal models of oxidative-stress 
based diseases including atherosclerosis, diabetes, ischemia/reperfusion damage 
and metabolic syndrome. Such promising effects can be explained in rodents, 
where carnosine, due to the absence of serum carnosinase, is bioavailable and acts 
as detoxifying agent of circulating RCS. 
The effect of carnosine in humans is not yet known, due to the absence of 
controlled intervention studies; what it is well established is the lack of carnosine 
bioavailability in serum due to the presence of carnosinase [62, 64]. 
Overall, taking into consideration the biological effect of carnosine as RCS 
detoxifying agent, its lack of bioavailability and the pathogenetic effects of 
circulating RCS, the design of novel carnosine derivatives stable to carnosinase 
represent a promising therapeutic approach [67] [40]. 
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5.8  Summary points 
 The chapter focuses on carnosine as detoxifying agent of reactive carbonyl 
species 
 Reactive carbonyl species (RCS) are generated by lipid and sugar oxidation 
and belong to different chemical classes including α,β-unsaturated aldehydes, 
di-aldehydes and keto-aldehydes; 
 RCS and the corresponding reaction products with proteins (AGEs and ALEs) 
are involved in the pathogenic mechanisms of several oxidative based 
pathologies, such as atherosclerosis and diabetes related diseases; 
 Several mechanisms have been considered to explain the damaging effects of 
RCS and of the corresponding adducts, among these the protein function 
derangement, the antigenic properties of RCS protein adducts, the damaging 
AGEs-RAGE axis and the amyloidogenic properties of RCS protein adducts; 
 RCS are recognized as important pathogenetic mediators and as innovative 
drug targets; 
 RCS are detoxified by phase I and II metabolism; 
 Carnosine is an endogenous histidine dipeptide of dietary source, presents in 
mM concentrations in some tissues but not in serum due to the presence of 
carnosinases that catalytically hydrolyze carnosine to its constitutive amino 
acids; 
 Carnosine was found to be a selective RCS sequestering agent, in particular 
towards α,β-unsaturated aldehydes; 
 Carnosine and its analogues, together with GSH, represent an efficient 
endogenous detoxifying system for α,β-unsaturated aldehydes;  
 the metabolites arising from the adduction of carnosine with α,β-unsaturated 
aldehydes are excreted in urine mainly in their reduced form, both in healthy 
humans and rodents;  
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    the carnosine adduction pathway seems a relevant metabolic fate of acrolein’s 
overall metabolism; 
    By considering the reduced bioavailability of carnosine in human serum due to 
the presence of serum carnosinase, carnosine analogues resistant to 
carnosinases have been proposed and tested in animal models as detoxifying 
agents of circulating RCS; 
  Carnosine derivatives represent a novel class of bioactive compounds. 
 
5.9 Definitions of words and terms 
 
Aldehyde dehydrogenases (ALDHs) are a group of phase I enzymes that 
catalyse the oxidation (dehydrogenation) of aldehydes to the corresponding 
carboxylic acids through a NAD(P)
+
 dependent reaction. 
AGEs: acronym for Advanced Glycation End products. AGEs indicates a 
heterogeneous class of covalent adducts arising from the reaction between 
proteins and RCS generated from the oxidative degradation of sugars. AGEs can 
also be generated by the direct condensation between reducing sugars and Lys 
residues (also called glycation) via the so called Maillard reactions.  
ALEs: acronym for Advanced Lipoxidation End products. ALEs indicates the 
covalent adducts arising from the reaction between protein and RCS generated 
from the oxidation degradation of lipids.  
Carnosine is a β-alanyl-L-histidine dipeptide discovered in 1900 as an abundant 
non-protein nitrogen-containing compound of meat. The dipeptide is not only 
found in skeletal muscle, but also in other excitable tissues. Although the 
biological role of carnosine is still unknown, several biological activities have 
been proposed, among which the carbonyl quenching activity.   
D-carnosine octylester is a new chemical entity synthetized to act as a pro-drug 
of D-carnosine. D-carnosine (β-alanyl-D-histidine) is the enantiomer of carnosine, 
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designed to be stable to carnosinases. D-carnosine octylester is absorbed through 
passive diffusion. 
Glutathione (GSH) is an endogenous tripeptide (γ-L-Glutamyl-L-
cysteinylglycine) acting as a substrate in both conjugation reactions (phase II 
reactions) and reduction reactions. GSH is the main endogenous antioxidant able 
to reduce oxidants and forming the oxidized form (GSSG). GSSG is reduced to 
GSH by glutathione reductase and using NADPH as an electron donor. 
4-hydroxy-trans-nonenal (HNE) is an α,β-unsaturated aldehyde generated by the 
lipid-peroxidation of -6 polyunsaturated fatty acids such as arachidonic and 
linoleic acids. HNE is an electrophilic by-product able to form covalent adducts 
with nucleophilic substrates such as proteins, nucleic acids and phospholipids. It 
is metabolized through phase I and II reactions. 
hPepT1 is a peptide transporter belonging to the POT (proton oligopeptide 
transporter) family. It modulates intestinal absorption and renal reabsorption of 
di- and tri-peptides in a proton dependent way, hence acting like as a 
cotransporter 
Reactive carbonyl species (RCS) are break-down products formed by the 
oxidative damage to lipids and sugars. RCS are electrophilic compounds able to 
form covalent adducts with nucleophilic substrates and in particular with protein, 
nucleic acids and phospholipids.   
Serum Carnosinase (CN2) is a hydrolytic metallo-enzyme found in plasma and 
responsible for the rapid and selective digestion of the absorbed carnosine. It is 
expressed also in CNS where it can hydrolyze homocarnosine thus modulating 
the release of GABA in the brain.  
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6.1 Introduction 
 
Reactive Carbonyl Species (RCS) are a class of highly electrophilic compounds 
that derives from the oxidation of lipids and sugars. RCS are toxic by-products, and 
due to their electrophilic nature, can covalently modify protein, nucleic acids and 
phospholipids, forming toxic adducts. 
RCS, and the corresponding protein adducts, have been studied as biomarkers of 
oxidative damage but it is only in recent years that RCS have also been 
investigated as pathogenetic factors in several diseases such as diabetes, 
atherosclerosis, some neurological disorders and cancer and consequentelly they 
are now considered as a potential drug target  
In physiological conditions, RCS are efficiently detoxified by phase I and phase II 
metabolism. In particular aldehyde dehydrogenase enzymes (ALDH) are mainly 
involved in phase I, while GSH conjugating enymes have a pivotal role in phase II 
metabolism. More recently, the importance of histidine dipeptides as phase II 
detoxifying agents has also been recognized: CAR and  derivatives such as anserine 
covalently react with RCS forming unreactive covalent adducts. The detoxifying 
efficacy of CAR and derivatives was firstly evaluated in vitro by incubating the 
target RCS with CAR and by monitoring the disappearance of RCS by HPLC-UV 
[1]. Then more complex experiments based on HPLC-UV and ESI-MS confirmed 
the CAR quenching activity towards ACR and HNE and the covalent unreactive 
adducts formed were then identified and characterized [2] [3]. Furthermore the 
quenching activity was also shown in oxidized rat muscle [4] , thereby confirming 
that the RCS scavenging activity of carnosine also occurs in biological media and 
that carnosine-HNE can be considered as a biomarker of lipid peroxidation. 
Finally, CAR and CAR derivatives were found to have a protective role against 
protein carbonylation induced by adding RCS to human and rat cell culture [5]. 
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Regarding in vivo/ ex vivo studies, CAR or CAR derivatives were tested in 
different animal models such as the Zucker rat, which is a well established model 
of metabolic syndrome where CAR-RCS adducts were identified, characterized and 
quantified by different MS approaches. It was found that CAR treatment was 
linked to an increase of CAR-HNE, CAR-DHN and 3-HPMA urinary excretion 
which was associated with a decrease of AGEs and ALEs [6]. 
The sequestering activity of CAR and derivatives designed to be stable to 
carnosinases was then confirmed in other animal models. [7, 8]. 
The first paper reporting the identification of carnosine-RCS metabolites in humans 
was published by Baba et al [9]. Urine samples from healthy, non-smoker adults 
were analyzed by LC/MS with the aim of identifying carnosine-aldehyde 
metabolites. The most abundant metabolites identified by this study were 
carnosine-propanol (m/z 285), carnosine-propanal (m/z 283), histidine-propanol 
(m/z 214) and histidine-propanal (m/z 212), resulting from  acrolein adduction by 
carnosine, followed by reduction and hydrolysis. The majority of the metabolites 
(75%) were in their reduced form, suggesting that the reduction of 
carnosine/histidine conjugates is an important step of their metabolism. The origin 
of the histidine conjugates is not clear, since they can arise either from the 
hydrolysis of the adducted carnosine, from the direct reaction between histidine and 
acrolein or from the hydrolysis of adducted histidines in proteins. HNE adducts 
were found as well, but in lower amounts than ACR metabolites; for example, the 
urinary concentration of His-HNE (m/z 310) was 75-fold lower than His-propanal 
concentration. Moreover, only trace levels of carnosine-HNE (m/z 383) and its 
reduced form carnosine-DHN (m/z 385) were detected. It is important to note that 
these observations were made on samples obtained from healthy volunteers, while 
no data have been reported for pathological conditions, where a significant increase 
of HNE is expected [10]. Hence, on the basis of the above mentioned studies, there 
is compelling evidence that carnosine acts as a detoxifying agent of RCS,  not only 
in rodents where it is bioavailable due to the lack of carnosinases but also in 
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humans and that the reduction of RCS, leading to a decrease AGEs, ALEs and 
protein carbonylation, is associated with a beneficial effect. 
Recent evidence links reactive carbonyl species and protein carbonylation to 
several human diseases including obesity and type 2 diabetes mellitus (T2DM). 
Proteomic studies indicate that obesity is accompanied by an increase in the 
carbonylation of a number of adipose-regulatory proteins that may serve as a 
mechanistic link between increased oxidative stress and the development of insulin 
resistance [11]. 
Considering these premises, and in particular that carnosine is an efficient dietary 
sequestering agent of RCS, that RCS are overproduced in obese subjects and that 
by reacting with proteins are linked to the obesity related diseases such as insluline 
resistance, a carnosine supplementation study in overweight/obese human subjects 
was set up. The end point of such an intervention study was to evaluate the 
bioavailability and metabolic fate of carnosine in obese subjects and to demonstrate 
the ability of CAR to detoxify RCS by a direct quenching mechanism by detecting 
and quantifing urinary CAR-RCS adducts. To our knwoledge, this is the first 
intervention study of CAR in overweight/obese human subjects . 
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6.2. Materials and Methods 
 
6.2.1.  Chemicals and Reagents 
 
HPLC-grade water was prepared with a Milli-Q water purification system of 
Millipore (Milan, Italy). 
Acrolein, NFPA (nonafluoropentanoic acid), trichloroacetic acid, sulphosalycilic 
acid, formic acid, sodium phosphate dibasic and LC-grade and analytical-grade 
organic solvents were from Sigma-Aldrich (Milan, Italy). Carnosine (-alanyl-L-
histidine) and the internal standard (IS) H-Tyr-His-OH were a generous gift from 
Flamma S.p.A (Chignolo d’Isola, Bergamo, Italy). 4-hydroxy2-nonenal (HNE) was 
prepared from synthesized 4-hydroxy-2 nonenal diethylacetal as previously 
described and quantitated by UV spectroscopy ( max 224 nm; x 10
4 
cm
-1
 
M
-1
)[12] 
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6.2.2. Biological samples used as the matrix for calibration curves 
 
Calibration curves of carnosine were prepared in human plasma obtained from  
blood samples withdrawn from a  28 years old donor. Blood was collected by 
venipuncture with Terumo venosafe K2EDTA tubes (CEA, Milan, Italy) and 
centrifuged for 10 min at 1000 g at 20 °C. Plasma aliquots were stored at -80 °C 
until their use. A 1.6 M aqueous solution (35 % w/v) of 5-sulfosalicilic acid was 
added to blood at a final concentration of 0.18 M (4% w/v) in order to precipitate 
proteins. Treated blood was kept for 5 minutes at 5 °C and then centrifuged at 
14.000 g at 5 °C in a refrigerated centrifuge, Thermo Heraeus Megafuge ( Thermo, 
Milan, Italy). The supernatant plasma was immediately separated from the 
precipitated red blood cells and stored at -80 °C until its use. 
For the quantitative analysis of carnosine in urine, calibration curves were prepared 
by spiking carnosine in  pooled human urines collected from 6 different volunteers, 
aged from 24 to 28 years old. Urines were kept at -80 °C until their use. 
All the volunteers followed for one day a lacto-ovo-vegetarian diet before the 
collection. 
 
6.2.3 Supplementation study design 
 
This was a single-center randomized double blind placebo controlled intervention 
study of carnosine supplementation to overweight/obese individuals. The daily 
dose of carnosine was 2 g divided into two 1 g doses, administered orally in the 
morning and in the evening for 12 consecutive weeks. The study protocol was 
approved by the local Ethics committee of University Hospital Bratislava, and it 
conforms to the ethical guidelines of the Helsinki declaration from 2000. All 
individuals signed a written informed consent prior study entry. There was one 
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drop-out from the study due to non-compliance. No side effects were reported in 
the course of the study. 
The study population consisted of 31 overweight to obese non-vegetarian sedentary 
individuals, 8 females and 23 males, age 42,45 +/- 7,64 years; BMI 31,87 +/- 4,04 
kg/m
2
. Volunteers did not receive any regular medication nor food supplements 
and were asked to refrain from substantial changes in their lifestyle habits in the 
course of the study. Prior to blood sampling, participants were asked to abstain 
from strenuous exercise, alcohol and caffeine for 3 days. The samples of blood and 
urine were taken in the morning at 8.00 oclock, after a 12-h overnight fast, before 
and after 12-week carnosine supplementation. The samples of urine were 
centrifuged for 10 min at 4°C, 400g. Plasma samples were taken into pre-cooled 
sample tubes containing EDTA and immediately spun down for 10 minutes, 1600g, 
at 4°C. All samples were stored at -80°C.  
 
 
6.2.4. Carnosine-RCS adducts quantification in urine 
 
6.2.4.1 Carnosine-RCS adducts preparation 
 
10 mM carnosine (CAR) was incubated in 100 mM sodium phosphate dibasic 
buffer pH 7.4 at 37 °C with the target reactive carbonyl species (RCS)  in a 10:1 
molar ratio. After an overnight period a first aliquot of the reaction mixture was 
stored at -20 °C  and a second  aliquot was reduced with 100 mM NaBH4 (final 
concentration), for 30 minutes at room temperature, in the dark. At the end of the 
incubation periods both the aliquots were diluted 1:50 with H2O mq. and then 
analysed by LC-ESI-MS in order to assay the type of adducts and to perform a 
semi quantitative calculation of the adducts formed. The ion responses of the CAR-
RCS-adducts were determined by measuring the peak areas in the selected ion 
chromatograms (SICs) reconstituted by using the corresponding [M+nH]
n
+ as filter 
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ions. The peptide responses were normalized with respect to Tyr-His (TH) 
dipeptide, chosen as internal standard. 
Afterwards both the aliquots were analysed by HPLC-UV to measure ACR and 
HNE consumption. These two RCS were determined by reverse-phase LC, using a 
Thermo-finnigan ( Thermo, Milan, Italy) instrument, equipped with a quaternary 
pump system, an on-line degasser and a UV-Vis diode array programmable 
detector operating at 223 nm. Analyses were performed on a Agilent Zorbax SB-
C18 (150 x 2.1 mm i.d., particle size 3.5 µm). The mobile phase (isocratic elution) 
was water/acetonitrile/ortophosphoric acid (6.6:3.4:0.001 v/v/v) delivered at a flow 
rate of 0.2 mL/min. 
The concentration of the adducts were calculated on the basis of acrolein and HNE 
consumption  (95 % and 93 % of consumption respectively) by using the semi 
quantitative values of each adducts calculated by ESI-MS spectra. In particular the 
reduced reaction mixture was evaluated in order to determine the adduct 
concentration, since the reduced adduct are chemically stabilised and the 
corresponding retro-reactions cannot occur. Stock solution of carnosine-RCS 
adducts were evaluated each time, before their use for the calibration curve, by 
means of LC-ESI-MS to ensure that the concentrations of the original solutions 
were within the limits of the maximum established error (≤ 5%). 
The semi-quantitative percent of each adducted derivative was calculated by the 
following equation: (normalized area of compound A / sum of the normalized areas 
of all the considered compounds)*100. All considered compounds are listed in 
table 1 and as an example the CAR-propanal adducts concentration was calculated 
as follows: 
[CAR-propanal]= [(normalized area of CAR-propanal) / (∑ normalized areas of 
compounds listed in table 1)] * [ RCS concentration used for the incubation * % of  
RCS consumption calculated by HPLC-UV] 
[Car-propanal]= [ (1.3 a.u. / 3.9 a.u )] * [1 mM * 0.95] = 0.32 mM 
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6.2.4.2 Carnosine-RCS calibration curves 
 
Internal standard calibration curves were set up for carnosine-propanal (CAR-
propanal) and carnosine-propanol (CAR-propanol) adducts. 
Urine pool sample from six volunteers was used as blank urine to prepare positive 
control urine samples. This urine was checked by the applied analytical procedure 
to ensure it did not contain the selected adduct above the FDA prescribed limit, that 
is ≤ 20 % of the LLOQ area [13]. Calibration samples for adducts were prepared by 
spiking blank urine samples with each adduct working solution to provide the 
following final concentrations: 0.1, 0.8, 1.6, 4.8, 9.6 µM for carnosine propanal and 
0.2, 1.6, 3.2, 9.6, 19.2 µM for carnosine-propanol. The internal Standard, TH, was 
added at a final concentration of 1 µM. Each sample was then treated as the ex vivo 
samples, as explained in the following paragraph. Calibration standards were 
analysed in duplicate in two independent runs. The calibration curves were 
constructed by least square linear regression analysis of the peak area ratios of each 
analyte to the IS against nominal analyte concentration. 
 
6.2.4.3 Ex vivo urine samples preparation for CAR-RCS adducts detection and 
quantification 
 
All the urine samples analysed in this study were treated as follows. 300 µL of 
urine were centrifuged at 14.000 g for 10 minutes by using a refrigerated 
centrifuge, Thermo Heraeus Megafuge (Thermo, Milan, Italy), in order to remove 
the particulate matter. 
All the urinary supernatants was collected and then 10 µL of TH stock solution 30 
µM was spiked into 290 µL of urine, in order to have a final TH concentration of 1 
µM. Afterwards in order to remove the possible proteins present in the urine, it was 
filtered by Amicon centrifugal filter device with a molecular cut-off of 3 KDa 
(Millipore, Milan, Italy). 
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The filtered urinary solution was then placed in a plate well, ready to be injected in 
the  liquid chromatography system. 
 
6.2.4.4 Liquid chromatography electrospray ionization mass spectrometry/mass 
spectrometry analysis (LC-ESI-MS/MS): LTQ Orbitrap XL mass spectrometer 
 
All the filtered urine samples were separated by online liquid chromatography 
(nanoLC) and analyzed by electrospray tandem mass spectrometry (ESI-MS/MS); 
The chromatographic system was the UltiMate 3000 RSLCnano System (Dionex). 
An aliquot of 20 µL of urines were loaded in a 20 µL sample loop in full loop 
mode and then injected in a Phenomenex Polar analytical column, 4 µm particle 
size, 2 mm i.d., 150 mm length, protected by a polar RP guard column 4µm particle 
size, 2 mm i.d., 4 mm length (Phenomenex, Italy). buffer A, H2O mq containing 
0.08 % nonafluoropentanoic acid (NFPA), and buffer B, pure acetonitrile, were 
used as mobile phases. For the initial 3 minutes the flow was diverted in the waste 
in order to perform on-line sample desalting. After 5 minutes of isocratic elution at 
99 % buffer A, Gradient elution started from 99 % buffer A to 80% acetonitrile (B) 
in 24 min at a flow rate of 0.2 mL/min followed by a 5 min isocratic elution. The 
composition of the eluent was then restored to 100% A within 1 min, and the 
system was re-equilibrated for 5 min. The samples rack was maintained at 4 °C. 
A LTQ Orbitrap XL mass spectrometer (Thermo Italia, Milan, Italy) with 
electrospray ionization (ESI) source was used for mass detection and analysis. 
Mass spectrometric analyses were performed in positive ion mode. ESI interface 
parameters were set as follows: middle position; capillary temperature 275 °C; 
spray voltage 4.5 k, tube lens voltage 100 V, capillary voltage 40 V. Nitrogen was 
used as nebulising gas at the following pressure: sheath gas 35 a.u.; auxiliary gas 
10 a.u. MS conditions and tuning were performed by mixing through a T-
connection the water-diluted stock solutions of analytes (flow rate 10 µL/min), 
with the mobile phase maintained at a flow rate of 0.2 mL/min: the intensities of 
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the [M + H]
+
 ions were monitored and adjusted to the maximum by using the 
Quantum Tune Master software (Thermo, Milan, Italy). Two runs for each samples 
were performed, with the method here described. 
 
6.2.4.4.1 Orbitrap data-dependent scan and targeted scan 
 
During analysis, a LTQ-Orbitrap XL mass spectrometer continuously performed 
scan cycles in which first an high-resolution (resolving power 30.000, fwhm at m/z 
400) full scan (150-1000 m/z) in profile mode was made by Orbitrap, after which 
MS2 spectra were recorded in centroid mode for the 3 most intense ions, using both 
CID and HCD modes (isolation width, 3 m/z; normalized collision energy, 50 CID 
arbitrary units, 45 HCD arbitrary units). Protonated phthlates [dibutylphthlate 
(plasticizer), m/z 279.159086; bis(2- ethylhexyl)phthalate, m/z 391.284286] and 
polydimethylcyclosiloxane ions [(Si(CH3)2O)6 + H]
+
; m/z 445.120025] were used 
for real time internal mass calibration. Dynamic exclusion was enabled (repeat 
count, 2; repeat duration, 30 s; exclusion list size, 500; exclusion duration, 60 s; 
relative exclusion mass width, 10 ppm). Charge state screening and monoisotopic 
precursor selection was enabled, four times and unassigned charged ions were not 
fragmented. 
Furthermore in the method was set a targeted ms/ms scan in which only the 
precursor ion listed in tab.1 were fragmented by CID collision ( precursor ion m/z 
width: 10 ppm, isolation width 3 m/z; normalized collision energy, 50 CID a. u.). 
The list of precursor ions as reported in table 1 was filled in by considering the 
known CAR-RCS adducts so far reported in the literature in in vitro and ex vivo 
studies. 
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m/z Analyte 
156.07675 His 
212.10296 His-propanal 
214.11861 His-propanol 
220.06380 3-HPMA 
227.11387 CAR 
265.12952 CAR-ACR-SB 
267.14517 CAR-ACR-SB-red 
283.14008 CAR-propanal 
285.15573 CAR-propanol 
302.14205 MA-HNE-SB 
312.19178 His-HNE 
314.20743 His-DHN 
319.14008 Tyr-His (IS) 
320.15262 HNE-MA 
321.15573 CAR-ACR-FDP 
322.16827 DHN-MA 
323.17138 CAR-ACR-FDP-red 
367.23398 CAR-HNE-SB-red 
383.22890 CAR-HNE-MA 
385.24455 CAR-DHN 
 
Tab. 1. Precursor ions list corresponding to the main target compound of this study 
  
6 Intervention study of Carnosine in obese volunteers: bioavailability and reactive 
carbonyls species sequestering effect 
177 
 
 
6.2.5 Carnosine quantification in urine and plasma  
 
The urine and plasma carnosine was measured by using an internal standard and a 
triple quadrupole (TSQ quantum ultra, Thermo, Milano, Italy) in MRM scan mode 
as mass analyzer. 
 
6.2.5.1 Calibration curves in urine and plasma 
 
Two different calibration curves were set up for carnosine quantification both in 
urine and plasma. Blank matrices for calibration curves set-up were obtained by 
pooling urine and plasma from six volunteers aged from 24 to 28 years old and 
following a lacto-ovo-vegetarian diet for one day before the collection. Before 
pooling, the biological fluids were analyzed to ensure they did not contain the 
selected adduct above the 20 % of limit of quantitation [2]. Calibration samples 
were prepared by spiking carnosine in blank matrices at the following final 
concentrations: 0.5, 1, 5, 25, 50, 100, 200 µM for urine and  0.1, 0.5, 1, 5, 10, 20, 
50, 100 µM for plasma. The internal standard, TH, was added at a final 
concentration of 35 and 5 µM for urine and plasma, respectively. Samples were 
then treated as the ex vivo samples, using the analytical procedure reported in the 
following paragraph. 
Three independent samples were prepared for each level of the calibration curve 
and each of them was analyzed in triplicate. The calibration curves were built by 
the least square linear regression analysis by plotting the ratios between the peak 
areas of the analyte and the IS against the analyte’s nominal concentration. 
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6.2.5.2 Ex vivo sample preparation for CAR quantification in urine and plasma 
 
For LC-MS analysis the urine samples were treated as follows: aliquots of 150 µL 
were mixed with 150 µL of an aqueous solution of 4 % TCA (v/v) and the spiked 
with TH to reach a final concentration of 70 µM. The sample was then centrifuged 
at 14.000 g for 10 minutes by using a refrigerated centrifuge, Thermo Heraeus 
Megafuge ( Thermo, Milan, Italy), in order to remove the particulate matter. 
All the urinary supernatant was collected and then an aliquot was placed in a plate 
well, ready to be injected in the chromatography system. 
Instead considering plasma samples an aliquot of 40 µL of deproteinized plasma 
was mixed with 360 µL of a solution consisted in 5 mM ( 0.08%) NFPA and 5.56 
µM of TH in water. Afterwards it was centrifuged as done for the urine and placed 
in a plate well. 
 
6.2.5.3 Liquid chromatography electrospray ionization multiple reaction 
monitoring analysis ( LC-ESI-MRM): TSQ mass spectrometer 
 
A Surveyor HPLC system ( Thermo, Milan, Italy) equipped with a quaternary 
pump and a thermostated autosampler was employed for solvent and sample 
delivery. Separations were perfomed with a Phenomenex Polar analytical column, 
4 µm particle size, 2 mm i.d., 150 mm length, protected by a polar RP guard 
column 4µm particle size, 2 mm i.d., 4 mm length (Phenomenex, Italy). Buffer A, 
H2O mq containing 0.08 % nonafluoropentanoic acid, and buffer B, pure 
acetonitrile, were used as mobile phases. 
An aliquot of 10 µL of urine was loaded in a 20 µL sample loop, partial loop mode, 
and then injected in the analytical column. Instead for the plasma an aliquot of 50 
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µL was loaded in a 100 µL sample loop, in partial loop loading mode. The gradient 
employed were the same for urine and plasma. 
For the initial 3 minutes the flow was diverted in the waste in order to perform on-
line sample desalting. The mobile phases were kept isocratic for five minutes at 99 
% buffer A and 1 % buffer B. Then in one minute the buffer B increased to 30 % 
and it was kept constant for 3 minutes, afterwards in one minute the buffer B 
increased to 60 % and it was maintained for one minute. Then in one additional 
minute the mobile phases were restored at the initial conditions and the 
equilibration lasted 5 minutes.  
A TSQ Quantum Ultra mass spectrometer (Thermo Italia, Milan, Italy) with 
electrospray ionization (ESI) source was used for mass detection and analysis. 
Mass spectrometric analyses were performed in positive ion mode. ESI interface 
parameters were set as follows: middle position; capillary temperature 275 °C; 
spray voltage 4.5 k, tube lens 100 V, skimmer lens 5 V, capillary 40 V. Nitrogen 
was used as nebulizing gas at the following pressure: sheath gas 35 a.u.; auxiliary 
gas 10 a.u. A MRM method was optimized in order to quantify Carnosine. The 
selected MRM transitions were for CAR: 227.1 110.1 + 122.1 ,and for TH: 319.1 
 110.1 + 156.1. The parameters influencing these transitions were optimized as 
follows: argon gas pressure in the collision Q2, 1.5 mbar; peak full width at half-
maximum (FWHM), 0.50 m/z at Q1 and Q3; scan width for all MRM channels, 0.5 
m/z; scan rate (dwell time), 0.1 s/scan. Data processing was performed by the 
Xcalibur 2.0 software. Fragmentation was done using CID mode (isolation width, 
0.5 m/z; normalized collision energy, 28 CID arbitrary units).  
MS conditions and tuning were performed by mixing through a T-connection the 
water-diluted stock solutions of analytes (flow rate 10 µL/min), with the mobile 
phase maintained at a flow rate of 0.2 mL/min: the intensities of the [M + H]+ ions 
were monitored and adjusted to the maximum by using the Quantum Tune Master 
software 
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6.2.6 Intact protein analysis of plasma to profile human plasma albumin  
 
Whole human plasma was analysed by ESI-MS intact protein analysis in order to 
profile human plasma albumin (HSA), in particular to determine the relative 
percentage content of mercapto-albumin ( HSA-SH), cysteinilated albumin (HSA-
S-S-Cys) and glycated albumin ( HSA-N-Glc). 
Human plasma was centrifuged at 14.000 g for 10 min at 4 °C for removal of 
particulate matter. Then the plasma was diluted 1:200 with denaturing buffer 70 % 
H2O , 30 % CH3CN and 0.2 % HCOOH. 
An automated loop injection was used to carry the sample to the ESI source. The 
autosampler and the pump used were modules of a Surveryor HPLC (Thermo, 
Milano, Italy). The mobile phase employed was the denaturing buffer. An aliquot 
of 10 µL of plasma were loaded in a 20 µL sample loop, partial loop mode. A flow 
of 10 µL/min carried the sample towards the ESI source, coupled to a TSQ 
Quantum mass spectrometer, that operated in positive ion mode. 
Analyses were carried out under the following instrumental conditions: full scan 
mode, mass range m/z 1400-1500, positive-ion mode, 3 microscan, peak full width 
at half-maximum (FWHM), 0.50 m/z at Q1 and Q3, capillary temperature 275°C , 
spray voltage applied to the needle 4.0 kV; capillary voltage 40 V ; tube lens 
voltage 200 V ; nebulizer gas (nitrogen) flow rate set 10 a.u. ; acquisition time 10 
min. The percentage of each albumin isoform was calculated by semiquantitative 
mode: [(intensity of isoform A peak) / ( sum of all the intensities considered)]*100 
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6.2.7 Fluorescence and UV-vis assays for urine samples quantification of total 
protein, Advanced Glycation End products (AGE) and creatinine.  
 
Fluorescence and UV-vis assays were used for determine the content of Advanced 
Glycation End products (AGE), creatinine and protein in urine.  
Concerning creatinine determination a colorimetric assay (Cayman, USA), based 
on Jaffe reaction, was employed to determine creatinine concentration in urine. The 
urine samples are diluted 1:10 with H2O mq and then treated with an alkaline 
picrate solution. When the creatinine reacts with the picrate a yellow/orange 
coloration is formed. The color intensity is proportional to creatinine concentration 
and it is measured at 500 nm. The sample creatinine concentration is determined 
using a creatinine standard curve The color derived by creatinine is then destroyed 
at acidic pH at the intensity is measured again as a factor of correction. The 
protocol followed is provided by the manufacturers and is based on a paper of 
Heinegard et al.[14] 
Total protein concentration in urine was calculated by means of Bradford assay, 
following the procedure reported in Bradford and Zor papers. [15, 16] 
Moreover  in order to measure urinary AGE 50 µL of urine of each sample were 
diluted with 950 µL of physiological solution ( 0.9 % NaCl). Then the diluted 
sample was read with a fluorimeter, Perkin Elmer LS50B (Perkin Elmer, Lissone, 
Italy). The excitation λ was set at 370 nm with a slit of 5 nm, instead the emission λ 
was set at 440 nm with a slit of 5 nm. 
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6.2.8 Fluorescence and UV-vis assays for plasma samples quantification of total 
protein, Advanced Glycation End products (AGE), Advanced Oxidation Protein 
Products (AOPP), Protein Carbonyls ( PCO) and Carboxy Methyl Lysine (CML). 
 
Total protein concentration in plasma was calculated by means of Bradford assay, 
following the procedure reported in [3, 4]. 
Furthermore AGE in plasma were measured as done for the urine, paragraph 6.2.7. 
The only difference was that an aliquot of 20 µL of each plasma sample was 
diluted with 980 µL µL of physiological solution ( 0.9 % NaCl). 
AOPP were quantified following the protocol reported in Witko-Sarsat et al article 
[17]. Briefly an aliquot of plasma was fivefold diluted with PBS solution, then 200 
µL of the diluted plasma was placed in a well and there were added 20 µL of 
concentrated acetic acid, then 10 µL of a 1.16 M potassium iodide solution, and 
finally 20 µL of concentrated acetic acid. The treated solution was read at a λ of 
340 nm by a Wallac Victor
2 
multilabel counter, Perkin Elmer (Perkin Elmer, 
Lissone, Italy). 
Protein carbonyls were measured by a PCO assay based on 2,4-
Dinitrophenylhydrazine (DNPH) reaction. The protocol followed is described in 
Levine et al article [18] 
CML levels in plasma were quantified by OxiSelect™  Nε-(carboxymethyl) lysine 
(CML) Competitive ELISA Kit (Cellbiolabs , Milan, Italy) and the procedure 
followed is described in the paper of Reddy et al [19]. 
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6.2.9 informatics 
 
Graphpad prism 5.0 ( Graphpad Software Inc, USA) was employed for ANOVA, t 
test analysis, outliers analysis and to display the graphs reported. Origin 6.0 ( 
Originlab Corp, USA) was used for the Principal Component Analysis (PCA) of 
the data. The dataset considered is reported in tab 2. 
Direct infusion ESI-MS spectra were deconvoluted using the software MagTran 
1.02 [20]. 
  
6 Intervention study of Carnosine in obese volunteers: bioavailability and reactive 
carbonyls species sequestering effect 
184 
 
 
Short 
name 
Pal 
 
Pol 
 
CAR 
 
uAGE 
 
Cre 
 
Treatment 
 
Long 
name 
CAR-
Propanal 
[µM] 
CAR- 
Propanol 
[µM] 
Carnosine 
[µM] 
Urinary 
AGE 
[UF/mg] 
Urinary 
Creatinine 
[µM] 
1= treated 
0= placebo 
Sample 
# 
      
1.1 0.60 0.98 0.09 95016.23 3359.33 1 
2.1 0.89 0.87 13.70 36248.38 10962.01 0 
3.1 0.79 0.59 1.38 179178.50 8928.74 0 
4.1 0.35 0.63 4.95 11607.98 10608.40 1 
5.1 0.85 0.99 8.84 50900.38 12376.47 1 
6.1 0.53 0.78 15.32 69441.75 14940.16 1 
7.1 0.60 0.98 3.65 31596.34 22100.83 1 
8.1 2.11 3.01 12.08 36506.03 17327.05 0 
9.1 1.69 1.69 21.15 49801.15 18387.89 1 
10.1 1.33 1.67 9.81 38852.83 20774.78 0 
11.1 5.58 5.93 8.84 56676.64 18034.28 1 
12.1 2.76 1.41 17.58 33252.95 18829.91 1 
13.1 2.35 2.69 19.20 40689.36 11669.24 1 
14.1 1.56 1.70 5.27 33021.29 28200.66 1 
15.1 0.38 0.60 0.50 41767.84 2210.08 0 
16.1 1.03 1.52 14.34 23034.14 20951.59 1 
17.1 0.66 0.92 10.46 94474.03 10431.59 0 
18.1 1.06 0.96 4.62 31868.90 19713.94 0 
19.1 0.88 1.08 5.92 20511.83 14586.55 0 
20.1 1.77 2.26 6.57 56482.91 25636.97 0 
21.1 1.33 1.51 20.82 82519.63 27493.44 0 
22.1 1.04 1.18 2.68 23565.11 9459.16 0 
23.1 1.16 1.14 3.33 75835.34 14763.36 1 
24.1 0.79 0.99 9.48 71383.66 12376.47 1 
25.1 0.67 1.02 7.22 16241.13 12906.89 0 
26.1 2.41 2.81 15.96 23539.91 35361.34 1 
27.1 0.35 0.66 1.06 30647.07 4066.55 0 
28.1 1.47 1.66 7.86 14332.35 12376.47 1 
29.1 0.45 0.75 1.38 15338.17 9547.56 1 
30.1 0.82 1.00 11.10 32018.84 23868.90 0 
31.1 2.92 2.39 15.32 31039.78 23161.67 0 
1.3 0.89 0.84 1.38 39736.23 6011.43 1 
2.3 1.16 1.02 14.34 29490.38 17857.47 0 
3.3 0.52 0.67 3.65 94568.77 13348.90 0 
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Short 
name 
Pal 
 
Pol 
 
CAR 
 
uAGE 
 
Cre 
 
Treatment 
 
Long 
name 
CAR-
Propanal 
[µM] 
CAR- 
Propanol 
[µM] 
Carnosine 
[µM] 
Urinary 
AGE 
[UF/mg] 
Urinary 
Creatinine 
[µM] 
1= treated 
0= placebo 
Sample 
# 
      
4.3 1.14 0.77 11.10 77766.83 6011.43 1 
5.3 0.64 0.78 7.54 19589.95 6983.86 1 
6.3 0.66 0.66 45.77 40372.10 8044.70 1 
7.3 0.89 0.84 13.05 30548.59 20597.98 1 
8.3 2.55 2.80 12.40 61299.19 23868.90 0 
9.3 1.86 1.04 306.58 43738.10 25106.55 1 
10.3 n.d n.d n.d n.d n.d 0 
11.3 0.61 0.83 0.74 13770.30 3536.13 1 
12.3 2.43 1.68 25.68 28168.29 19448.73 1 
13.3 5.49 4.05 350.00 34044.32 12906.89 1 
14.3 3.39 1.75 33.13 31601.24 31117.98 1 
15.3 0.65 0.77 3.98 24895.03 6630.25 0 
16.3 1.80 1.40 31.51 35076.54 20951.59 1 
17.3 0.83 0.89 7.54 147585.00 10077.98 0 
18.3 1.16 1.04 5.60 25859.63 16619.83 0 
19.3 1.06 1.23 4.62 18000.23 11669.24 0 
20.3 1.20 1.06 1.38 93316.45 24752.93 0 
21.3 1.00 1.00 6.89 87777.01 15382.18 0 
22.3 0.67 0.84 1.38 22199.30 5481.01 0 
23.3 1.65 1.44 8.19 74043.56 16177.81 1 
24.3 3.74 2.47 52.90 64373.43 21482.01 1 
25.3 0.56 1.13 6.89 78083.61 23868.90 0 
26.3 4.81 3.47 19.53 22171.63 32355.62 1 
27.3 3.01 1.25 9.16 31386.72 12553.27 0 
28.3 1.61 1.25 146.86 52720.72 7160.67 1 
29.3 1.88 1.56 12.72 24416.88 20421.17 1 
30.3 0.57 0.80 5.27 24255.29 9635.96 0 
31.3 1.53 1.36 9.48 41847.23 18211.09 0 
 
Tab. 2. Urinary variables submitted to PCA analysis. In sample number column n.1 
means before supplementation, n.3 means after supplementation  
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6.3 Results 
 
6.3.1 Carnosine-RCS-adducts preparation and quantification  
 
Table 3 shows the concentrations of the reduced forms of ACR and HNE carnosine 
adducts prepared in in vitro conditions. Reduction of the carbonyl adducts was 
carried out using in order to make the adducts more stable. Calibration curves built 
using the reduced forms were also used to estimate the amount of the non reduced 
derivatives.   
When  CAR was incubated in the presence of ACR, the following adducts were 
identified and are here ordered from the most to the least abundant: carnosine-
formyl-dehydropiperidinyl adduct (CAR-FDP), carnosine-aldimine-adduct (CAR-
SB-ACR), carnosine-propanol (CAR-propanol) and carnosine-methyl-pyridine 
adduct (CAR-MP). 
Only two adducts were formed when carnosine was incubated with HNE, namely 
carnosine dihydroxynonane (CAR-DHN) and CAR-aldimine-HNE (CAR-SB-
HNE). Table 4 depicts the chemical structures of the above mentioned carnosine 
adducts.  
Carnosine adducts were then analyzed by LC-ESI-MS. Figure 1 shows the Single 
Ion Chromatograms (SIC) traces of the CAR-RCS adducts extracted by using the 
[M+nH]
n+
 as filter ions (table 1) and using a mass tolerance of 5 ppm.. 
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A) CAR 10:1 ACR 
Adduct 
CAR-
propanol 
Car SB ACR-
red 
CAR FDP-
red 
CAR-MP 
Concentration 230 uM 295 uM 415 uM 10 µM 
B) CAR 10:1 HNE 
Adduct CAR-DHN CAR-SB-HNE-Red 
Concentration 497 uM 453 uM 
 
Tab. 3. The concentration of the various CAR-RCS adducts are reported. In A) 
section there are the CAR-ACR incubation derived adducts, instead in section B) 
there are the CAR-HNE incubation derived adducts. 
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O
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Tab. 4. Structural formulas of the CAR-RCS adducts identified and quantified after 
incubation of CAR with ACR and HNE. For each compound the corresponding 
reduced form is displayed, except for CAR-MP that can’t be reduced by NaBH4 
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Fig.1. SIC traces of the adducts formed by incubating CAR with ACR (panel A) and 
HNE (panel B) followed by NaBH4 reduction. . The bottom pnarl reports the SIC 
trace relative to the internal standard, Tyr-His. 
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6.3.2 Preliminary LC-Orbitrap-MS/MS analysis for adduct identification 
 
Carnosine-RCS adducts were searched for in the urine samples by using LC-
orbitrap as described in the methods section and using Tyr-His as internal standard. 
Among the searched for adducts, only CAR-propanal and CAR-propanol adducts 
were found. The presence of the two adducts was confirmed in all 31 patients both 
before and after carnosine supplementation. The SIC traces of both the adducts 
identified in urine samples are shown in Figures 2 and 4.  Figure 2  relates to the 
SIC trace of carnosine propanal (ion current at m/z 283.14008 and a mass tolerance 
of 5 ppm) as identified in the urine of patient number four. 
Identification of the CAR-propanal adduct was firstly based on the accurate mass 
and retention time; accurate mass showed a mass difference of only 0.14 ppm in 
respect to the simulated mass; the retention time at 14 ± 0.3 min was found 
superimposable in respect to that observed for the CAR-propanal standard. Final 
assignment of the structure was achieved by MS/MS experiments: the ion at m/z 
283.1400 was fragmented and the acquired tandem mass spectrum is reported in 
figure 3 (upper panel). The lower panel shows the MS/MS spectrum of the CAR-
propanal standard. The two MS spectra are almost superimposable, showing ten 
common fragment ions whose structural attribution is listed in tab.5. 
Fig 4 shows the SIC trace of the ion at m/z 285.15573 relative to the urine of 
patient number four. The SIC shows a peak characterized by a retention time of 
14.5 ± 0.3 min which can be attributed to the carnosine propanol adduct. The 
experimental m/z was 285.15588, characterized by a mass error of 0.53 ppm in 
respect to the theoretical mass. The tandem mass spectrum of the ion at m/z 
285.15588 identified in the urine sample is shown in fig 5 (upper panel) and is 
characterized by a fragmentation pattern very similar to that recorded for the CAR-
propanol standard (lower panel); nine diagnostic fragment ions were found in 
common in the two spectra and their structural attribution is summarized in tab.6. 
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Fig. 2. Upper panel:  SIC chromatogram reconstituted by setting the ion at m/z 
283.14008 as filter ion and a 5 ppm tolerance. Lower panel: full mass spectrum 
relative to the peak at a retention time of 14.0 min and identified as CAR-propanal 
ion
Patient 4 post 
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Fig. 3. Tandem mass spectrum of the ion at m/z 283.14004 identified in the urine sample. The lower panel shows the 
MS/MS spectrum of the carnosine-propanal standard. The attribution of the diagnostic fragments is reported in tab.5 
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Tab. 5. Structure attribution of the fragment ions present in MS2 spectrum of 
car-propanal   
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Fig. 4. In upper panel there is the  SIC chromatogram of CAR-propanal ion 
based on m/z: 283.14008, extracted with 5 ppm of mass filter. Instead in the 
lower panel there is the corresponding full mass spectrum in which the top 
peak was identified as CAR-propanol ion
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Fig. 5. Tandem mass spectrum of ion 285.15573. The corresponding fragments are reported in tab.6 
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Tab. 6. The fragment ions present in MS2 spectrum of car-propanol 
precursor ion are reported   
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6.3.3 Carnosine propanal and Carnosine propanol calibration curves in 
urine. 
 
Quantification of the carnosine adducts was carried out by using an internal 
standard calibration method. Urines of young volunteers were chosen as 
matrices to set-up the method and both the analytes were detected in such 
samples.  
Samples were then spiked with the standards and the LLOQs were 0.10 µM 
for CAR-propanal and 0.20 µM for CAR-propanol; the LOD of both the 
analytes were of 0.03 µM. 
The endogenous content of both the analytes was not quantified in the urine 
of young volunteers, since the area under the peak was 16 % and 18 % of the 
LLOQ peak for CAR-propanal and for CAR-propanol respectively. Fig.6 and 
7 show the extracted single ion chromatograms (SICs) of CAR-propanal at 
m/z 283.14008 and CAR-propanol at m/z 285.15573. Each figure shows the 
SIC relative to the standard  LLOQ (upper panel) and to the urine sample 
(lower panel).Tyr-His peptide was not detectd (Fig 8). 
The method was found specific, precise and accurate according to the FDA  
guidelines [2] :  CV % range from 5 to 15 % and the bias didn’t exceed 
±15%. FDA guidelines recommend   both for precision and accuracy (CV % 
and bias respectively) a value below ±15%, except for the LLOQ that is 
admitted also a value of ±20%. 
The equations relative to the calibration curve for carnosine-propanal and 
carnosine-propanol are as follows: y = (0.3951 ± 0.0070)x - (0.0029 ± 
0.0352) (fig.9 upper panel) and y= (1.185 ± 0.0176)x - (0.3879 ± 0.1717) 
lower panel; for both the curves the r
2
 is 0.99. Stability of the adducts and IS 
was assessed at 5 °C after 24 hours; since the areas of the analystes and of the 
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IS decreased of a similar extent (12% and 14%, respectively) the content of 
the analytes determined with the internal std method was found constant. 
 
 
 
Fig. 6. In the upper panel there is the SIC trace of CAR-propanal of the 
LLOQ standard concentration spiked in blank urine. Instead in the lower 
panel it is reported the SIC trace of CAR-propanal extracted in blank urine 
sample. Its area is the 16 % of the LLOQ concentration area. 
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Fig. 7. In the upper panel there is the SIC trace of CAR-propanol of the 
LLOQ standard concentration spiked in blank urine. Instead in the lower 
panel it is reported the SIC trace of CAR-propanol extracted in blank urine 
sample. It is the 18 % of the LLOQ concentration area. 
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Fig. 8. In the upper panel it is reported the SIC trace of the internal standard 
(TH) spiked in blank urine, and TH it is not present in the blank urine used. 
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Fig. 9. in the upper panel it is repoted the calibration curve of CAR-
propanal, y = (0.3951 ± 0.0070)x - (0.0029 ± 0.0352), r
2
 = 0.99; Instead in 
the lower panel it is reported that of CAR-propanol, y= ( 1.185 ± 0.0176)x - 
(0.3879 ± 0.1717) r
2
 = 0.99  
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6.3.4 Carnosine propanal and Carnosine propanol determination in urine 
samples of overweight/obese individuals 
 
Table 7 reports the concentration of urinary CAR-propanal and CAR-
propanol for each patient. The mean of CAR-propanal before CAR intake 
and in placebo was 1.2 µM ± 0.7 µM, ranging from 0.3 µM to 2.9 µM, and 
increased to 1.7 ± 1.3 µM in the supplemented  group (ranging from 0.5 µM 
to 5.5 µM). 
The mean of CAR-propanol before CAR intake and in placebo subjects was 
1.4 ± 0.7µM,  ranging from 0.6 to 3.0 µM and of 1.4 ± 0.8 µM after the 
supplementation. 
 
  PRE POST PRE POST 
Patient Car-propanal [µM] Car-propanal [µM] Car-propanol [µM] Car-propanol [µM] 
1 0.60 0.89 0.98 0.84 
2 0.89 1.16 0.87 1.02 
3 0.79 0.52 0.59 0.67 
4 0.35 1.14 0.63 0.77 
5 0.85 0.64 0.99 0.78 
6 0.53 0.66 0.78 0.66 
7 0.60 0.89 0.98 0.84 
8 2.11 2.55 3.01 2.80 
9 1.69 1.86 1.69 1.04 
10 1.33 n.d. 1.67 n.d 
11 5.58 0.61 5.93 0.83 
12 2.76 2.43 1.41 1.68 
13 2.35 5.49 2.69 4.05 
14 1.56 3.39 1.70 1.75 
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  PRE POST PRE POST 
Patient Car-propanal [µM] Car-propanal [µM] Car-propanol [µM] Car-propanol [µM] 
15 0.38 0.65 0.60 0.77 
16 1.03 1.80 1.52 1.40 
17 0.66 0.83 0.92 0.89 
18 1.06 1.16 0.96 1.04 
19 0.88 1.06 1.08 1.23 
20 1.77 1.20 2.26 1.06 
21 1.33 1.00 1.51 1.00 
22 1.04 0.67 1.18 0.84 
23 1.16 1.65 1.14 1.44 
24 0.79 3.74 0.99 2.47 
25 0.67 0.56 1.02 1.13 
26 2.41 4.81 2.81 3.47 
27 0.35 3.01 0.66 1.25 
28 1.47 1.61 1.66 1.25 
29 0.45 1.88 0.75 1.56 
30 0.82 0.57 1.00 0.80 
31 2.92 1.53 2.39 1.36 
 
Tab. 7. CAR-propanal and CAR-propanol concentration for each patient 
both before (PRE) and after (POST) CAR or placebo intake. The number of 
the patient in bold type refers to the CAR treated patients, the italic type 
refers to the placebo group. 
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6.3.5 Carnosine determination in urine and plasma 
 
A LC-MRM approach based on a triple quadrupole mass spectrometer was 
then developed in order to detect and quantify free carnosine in urine and 
plasma. TH was selected as internal standard and the method was found 
specific for this compound. Fig. 12 shows the SRM of TH in a blank urine 
sample and in urine spiked with TH at a final concentration of x µM. 
The MRM approach was firstly applied to blank urine and plasma to measure 
the endogenous concentration of free carnosine. According to previous 
studies reporting that carnosine is an endogenous dipeptide present in urine 
but not in plasma, carnosine was detected but not quantified in the blank 
urine (the peak area was lower than 20 % the LLOQ, Fig.10) and not detected 
in the blank plasma (Fig. 11).  
The calibration curves for carnosine built in urine and plasma are displayed 
in fig.13 and the equation calculated in urine and plasma are as follows: y = 
(0.01543 ± 0.00039)x - (0.02865 ± 0.03653), r
2
 is 0.990 and y = (0.11970 ± 
0.00155)x - (0.01417 ± 0.00778), r
2
 is 0.998 
The LLOQs of carnosine was 0.5 µM in urine and 0.1 µM in plasma. The 
LLODs were as follows: 0.2 µM in urine and 0.05 µM in plasma 
The intra and interday precision (CV%) and the accuracy of the method were 
determined on QC samples prepared separately from calibration standards, by 
analysing five replicates at three concentration levels, and data are reported in 
table 8. 
Carnosine was found stable at 4 °C for at least for 18 hours both for CAR 
spiked in urine and plasma, instead after one freeze and thaw cycle, from -80 
°C to room temperature, carnosine decreased by 4.5 % and 5.1 %, moreover 
after 3 freeze and thaw cycles carnosine decreased by 8.5 % in urine and 10.4 
% in plasma. 
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Fig. 10. Upper panel: SRM trace of CAR spiked in blank urine at the LLOQ; 
lower panel: SRM relative to CAR in blank urine: the peak area is 16 % in 
respect to the peak area of CAR spiked at the LLOQ. 
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Fig. 11. Upper panel: SRM trace of CAR spiked at the LLOQ in blank 
plasma; lower panel: SRM trace of CAR in blank plasma. 
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Fig. 12. Upper panel: SRM trace of TH as internal std spiked in blank 
plasma at a final concentration of 5 µM; lower panel, SRM trace of TH in a 
blank plasma. No peak are detected demonstrating the method’s specificity. 
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Fig. 13. Calibration curve of CAR in urine y = (0.01543 ± 0.00039)x - 
(0.02865 ± 0.03653), r
2
 = 0.990; lower panel - calibration curve of CAR in 
plasma y = (0.11970 ± 0.00155)x - (0.01417 ± 0.00778) r
2
 = 0.998 
  
6 Intervention study of Carnosine in obese volunteers: bioavailability and 
reactive carbonyls species sequestering effect 
210 
 
 
analytical method for urine 
Concentration (µM) Intraday (CV %) Interday (CV%) Accuracy 
1 8.6 10.1 ± 9.3% 
25 5.3 11.3 ± 5.1 % 
200 6.1 6.8 ± 4.7% 
analytical method for plasma 
Concentration (µM) Intraday (CV %) Interday (CV%) Accuracy 
0.5 9.7 12.3 ± 8.8% 
10 6.6 10.5 ± 6.3 % 
100 4.9 5.8 ± 4.1% 
 
Tab. 8. Intra and interday precision and accuracy data for CAR in urine and 
CAR in plasma 
 
Table 9 shows the data on urine CAR concentration for each patient. Before 
supplementation (PRE), carnosine ranged from 0.1 to 21 µM with a mean of 
9 ± 6.3 µM. After the supplementation (POST), carnosine ranged from 1.4 
µM to 350.0 µM and the mean raised to 40 ± 85 µM. The intra-run precision 
in terms of CV % was always below the 15 %. 
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Urine PRE POST 
Patient CAR [µM] CAR [µM] 
1 0.1 1.4 
2 13.7 14.3 
3 1.4 3.7 
4 4.9 11.1 
5 8.8 7.5 
6 15.3 45.8 
7 3.7 13.0 
8 12.1 12.4 
9 21.1 306.6 
10 9.8 n.d. 
11 8.8 0.7 
12 17.6 25.7 
13 19.2 350.0 
14 5.3 33.1 
15 0.5 4.0 
   
Urine PRE POST 
Patient CAR [µM] CAR [µM] 
16 14.3 31.5 
17 10.5 7.5 
18 4.6 5.6 
19 5.9 4.6 
20 6.6 1.4 
21 20.8 6.9 
22 2.7 1.4 
23 3.3 8.2 
24 9.5 52.9 
25 7.2 6.9 
26 16.0 19.5 
27 1.1 9.2 
28 7.9 146.9 
29 1.4 12.7 
30 11.1 5.3 
31 15.3 9.5 
 
Tab. 9. CAR concentration in urine for each patient before (PRE) and after 
(POST) CAR or placebo intake. CAR treated patients are recognized by the 
patient’s number in bold,   placebo subjects have the number in italic. 
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6.3.6 Top down ESI-MS analysis of albumin’s isoforms  
 
Thre main HSA isofomrs are detected by ESI-MS intact protein analysis of 
human serum:  mercapto-albumin (HSA-SH), cysteinylated-albumin (HSA-
S-S-Cys) and glycated albumin ( HSA-N-Glc). Figure 14 shows the full ESI-
MS spectrum of HSA and the corresponding deconvoluted spectrum. The 
ESI-MS spectrum (upper panel) shows the +45, +46, +47 multicharged ions 
relative to the three isoforms. The corresponding deconvoluted spectrum is 
shown in the lower panel, characterized by a base peak at 66448 Da, 
corresponding to mercapto-albumin and differing of only 0.1 milli-mass unit 
(mmu) in respect to the theoretical mass  (66454.6 Da). 
In the spectrum there are two other minor peaks at 66565 Da (+117 Da) and 
66610 Da (+162 Da) which are attributed to the cysteinylated and glycated 
forms, respectively, as previously reported [21] 
Table 10 summarizes the relative percentage of the three isoforms for each 
patient, both before and after the supplementation. The intra-run precision in 
terms of CV % was always below the 15 %. 
 
  PRE POST 
Patient HSA-SH HSA-S-S-Cys HSA-N-Glc HSA-SH HSA-S-S-Cys HSA-N-Glc 
1 58.9 22.6 18.5 60.6 21.9 17.6 
2 59.9 22.6 17.4 60.1 23.2 16.7 
3 55.4 27.0 17.6 58.2 24.7 17.1 
4 56.8 24.3 18.9 59.3 22.9 17.7 
5 61.0 21.1 17.9 61.4 21.9 16.7 
6 58.4 22.5 19.1 58.2 24.1 17.7 
7 53.9 28.2 17.9 55.0 25.6 19.4 
8 59.4 23.1 17.5 60.0 22.8 17.3 
9 62.4 21.3 16.3 59.5 24.1 16.4 
10 58.8 23.5 17.7 n.d. n.d. n.d. 
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  PRE POST 
Patient HSA-SH HSA-S-S-Cys HSA-N-Glc HSA-SH HSA-S-S-Cys HSA-N-Glc 
11 60.4 23.0 16.7 60.5 23.4 16.2 
12 60.4 22.5 17.1 60.0 23.4 16.6 
13 62.2 20.9 16.8 63.3 20.2 16.5 
14 58.9 23.5 17.6 59.0 23.9 17.1 
15 61.0 22.3 16.7 64.7 19.1 16.2 
16 59.2 23.4 17.4 60.1 22.7 17.2 
17 59.1 22.5 18.4 59.8 22.1 18.1 
18 59.4 22.0 18.6 61.8 20.8 17.4 
19 56.2 24.9 18.9 56.2 26.5 17.3 
20 58.1 23.2 18.7 58.8 23.2 18.0 
21 56.6 26.0 17.4 57.8 25.6 16.7 
22 61.0 22.2 16.7 62.8 20.3 16.9 
23 58.4 23.9 17.7 60.9 21.9 17.2 
24 59.1 24.1 16.8 59.1 24.0 16.9 
25 57.3 25.4 17.3 59.1 24.0 16.9 
26 62.0 21.3 16.7 62.7 20.4 16.9 
27 60.6 22.4 17.0 57.6 24.9 17.6 
28 60.0 22.4 17.6 60.5 21.9 17.5 
29 57.4 25.1 17.5 57.8 25.0 17.2 
30 56.9 26.8 16.3 56.3 26.6 17.1 
31 60.4 22.8 16.8 62.4 21.6 16.1 
 
Tab. 10. For each patient the relative abundance of HSA-SH, HSA-S-S-Cys 
and HSA-N-Glc are reported. Green background refers to the relative values 
before the treatment (PRE), red background after treatment (POST). Treated 
patient numbers are in bold, placebo patient numbers are in italics. 
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Fig. 14. Panel A: ESI full MS spectrum of HSA characterized by three  
intense multicharged ion series. Panel B: deconvoluted spectrum 
characterized by a base peak attributed to mercapto-albumin at 66448 (HSA-
SH) and by two other less intense peaks referred to cysteinylated and 
glycated albumin at 66565 Da and 66610 Da, respectively 
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6.3.7 Creatinine determination in urine 
 
In table 11 the concentration of urinary creatinine is reported. The intra-run 
precision in terms of CV % was always below the 15 %. 
 
 Urine PRE POST 
Patient CRE [µM] CRE [µM] 
1 3359.3 6011.4 
2 10962.0 17857.5 
3 8928.7 13348.9 
4 10608.4 6011.4 
5 12376.5 6983.9 
6 14940.2 8044.7 
7 22100.8 20598.0 
8 17327.1 23868.9 
9 18387.9 25106.5 
10 20774.8 n.d. 
11 18034.3 3536.1 
12 18829.9 19448.7 
13 11669.2 12906.9 
14 28200.7 31118.0 
15 2210.1 6630.3 
   
 Urine PRE POST 
Patient CRE [µM] CRE [µM] 
16 20951.6 20951.6 
17 10431.6 10078.0 
18 19713.9 16619.8 
19 14586.6 11669.2 
20 25637.0 24752.9 
21 27493.4 15382.2 
22 9459.2 5481.0 
23 14763.4 16177.8 
24 12376.5 21482.0 
25 12906.9 23868.9 
26 35361.3 32355.6 
27 4066.6 12553.3 
28 12376.5 7160.7 
29 9547.6 20421.2 
30 23868.9 9636.0 
31 23161.7 18211.1 
 
Tab. 11. Urine creatinine concentration.  
Treated patient numbers are in bold, placebo patient numbers are in italics. 
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6.3.8 Advanced Glication End products (AGE) in urine and plasma 
 
Urinary and plasma AGE levels are reported in table 12 and 13. The intra-run 
precision calculated as CV % was always below the 20 % 
 
Urine PRE POST 
Patient 
AGE [ UF/ 
mg protein] 
AGE [ UF/ 
mg protein] 
1 95016.2 39736.2 
2 36248.4 29490.4 
3 179178.5 94568.8 
4 11608.0 77766.8 
5 50900.4 19590.0 
6 69441.8 40372.1 
7 31596.3 30548.6 
8 36506.0 61299.2 
9 49801.2 43738.1 
10 38852.8 n.d. 
11 56676.6 13770.3 
12 33253.0 28168.3 
13 40689.4 34044.3 
14 33021.3 31601.2 
15 41767.8 24895.0 
   
   
Urine PRE POST 
Patient 
AGE [ UF/ 
mg protein] 
AGE [ UF/ 
mg protein] 
16 23034.1 35076.5 
17 94474.0 147585.0 
18 31868.9 25859.6 
19 20511.8 18000.2 
20 56482.9 93316.5 
21 82519.6 87777.0 
22 23565.1 22199.3 
23 75835.3 74043.6 
24 71383.7 64373.4 
25 16241.1 78083.6 
26 23539.9 22171.6 
27 30647.1 31386.7 
28 14332.4 52720.7 
29 15338.2 24416.9 
30 32018.8 24255.3 
31 31039.8 41847.2 
 
Tab. 12. Urinary AGE levels reported as fluorescence units per mg of protein.  
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Plasma PRE POST 
Patient 
AGE [ UF/ 
mg protein] 
AGE [ UF/ 
mg protein] 
1 10.3 10.2 
2 9.9 7.8 
3 11.6 11.4 
4 8.5 7.9 
5 9.0 7.4 
6 9.4 9.9 
7 10.3 7.8 
8 8.7 16.5 
9 8.3 9.6 
10 9.3 n.d. 
11 12.7 11.9 
12 13.2 9.4 
13 8.6 7.5 
14 16.8 20.9 
15 8.4 7.8 
   
   
Plasma PRE POST 
Patient 
AGE [ UF/ 
mg protein] 
AGE [ UF/ 
mg protein] 
16 10.3 9.6 
17 11.8 11.1 
18 9.9 10.2 
19 11.4 11.7 
20 12.2 13.6 
21 8.9 12.1 
22 26.6 13.1 
23 7.4 12.2 
24 11.5 16.0 
25 7.2 8.7 
26 8.3 9.2 
27 8.9 9.8 
28 9.6 11.2 
29 14.8 13.6 
30 8.8 12.4 
31 8.4 9.6 
 
Tab. 13. Plasma AGE levels are reported as fluorescence units per mg of protein. 
Treated patient numbers are in bold, placebo patient numbers are in italics. 
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6.3.9 Carboxymethyl lysine (CML)in plasma 
 
Table 14 reportes the CML levels in plasma . 
 
CML PRE POST 
Patient 
ng CML / 
mg protein 
ng CML / 
mg protein 
1 50.1 48.8 
2 49.0 62.2 
3 51.8 53.1 
4 41.9 42.8 
5 50.0 45.7 
6 45.4 42.2 
7 55.9 47.1 
8 48.2 47.8 
9 115.8 50.1 
10 46.5 n.d. 
11 47.4 46.0 
12 53.2 42.3 
13 79.4 54.5 
14 50.2 42.0 
15 43.5 44.9 
   
   
CML PRE POST 
Patient 
ng CML / 
mg protein 
ng CML / 
mg protein 
16 45.1 42.5 
17 42.7 42.2 
18 42.5 52.2 
19 52.1 51.5 
20 45.7 46.1 
21 44.0 45.0 
22 122.9 41.8 
23 42.8 45.2 
24 41.4 62.6 
25 50.6 52.5 
26 46.3 46.0 
27 45.4 45.6 
28 40.9 49.7 
29 46.4 54.0 
30 38.4 39.1 
31 55.3 53.8 
 
Tab. 14. CML plasma levels reported as nanograms of CML per mg of protein. 
Treated patient numbers are in bold, placebo patient numbers are in italics. 
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6.3.10 Advanced Oxidation Protein Products (AOPP) in plasma 
 
Table 15 summarizes the plasma levels of AOPP. 
 
AOPP PRE POST 
Patient 
nanomol / 
mg protein 
nanomol / 
mg protein 
1 5.3 3.7 
2 1.9 4.6 
3 2.8 3.9 
4 5.2 4.6 
5 2.7 2.4 
6 2.5 3.9 
7 4.9 3.3 
8 3.4 4.2 
9 4.9 3.5 
10 3.1 n.d. 
11 2.9 6.3 
12 5.5 7.6 
13 3.4 4.5 
14 5.1 7.8 
15 3.6 7.1 
   
AOPP PRE POST 
Patient 
nanomol / 
mg protein 
nanomol / 
mg protein 
16 4.1 4.4 
17 4.3 8.4 
18 6.2 4.9 
19 6.2 6.0 
20 6.2 6.5 
21 4.2 6.0 
22 24.9 7.7 
23 5.8 8.5 
24 10.1 6.0 
25 7.5 6.8 
26 7.2 6.3 
27 8.8 7.5 
28 3.9 5.1 
29 5.5 5.1 
30 10.1 7.9 
31 3.8 8.0 
 
Tab. 15. The plasma levels of AOPP are reported as nanograms per mg of 
protein. Treated patient numbers are in bold, placebo patient numbers are in 
italics. 
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6.3.11 Protein Carbonyl (PCO) in plasma 
 
Table 16 shows the plasma PCO levels in plasma. 
 
PCO PRE POST 
Patient 
nanomol/mg 
protein 
nanomol/mg 
protein 
1 1.52 1.80 
2 1.61 1.99 
3 2.23 1.85 
4 2.52 1.71 
5 2.33 1.69 
6 2.21 1.66 
7 2.60 1.46 
8 2.10 1.63 
9 2.22 1.72 
10 3.18 1.50 
11 2.61 1.68 
12 2.32 1.53 
13 0.91 1.67 
14 1.25 1.89 
15 0.85 1.63 
 
  
PCO PRE POST 
Patient 
nanomol/mg 
protein 
nanomol/mg 
protein 
16 1.53 1.96 
17 1.35 1.12 
18 0.90 1.42 
19 1.06 1.44 
20 1.00 1.36 
21 0.97 1.88 
22 3.67 1.56 
23 1.32 2.05 
24 1.82 1.58 
25 1.68 1.82 
26 1.90 1.80 
27 1.80 1.72 
28 2.02 1.56 
29 2.04 1.74 
30 2.38 2.00 
31 2.33 1.81 
 
Tab. 16. The plasma levels of PCO are reported as ng per mg of protein.  
Treated patient numbers are in bold, placebo patient numbers are in italics. 
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6.3.12 Statistical Analysis: T test 
 
As already mentioned at the beginning of the results section, free carnosine, 
CAR-propanol and CAR-propanal were found in all the 31 patients urine, both 
before and after carnosine supplementation. Considering these results different 
statistical tests were applied in order to determine if CAR treatment significantly 
changes the urinary levels of both free carnosine and CAR-ACR-adducts as well 
as the other parameters measured. Patient n° 10 was excluded by all the statistical 
analysis since it was a drop out subject and we couldn't analyze his samples after 
the treatment. 
ANOVA test was firstly launched and it didn't indicate any significant difference 
for any groups and parameters considered. Hence unpaired t test was applied for 
all the analytes considered and between the different groups. For each considered 
analyte, there was no significant difference between the placebo and treated 
groups before starting the CAR supplementation thus indicating the homogeneity 
at the starting point between the two groups. The placebo and treated group after 
CAR intake as well as the treated group before and after the treatment were then 
matched and analysed by t-test in order to assess any possible significant variation 
induced by the treatment. The placebo group before and after the treatment was 
then analyzes in order to recognize any placebo effect after the supplementation.  
The t test revealed significant variations only in the case of free carnosine and 
carnosine propanal, unfortunately for all the other parameters reported above we 
couldn't find any significant variation. 
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6.3.12.1 Free carnosine t test results  
 
As shown in graph 1, placebo and treated groups were homogeneous in terms of 
urinary content of carnosine before  CAR supplementation ( P value = 0.46). 
After three months of CAR intake, the urinary CAR levels were significantly 
higher in the treated group than in placebo ( P value ≤ 0.05) (graph 2). The effect 
of carnosine intake on the urinary levels was then confirmed by analysing the 
treated group before and after supplementation (p <0.05, graph 4). By contrast, 
placebo treatment was found not able to affect carnosine excretion (p=0.44, graph 
3).  
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Graph 1. Scatter plot that compares the urinary content of CAR between placebo 
and treated group before the treatment (PRE).  
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Graph 2. Scatter plot that compares the CAR concentration between placebo and 
treated group after the treatment (POST). 
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Graph 3. Scatter plot that compares the CAR concentration of the placebo group 
before and after the placebo supplementation 
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Graph 4. Scatter plot that compares the CAR concentration of treated group 
before and after CAR supplementation 
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6.3.12.2 CAR-propanal t test results 
 
Similarly to carnosine, the urinary levels of CAR-propanal in placebo and treated 
groups were homogeneous before CAR supplementation (P value = 0.33, graph 
5). After three months of treatment, the urinary CAR-propanal levels were 
significantly higher in the treated group than in placebo ( P value ≤ 0.05, graph 5). 
The result was confirmed by considering the effect of each treatment for each 
group, placebo did not change the levels of the adduct (p= 0.83, graph 7) while 
CAR treatment was significantly effective (p< 0.05, graph 8). 
Patient 11 and 13 were excluded by this t test analysis since the instrumental 
response had sensibility problem considering CAR-propanal for those samples.  
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Graph 5. Scatter plot that compares the CAR-propanal concentration between 
placebo and treated group before the treatment (PRE).  
 
Car-propanal POST:placebo vs treated
P
la
ce
bo
 (P
O
S
T)
Tr
ea
te
d 
(P
O
S
T)
0
2
4
6
C
o
n
c
 µ
M
 
 
Graph 6. Scatter plot that compares the CAR-propanal concentration between 
placebo and treated group after the treatment (POST). 
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Graph 7. Scatter plot that compares the CAR-propanal concentration of the 
placebo group before and after the placebo supplementation 
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Graph 8. Scatter plot that compares the CAR-propanal concentration of the 
treated group before and after the placebo supplementation 
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6.3.12.3 Correlation between CAR-ACR adducts and CAR concentration in urine 
 
We then found that the increase of free carnosine in urine is associated to an 
increase of CAR-ACR adducts formation. In particular we observed a significant  
positive correlation between CAR-ACR adducts (CAR-propanal and CAR-
propanol) and free carnosine in urine (graph 9).  
Data regqarding the parametric correlation, the Pearson r, the P value and the r
2
 
for each adduct are reported in tab. 17. 
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Graph 9. Points graph that shows the correlation between CAR.ACR adduct 
urinary concentration and CAR urinary concentration. The red dots referers to 
CAR-propanal, instead the green squares refers to CAR-propanol 
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Parametric correlation CAR-propanal CAR-propanol 
Pearson r 0.58 0.49 
P value 0.0013 0.0085 
r
2 0.33 0.24 
 
Tab. 17. Parametric correlation coefficients regarding CAR-propanal and CAR-
propanol correlation with CAR. 
 
6.3.13 Statistical analysis: Principal Component Analysis (PCA) 
 
The data set was then analyzed by the Principal Component Analysis (PCA), a 
data simplification technique used in the field of the multivariate statistics. PCA 
convert a set of possibly correlated variables into a set of values of linearly 
uncorrelated variables called principal components. Each principal component 
explain a percentage of the total variance of the data. PCA was applied separately 
to the analytes measured in urine and in plasma, moreover the pre-treatment 
group was separated from the post-treatment group. No significant results were 
observed when PCA was applied to the data set regarding plasma parameters 
either considering the pre and post treatment groups. 
By contrast, when PCA analysis was applied to urine, significant results were 
observed as reported in the following paragraph. 
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6.3.13.1 PCA on urinary analytes before carnosine administration: 
 
Graph 10 reports the loading plot reporting the eigenvalues on the y axis and the 
principal component number on the x axis. Each principal component found by 
the analysis have its own eigenvalue and describes a percentage of variance. As 
shown in figure 10, two principal components have an eigenvalues above 1: the 
principal component 1 (PC1) that have an eigenvalue of 2.6 and reporting the 43 
% of data variance and the principal component 2 (PC2) which describes the 17 
% of data variance; globally PC1 and PC2 account for 61.2 % of the variance. 
This two component were chosen also because their coefficients were consistent 
and logical in respect to the biological meaning of the experiment. 
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Loading plot: 
 
 
Graph 10. The Loading plot reports on the y axis the eigenvalues of each 
component and on the x axis the principal component number. PC1 and PC2 have 
an eigenvalue higher or equal to 1. 
 
 Eigenvalue Percentage of Variance Cumulative 
1 2.62084 43.68% 43.68% 
2 1.04886 17.48% 61.16% 
3 0.97245 16.21% 77.37% 
4 0.83096 13.85% 91.22% 
5 0.46914 7.82% 99.04% 
6 0.05775 0.96% 100.00% 
 
Tab. 18: Each derived component is reported. There are six principal components 
but component 1 and 2 describe the 43% and 17% of data variance, respectively.  
0 2 4 6
0
1
2
3
E
ig
e
n
v
a
lu
e
s
Principal Component Number
6 Intervention study of Carnosine in obese volunteers: bioavailability and 
reactive carbonyls species sequestering effect 
232 
 
 Coefficients of PC1 Coefficients of PC2 
Pal 0.55164 0.29915 
Pol 0.53993 0.285 
CAR 0.4093 -0.14005 
uAGE -0.13799 0.82036 
Cre 0.43121 -0.22215 
Treatment 0.17796 -0.29552 
 
Tab. 19. The coefficients of PC1 and PC2 are reported. Pa stand for CAR-
propanal, Po for CAR-propanol, CAR for Carnosine, uAGE for urinary AGE, Cre 
for Creatinine. 
 
Table 19 reports the coefficients of PC1 and PC2. Each component have different 
coefficients for all the variables taken into account. The value of the coefficient is 
related to the importance of the variable for the corresponding principal 
component.  The variables  are positively related when they have the same sign, 
negatively when characterized by an opposite sign. The strength of the correlation 
depends on the value of the coefficients, higher the value, higher the correlation. 
The first component (PC1) describes a positive covariance of Carnosine (CAR), 
Carnosine adducts (Pal, Pol) and Creatinine (Cre). The second component (PC2) 
is strongly associated to the urinary AGE concentration (uAGE). 
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Graph 11. Biplot of PC1 against PC2. Subjects treated for CAR supplementation 
are visualized as filled dots and solid line, instead subjects chosen for placebo 
treatment are represented in empty dots, dashed line. 
 
Graph 11 reports the PCA analysis applied to the set of data related to the subjects 
before the carnosine treatment. In particular the biplot of principal components 
(PC1 vs PC2) (graph 11) shows that subjects chosen for Carnosine administration 
(filled dots, solid line) and subjects chosen for placebo treatment (empty dots, 
dashed line) are quite evenly distributed on the biplot space thus demonstrating 
the homogeneity of the two groups. 
  
-4 -2 0 2 4 6
-2
0
2
4
-0.5 0.0 0.5 1.0
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
Pal
Pol
Car
uAGE
Cre
Treatment
P
ri
n
c
ip
a
l 
C
o
m
p
o
n
e
n
t 
2
Principal Component 1
6 Intervention study of Carnosine in obese volunteers: bioavailability and 
reactive carbonyls species sequestering effect 
234 
 
 
6.3.13.2 PCA on urinary analytes after carnosine administration: 
 
PCA was then performed to the data set after Carnosine administration. Graph 12 
reports the loading plot and two principle components characterized by a value 
higher than 1 were observed,  which explains almost the 67 % of the variance. 
In particular component 1 and 2 describe the 46% and 20% of data variance, 
respectively. Notably, the percentage of variance of samples described by PCA 
after treatment is higher than before treatment. 
 
Loading plot: 
 
 
Graph 12. The loading plot is almost similar to previous graph 10. PC1 and PC2 
eigenvalues are slightly higher than previous analysis on pre treatment group. 
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 Eigenvalue Percentage of Variance Cumulative 
1 2.77071 46.18% 46.18% 
2 1.2308 20.51% 66.69% 
3 0.86783 14.46% 81.16% 
4 0.63524 10.59% 91.74% 
5 0.42633 7.11% 98.85% 
6 0.06909 1.15% 100.00% 
 
Tab 19. Each derived component is reported. There are six principal components 
but component 1 and 2 describe the 46.2 % and 20.5 % of data 
 
 Coefficients of PC1 Coefficients of PC2 
Pal 0.56702 0.11224 
Pol 0.54314 0.18071 
CAR 0.38613 -0.21844 
uAGE -0.14401 0.61481 
Cre 0.34189 0.50698 
Treatment 0.31107 -0.52155 
 
Tab. 20. The coefficients of PC1 and PC2 are reported. Pa stand for CAR-
propanal, Po for CAR-propanol, CAR for Carnosine, uAGE for urinary AGE, Cre 
for Creatinine. It is remarkable that in PC2 uAGE and the treatment are negative 
correlated. 
 
Similarly to the results of samples analyzed before treatment, the PC1 describes a 
positive covariance of carnosine (CAR), carnosine adducts (Pal, Pol) and 
Creatinine (Cre), while PC2 is more related to the increase of urinary AGE 
(uAGE) and Creatinine (Cre). However, treated subjects (i.e. subject administered 
with carnosine) show a positive covariance in PC1 which is higher than that 
observed before treatment (see above, tab 20) as well as a strong, negative 
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covariance in PC2. This can be interpreted as an increased excretion of carnosine 
and related adduct, along with a decrease in the excretion of AGEs in carnosine 
administered subjects. 
In particular the biplot of principal components (graph 13) (PC1 vs PC2) shows 
that PCA quite completely separates carnosine treated subjects (filled dots, solid 
line) form placebo subjects (empty dots, dashed line). Urinary creatinine is 
positively related to both components indicating that it has a random variability 
within the subjects tested. This variability is probably due to the broad 
concentration range detectable using a single time urine sampling as it was in the 
protocol used for urine collection. 
 
 
 
Graph 13. Biplot of PC1 against PC2. CAR treated subjects are displayed as 
filled dots and solid line, placebo subjects in empty dots, dashed line. The treated 
and placebo group are separated by a strong negative correlation between uAGE 
and treatment and also CAR.  
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6.4 Discussion and conclusions 
 
To our knowledge this is the first intervention study based on CAR 
supplementation in overweight/obese individuals. The bioavailability of carnosine 
and its effect on the oxidative stress and AGE/ALEs formation has been evaluated 
in both urine and serum samples and in particular the following biomarkers have 
been evaluated: AGEs (urine and plasma), CML (plasma), PCO (plasma), AOPP 
(plasma), HSA isoforms (plasma), CAR (urine) and CAR-RCS adducts (urine). 
In serum, no significant differences (ANOVA or t test) were observed among the 
different experimental groups and for any of the considered parameters. 
Moreover, serum carnosine was not detected in any subject (LOD= 0.1 µM ) 
accordingly to  previous studies [22] and this is well explained by considering the 
presence of human carnosinases that rapidly hydrolyses the dipeptide. Serum 
carnosine can be detected only at high doses of supplemented carnosine (i.e. 6 gr 
as reported by x) which is able to induce a saturating effect of the hydrolytic 
enzyme.  
By contrast, urine carnosine was detected in all the 31 patients either before and 
after CAR intake. It should be noted that free CAR, in particular after CAR 
supplementation, is characterized by an high variation among the subjects of the 
same group and this can be due to different reasons such as differences in 
carnosinases activity/content among the subjects, collection of the urine that was 
at one time point, no ovo-lacto-vegetarian diet assumed by the subjects during the 
intervention study. Normalization of the data on the basis of creatinine content 
did not reduce the variability. 
The presence of CAR in urine but not in serum can be explained by the fact that a 
certain amount of carnosine, lower than the LLOD, is reached at serum level and 
that it is excreted as such in the urine where it is accumulated reaching a detected 
amount. Another explanation can be due considering that CAR is synthetized in 
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the kidney starting from the two constitutive aa that are formed in circulation by 
the hydrolytic effect of carnosinase on the dipeptide. Although the large 
variability of CAR within each group, we observed that carnosine treatment 
significantly increased the urinary content of carnosine. 
Two CAR-ACR adducts were detected in all the 31 patients both before and after 
the supplementation: CAR-propanal and CAR-propanol. CAR-propanal derives 
from the Michael adduction of acrolein (ACR) to carnosine, while CAR-propanol 
is formed by the reduction of the carbonyl group belonging to CAR-propanol to 
the corresponding alcohol derivative. It is noteworthy that these adducts were 
found also before CAR supplementation, suggesting that carnosine acts as an 
endogenous detoxifier of acrolein. 
The identification of the two CAR-ACR adducts confirm the data previously 
published by Baba et al [10], reporting that CAR-propanal and CAR-propanol 
were found as the most abundant CAR adducts in the urine of healthy non-smoker 
volunteers. Moreover Baba et al found other CAR adducts and metabolites such 
as histidine-propanal, histidine-propanol and low levels of histidine-HNE and 
histidine-DHN. We identified such adducts in previous animal studies but not in 
the current human study and this can be due to several reasons such as the 
differences in terms of the CAR treatment in the volunteers (acute vs chronic), 
analytical methods and urine collection (single spot vs 24 hours collection). 
Furthermore we found that before the supplementation 55 % of the adduct was in 
the reduced form, CAR-propanol; after the treatment the reduced form decreased 
to 46 %. For sake of comparison Baba et al found in reduced form 75 % of 
carnosine conjugates of acrolein. 
Then it is to take in account that in the urine of six young volunteers we could 
detect only a very low amount of CAR-propanal and CAR-propanol, that was 
roughly 160 nM and 360nM respectively. It is to remark that these subjects were 
set on a ovo-lacto-vegetarian diet in order to considerably decrease CAR 
excretion in urine. Since we’ve found a positive correlation between CAR 
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excretion and CAR-ACR-adducts excretion it could be proposed that a 
withdrawal of carnosine could decrease also the CAR-ACR adducts levels. 
As already reported in the results chapter, we performed ANOVA test between all 
the possible groups with all the urinary and serum parameters evaluated, but 
eventually we could not find any significant difference between treated and 
placebo groups neither between pre and post treatment groups. However, by 
means of t test previously reported, we found a significant increase trend of free 
CAR and CAR-propanal adduct in the treated group after 3 months of CAR 
intake. Unfortunately considering CAR-propanol a significant variation between 
treated and placebo group wasn’t find, but more interestingly a positive 
parametric correlation between the excretion of CAR and CAR-ACR-adducts was 
identified. Based on these evidences it could be suggested that, also in vivo, CAR 
effectively detoxify RCS like acrolein by a direct quenching mechanism that 
leads to the formation of unreactive CAR-adducts. This detoxifying metabolic 
pathway based on histidine dipeptides have been already evaluated and confirmed 
both in vitro and in vivo studies, both in healthy lean humans and rodents. 
These ex vivo findings support previous in vitro studies, published by our 
research group, that confirmed an efficient acrolein sequestering ability of CAR 
by means of HPLC-UV studies and moreover all possible CAR-ACR adducts 
formed after in vitro incubation were characterized by ESI-MS analysis [3]. In 
this framework it is important to point out that acrolein is the most reactive 
electrophilic compound among RCS and it is neurotoxic, furthermore ACR, 
besides endogenous sources, acrolein is also generated by the processing of 
several foods and it is present in tobacco smoke and automobile exhaust [23]. 
hence it is noteworthy that CAR can efficiently quench ACR also in vivo. 
Moreover concerning in animal models of metabolic syndrome and 
atherosclerosis, carnosine treatment induced a significant protective effect, which 
was associated with a reduction of RCS-modified proteins (ALEs and AGEs) and 
with the excretion of carnosine-RCS adducts both in APO E null mice and Zucker 
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obese rats [7] [8]. However it is still not clear if this protective effect, mediated by 
histidine dipeptides, is related only to a direct quenching mechanism or it 
involves other pathways such as interaction with AGE receptor.  
PCA analysis was then performed in order to find some relationship between all 
the parameters measured in urine and plasma. PCA was taken in account because 
multiple regression analysis such as ANOVA requires that the parameters 
considered should be orthogonal, ie they cannot be mutually related [24]. An 
ANOVA performed on mutually related parameters could give limited reliability 
results. In the context of this study the various parameters measured are in reality 
mutually interact, as in the case of many biological variables. 
Principle component analysis is a statistical procedure that reduce the 
dimensionality of the original possibly correlated variables and convert them in 
principal components. These principal components (PC) are calculated by finding 
a linear combination of those variables that explains most of the variability within 
the data-set considered. The resulting principal components are linearly 
uncorrelated variables and each PC explain a percentage of the variance of the 
data. 
This kind of statistical analysis have been recently used to perform clinical data 
analysis concerning breast cancer [25] but also to develop a single parameter 
screening tool for metabolic syndrome [26]. Hence PCA could represent an 
alternative to classical regression analysis of multivariable dataset. 
Concerning the serum parameters we couldn’t find any correlation or 
discrimination of the results, but more interestingly remarkable and consistent 
results were found by the analysis of urinary parameters. 
As reported in the corresponding results paragraph it was shown, from the first 
component, that both before and after the CAR intake, the levels of free CAR and 
CAR-ACR-adducts as well as creatinine positively correlate thus corroborating 
the direct quenching mechanism of CAR. Moreover the second component shown 
that the urinary AGE levels were strongly negative correlated with the treatment 
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and mildly negative correlated with CAR concentration in urine. In particular the 
treated and placebo groups after the treatment are completely separated on the 
basis of this negative covariance between treatment and urinary AGE. Therefore 
it is logical to suppose that carnosine can detoxify RCS by a direct quenching 
mechanism and this could lead to reduced levels of RCS, thus attenuating RCS 
induced cellular injury as well as tissue inflammation.  
In the light of these results it appears noteworthy continuing to study the in vivo 
RCS detoxifying action induced by histidine dipeptides in order to gain a deeper 
understanding of their mechanism of action and to once more demonstrate that 
this class of compounds are promising preventing and therapeutic agents 
concerning RCS based disaeses. 
  
6 Intervention study of Carnosine in obese volunteers: bioavailability and 
reactive carbonyls species sequestering effect 
242 
 
 
6.5 References 
 
1. Zhou S, Decker EA. Ability of carnosine and other skeletal muscle 
components to quench unsaturated aldehydic lipid oxidation products. J Agric 
Food Chem. 1999 Jan;47(1):51-5. 
2. Aldini G, Carini M, Beretta G, Bradamante S, Facino RM. Carnosine is a 
quencher of 4-hydroxy-nonenal: through what mechanism of reaction? Biochem 
Biophys Res Commun. 2002 Nov;298(5):699-706. 
3. Carini M, Aldini G, Beretta G, Arlandini E, Facino RM. Acrolein-
sequestering ability of endogenous dipeptides: characterization of carnosine and 
homocarnosine/acrolein adducts by electrospray ionization tandem mass 
spectrometry. J Mass Spectrom. 2003 Sep;38(9):996-1006. 
4. Aldini G, Granata P, Carini M. Detoxification of cytotoxic alpha,beta-
unsaturated aldehydes by carnosine: characterization of conjugated adducts by 
electrospray ionization tandem mass spectrometry and detection by liquid 
chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrom. 2002 
Dec;37(12):1219-28. 
5. Hipkiss AR. Carnosine and its possible roles in nutrition and health. Adv 
Food Nutr Res. 2009;57:87-154. 
6. Orioli M, Aldini G, Benfatto MC, Facino RM, Carini M. HNE Michael 
adducts to histidine and histidine-containing peptides as biomarkers of lipid-
derived carbonyl stress in urines: LC-MS/MS profiling in Zucker obese rats. Anal 
Chem. 2007 Dec;79(23):9174-84. 
7. Aldini G, Orioli M, Rossoni G, Savi F, Braidotti P, Vistoli G, et al. The 
carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in 
Zucker obese rats. J Cell Mol Med. 2011 Jun;15(6):1339-54. 
8. Menini S, Iacobini C, Ricci C, Scipioni A, Blasetti Fantauzzi C, Giaccari 
A, et al. D-Carnosine octylester attenuates atherosclerosis and renal disease in 
ApoE null mice fed a Western diet through reduction of carbonyl stress and 
inflammation. Br J Pharmacol. 2012 Jun;166(4):1344-56. 
9. Baba SP, Hoetker JD, Merchant M, Klein JB, Cai J, Barski OA, et al. Role 
of aldose reductase in the metabolism and detoxification of carnosine-acrolein 
conjugates. J Biol Chem. 2013 Aug. 
10. Baba SP, Hoetker JD, Merchant M, Klein JB, Cai J, Barski OA, et al. Role 
of aldose reductase in the metabolism and detoxification of carnosine-acrolein 
conjugates. J Biol Chem. 2013 Sep;288(39):28163-79. 
6 Intervention study of Carnosine in obese volunteers: bioavailability and 
reactive carbonyls species sequestering effect 
243 
 
11. Grimsrud PA, Picklo MJ, Griffin TJ, Bernlohr DA. Carbonylation of 
adipose proteins in obesity and insulin resistance: identification of adipocyte fatty 
acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell 
Proteomics. 2007 Apr;6(4):624-37. 
12. Aldini G, Granata P, Orioli M, Santaniello E, Carini M. Detoxification of 
4-hydroxynonenal (HNE) in keratinocytes: characterization of conjugated 
metabolites by liquid chromatography/electrospray ionization tandem mass 
spectrometry. J Mass Spectrom. 2003 Nov;38(11):1160-8. 
13. FDA. Guidance for industry: bioanalytical method validation. Food and 
Drug Administration, Center for Drug Evaluation and Research (CDER), Center 
for Veterinary Medicine (CV) 2001. 
14. Heinegård D, Tiderström G. Determination of serum creatinine by a direct 
colorimetric method. Clin Chim Acta. 1973 Feb;43(3):305-10. 
15. Bradford MM. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem. 1976 May;72:248-54. 
16. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its 
sensitivity: theoretical and experimental studies. Anal Biochem. 1996 
May;236(2):302-8. 
17. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, 
Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel 
marker of oxidative stress in uremia. Kidney Int. 1996 May;49(5):1304-13. 
18. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for 
determination of oxidatively modified proteins. Methods Enzymol. 
1994;233:346-57. 
19. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-
(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) 
antigen in tissue proteins. Biochemistry. 1995 Aug;34(34):10872-8. 
20. Zhang Z, Marshall AG. A universal algorithm for fast and automated 
charge state deconvolution of electrospray mass-to-charge ratio spectra. J Am Soc 
Mass Spectrom. 1998 Mar;9(3):225-33. 
21. Aldini G, Gamberoni L, Orioli M, Beretta G, Regazzoni L, Maffei Facino 
R, et al. Mass spectrometric characterization of covalent modification of human 
serum albumin by 4-hydroxy-trans-2-nonenal. J Mass Spectrom. 2006 
Sep;41(9):1149-61. 
6 Intervention study of Carnosine in obese volunteers: bioavailability and 
reactive carbonyls species sequestering effect 
244 
 
22. Yeum KJ, Orioli M, Regazzoni L, Carini M, Rasmussen H, Russell RM, et 
al. Profiling histidine dipeptides in plasma and urine after ingesting beef, chicken 
or chicken broth in humans. Amino Acids. 2010 Mar;38(3):847-58. 
23. Aldini G, Orioli M, Carini M. Protein modification by acrolein: relevance 
to pathological conditions and inhibition by aldehyde sequestering agents. Mol 
Nutr Food Res. 2011 Sep;55(9):1301-19. 
24. Larson MG. Analysis of variance. Circulation. 2008 Jan;117(1):115-21. 
25. Buciński A, Bączek T, Krysiński J, Szoszkiewicz R, Załuski J. Clinical 
data analysis using artificial neural networks (ANN) and principal component 
analysis (PCA) of patients with breast cancer after mastectomy. Reports of 
Practical Oncology & Radiotherapy. 2007 1//;12(1):9-17. 
26. Chang CH, Yen CH, Chen MY. Using principal component analysis to 
develop a single-parameter screening tool for metabolic syndrome. BMC Public 
Health. 2010;10:708. 
 
7 Conclusions 
245 
 
7 Conclusions 
 
Non enzymatic protein covalent modifications are involved in the toxic effects 
induced by xenobiotics and endogenous electrophilic compounds. Once the 
protein is covalently modified, the corresponding protein function is deranged due 
to several mechanisms such as the direct modification of the active site, the 
change of protein conformation and protein oligomerization and aggregation. 
Covalently modified proteins can also be toxic by acting as antigens, eliciting an 
immuno based response, and as ligands of RAGE receptors inducing an 
inflammatory response. 
By considering that covalently modified proteins are involved in many human 
diseases and toxic responses but are poorly analytically characterized, the aim of 
the Ph.D thesis was to set up novel mass spectrometric strategies in order to 
identify, characterize and quantify protein adducts in vitro as well as in ex vivo 
conditions. 
Mass spectrometric hyphenated techniques have greatly improved the study of 
protein covalent modification, and this is due to the development of soft 
ionization techniques, such as ESI and MALDI, along with the advent of 
commercially available high resolution analysers such as TOF reflectron and 
Orbitrap. Before the establishment of MS based techniques, immunochemistry 
analysis such as RIA, EIA and SDS-PAGE or 2D-electrophoresis analysis were 
the most used. Even though these techniques are still used, they are limited 
because they do not permit full characterization of the adduct (site of 
modification, identity of the protein undergoing modification, structure of the 
adducted moiety) or quantify it.  
The results reported in the present Ph.D thesis have clearly shown the importance 
of novel high resolution mass spectrometric strategies in obtaining molecular 
insights into protein covalent modifications. 
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The MS strategies were applied to two different applications: elucidation of 
amoxicillin protein haptenation and covalent binding of peptides by endogenous 
electrophilic compounds. In both studies MS strategies were applied to both in 
vitro and ex vivo samples. 
Amoxicillin (AX), a β lactam antibiotic widely prescribed in Europe and the 
USA, is very often involved in drug allergic reactions due to protein haptenation. 
Identification of Amoxicillin target protein and the reaction mechanism represents 
one aim of the present research program.  
Human serum was incubated with AX at different concentrations and Western 
blotting analyses identified human serum albumin (HSA), transferrin and 
immunoglobulin as AX protein target. HSA was found as the most reactive target 
and 5 Lys residues were found to be covalently modified by AX, namely  Lys 
190, Lys 199, Lys 541, Lys351 and Lys432. Moreover molecular modelling was 
used in order to determine the key features of modified Lys and it was found that 
low basicity, reduced surface accessibility to solvent and the interaction of AX 
with the surrounding residues are crucial for Lys reactivity. An index of reactivity 
was also drawn and Lys 190 was the most reactive residue, followed by Lys 199 
and the other three residues, namely Lys 541, 351 and 432. This index of 
reactivity was then confirmed by an ex vivo study that identified Lys 190 as the 
only modification site in volunteers orally treated with AX. This noteworthy 
result was obtained by setting-up a customized MS analysis carried out by a high 
resolution mass spectrometer, LTQ Orbitrap XL, and then confirmed by using 
different analytical strategies based on Western blotting, triple quadrupole MRM 
scan.  
It should be noted that the residues found modified in this work were the same as 
those found by other research groups involving other β-lactam antibiotics such as 
penicillin [1], flucloxacillin [2] and piperacillin [3], confirming the reactivity of 
recurrent Lys residue towards this class of drug.  
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Another important issue evidenced by this study is that the AX protein adducts 
were detected in non AX allergic patients. Hence it is logical to suppose that there 
are concomitant factors that are required for the allergic reaction, such as danger 
signals or concurrent diseases. Hence future studies will be aimed correlating AX 
protein adducts and allergic reactions. 
In summary, a highly sensitive mass spectrometric strategy for the detection and 
identification of AX-protein adducts was firstly applied to an vitro study and this 
permitted the identification of the main protein targets of AX. The analytical 
approach was then applied to an ex vivo study permitting to identify albumin Lys 
190 as the modified site after AX oral intake. These studies  represent a starting 
point to characterize other AX binding proteins such as transferrin and 
immunoglobulin G and more in general for the untargeted identification and 
quantification of penicillin-protein adducts.  
So it could be stated that HRMS based analytical approaches concur to better 
understand the protein haptenation mechanism and to design more relevant and 
specific antigens to be used in diagnostic tests. 
Since MS-hyphenated techniques can provide a broad range of information about 
the covalent modification of proteins and peptides, this analytical strategy was 
also used to evaluate the direct quenching mechanism of reactive carbonyl species 
by carnosine (CAR). CAR was supplemented to overweight and obese individuals 
and both urine and plasma samples were analyzed to study the metabolic fate of 
carnosine as RCS quencher. Carnosine RCS adducts were searched for in the 
urine by LC-MS/MS analysis and using a high resolution Orbitrap mass 
spectrometer employed in a customised data dependent scan. 
CAR and two CAR-acrolein adducts, CAR-propanal and CAR-propanol, were 
detected, identified and quantified. It is interesting to point out that the two 
adducts as well as CAR were detected both before and after carnosine 
supplementation, as well as in the placebo group, thus demonstrating that 
carnosine acts as an endogenous detoxifier of acrolein. 
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CAR and CAR-propanal significantly increased after three months of CAR-intake 
and a parametric correlation showed that urinary CAR-ACR adducts directly 
correlate with CAR urinary levels. Considering these results it could be stated that 
CAR effectively detoxifies ACR by a direct quenching mechanism in obese 
subjects. 
Moreover, thanks to principle component analysis (PCA) a positive correlation 
between urinary CAR and CAR-ACR adducts was confirmed and that the urinary 
AGE levels were negative correlated with CAR treatment. 
These results are notable since they demonstrate the sequestering ability of CAR 
towards ACR which is a neurotoxic intermediate and the most reactive compound 
among RCS [4]. Nonetheless, these results confirm previous studies on animal 
models of metabolic syndrome diseases in which CAR treatment increased CAR-
RCS adducts in urines and decreased AGEs and ALEs levels [5, 6].  
In conclusion, the development of dedicated MS strategies have enhanced the 
knowledge of CAR metabolism and the detoxifying role of CAR in ex vivo 
context and once again confirmed the importance of high resolution MS strategies 
in the study of protein covalent modification. 
  
7 Conclusions 
249 
 
 
7.1 References 
 
1. Yvon M, Anglade P, Wal JM. Identification of the binding sites of benzyl 
penicilloyl, the allergenic metabolite of penicillin, on the serum albumin 
molecule. FEBS Lett. 1990 Apr;263(2):237-40. 
2. Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, Park 
BK. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin 
haptenated HSA in vitro and in vivo. Proteomics Clin Appl. 2009 Jun;3(6):720-9. 
3. Whitaker P, Meng X, Lavergne SN, El-Ghaiesh S, Monshi M, Earnshaw 
C, et al. Mass spectrometric characterization of circulating and functional 
antigens derived from piperacillin in patients with cystic fibrosis. J Immunol. 
2011 Jul;187(1):200-11. 
4. Carini M, Aldini G, Beretta G, Arlandini E, Facino RM. Acrolein-
sequestering ability of endogenous dipeptides: characterization of carnosine and 
homocarnosine/acrolein adducts by electrospray ionization tandem mass 
spectrometry. J Mass Spectrom. 2003 Sep;38(9):996-1006. 
5. Menini S, Iacobini C, Ricci C, Scipioni A, Blasetti Fantauzzi C, Giaccari 
A, et al. D-Carnosine octylester attenuates atherosclerosis and renal disease in 
ApoE null mice fed a Western diet through reduction of carbonyl stress and 
inflammation. Br J Pharmacol. 2012 Jun;166(4):1344-56. 
6. Aldini G, Orioli M, Rossoni G, Savi F, Braidotti P, Vistoli G, et al. The 
carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in 
Zucker obese rats. J Cell Mol Med. 2011 Jun;15(6):1339-54. 
 250 
 
8 Scientific activity during the PhD course 
 
List of publications 
 
1.  On the self-condensation of aminoguanidine leading to 1, 1, 4, 10, 10-
pentaamino-2, 3, 5, 6, 8, 9-hexaazadeca-1, 3, 5, 7, 9-pentaene (structure 
elucidation through X-ray powder diffraction) 
Tasso B, Pirisino G, Novelli F, Garzon D, Fruttero R, Sparatore F, 
Colombo V, Sironi A. 
Tetrahedron 2014 Oct 28 
 
2. Mass spectrometric strategies for the identification and characterization of 
human serum albumin covalently adducted by amoxicillin: ex vivo 
studies. 
Garzon D, Ariza A, Regazzoni L, Clerici R, Altomare A, Sirtori FR, Carini 
M, Torres MJ, Pérez-Sala D, Aldini G. 
Chem. Res.Toxicol 2014 Sep 14 
 
3. Standardization of solvent extracts from Onopordum acanthium fruits by 
GC-MS, HPLC-UV/DAD, HPLC-TQMS and 1H-NMR and evaluation of 
their inhibitory effects on the expression of IL-8 and E-selectin in 
immortalized endothelial cells (HUVECtert). 
Daci A, Gold-Binder M, Garzon D, Patea A, Beretta G 
Nat. Prod. Commun 2014 Jul 9 
  
 251 
 
4.  A novel high resolution MS approach for the screening of 4-hydroxy-
trans-2-nonenal sequestering agents. 
Colzani M, Criscuolo A, De Maddis D, Garzon D, Yeum KJ, Vistoli G, 
Carini M, Aldini G. 
J Pharm Biomed Anal 2014 Mar 25 
 
5. A rapid profiling of gallotannins and flavonoids of the aqueous extract of 
Rhus coriaria L. by flow injection analysis with high-resolution mass 
spectrometry assisted with database searching. 
Regazzoni L, Arlandini E, Garzon D, Santagati NA, Beretta G, Maffei 
Facino R. 
J Pharm Biomed Anal 2013 Jan 18 
 
6. Protein haptenation by amoxicillin: high resolution mass spectrometry 
analysis and identification of target proteins in serum. 
Ariza A, Garzon D, Abánades DR, de los Ríos V, Vistoli G, Torres MJ, 
Carini M, Aldini G, Pérez-Sala D. 
J Proteomics 2012 Dec 21  
 
Book chapters 
 
1. Carnosine and derivatives as inhibitors of protein covalent modifications 
induced by reactive carbonyl species 
Colzani M, Garzon D and Aldini G 
Imidazole Dipeptides: Chemistry, Analysis, Function, and Effects 
Victor Preedy 
Royal Society of Chemistry, ISBN 9781849738903, 2015 
  
 252 
 
 
Communication to national and international congresses 
 
Oral Communication 
 
1. High resolution mass spectrometric strategies for detection of proteins and 
peptides covalently modified by electrophilic xenobiotics and endogenous 
intermediates 
Garzon D 
Summer School in Pharmaceutical Analysis SSPA 2014 
September 23-25, 2014 Rimini (RN) Italy 
 
2. Mass spectrometric strategies for studying albumin covalent modifications 
induced by xenobiotics and endogenous electrophilic cytotoxic compounds 
Garzon D., Colzani M., Cannizzaro L., Carini M. and Aldini G. 
Nuove Prospettive in Chimica Farmaceutica NPCF 7 
May 29-31, 2013 Savigliano (CN) Italy 
  
Poster 
  
1. A new high resolution mass spectrometry application for the comprehensive 
analysis of the ligand binding properties of RAGE 
De Maddis D, Degani G, Pancotti A, Garzon D, Vistoli G, Romeo S, Carini M, 
Popolo L, Aldini G 
Nuove Prospettive in Chimica Farmaceutica NPCF 6 
April 15-17, 2012 Riccione (RN) Italy 
  
 253 
 
2. Reactive carbonyl species quenching ability and selectivity of a bioavailable 
carnosine peptidomimetic (FL-926-A16) in respect to L-carnosine and selected 
reference compounds 
Regazzoni L, De Maddis D, Garzon D, Carini M, Aldini G 
International Congress on " Carnosine in exercise and disease" 
July 10-12, 2011 Ghent (Belgium) 
 
